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ABSTRACT 
 
Regulation of Vascular Endothelial Growth Factor Receptor-2 in Pancreatic and 
Breast Cancer Cells by Sp Proteins. (May 2006) 
Kelly Jean Higgins, B.S.; B.A., New Mexico State University 
Chair of Advisory Committee:  Dr. Stephen H. Safe 
 
 
Vascular endothelial growth factor receptor-2 (VEGFR2) is a key 
angiogenic factor, and angiogenesis is an important physiological process 
associated with neovascularization, growth, and metastasis of many different 
tumors.  The mechanism of VEGFR2 gene expression was investigated in 
MiaPaCa-2, Panc-1, and AsPC-1 pancreatic cancer cells transfected with a 
series of VEGFR2 promoter deletion/mutated constructs, and the results 
indicated that the GC-rich –60 to –37 region of the promoter was essential for 
VEGFR2 expression in these cell lines.  EMSA and ChIP assays showed that Sp 
proteins are expressed and bind to the proximal GC-rich region of the VEGFR2 
promoter.  RNA interference studies on Sp proteins demonstrated that Sp1, Sp3, 
and Sp4 all contributed to VEGFR2 gene/protein expression in pancreatic 
cancer cells.  
VEGFR2 gene expression was also investigated in ZR-75 and MCF-7 
breast cancer cells.  ZR-75 cells treated with 10 nM 17β-estradiol (E2) increased 
VEGFR2 mRNA levels/protein expression.  The VEGFR2 promoter was induced 
by E2 in ZR-75 cells, and analysis of the VEGFR2 promoter identified the GC-
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rich -60 to -37 region that was required for E2-mediated transactivation.  EMSA 
and ChIP assays confirmed that Sp1, Sp3, and Sp4 proteins are expressed in 
ZR-75 cells and bind the proximal GC-rich region of the VEGFR2 promoter.  
RNA interference was used to determine the relative contributions of Sp proteins 
on hormonal regulation of VEGFR2 through ER/Sp complexes, and interestingly, 
in ZR-75 cells, hormone-induced activation of VEGFR2 involves ERα/Sp3 and 
ERα/Sp4 but not ERα/Sp1.  
In MCF-7 cells treated with 10 nM E2, VEGFR2 mRNA levels were 
decreased.  Analysis of the VEGFR2 promoter revealed that the same GC-rich 
region important for E2-mediated upregulation in ZR-75 cells was responsible for 
E2-dependent downregulation of VEGFR2 gene expression in MCF-7 cells.  
EMSA and ChIP assays confirmed that Sp1, Sp3, and Sp4 proteins are 
expressed in MCF-7 cells and bind to the proximal GC-rich region of the 
VEGFR2 promoter.  RNA interference studies showed that Sp1, Sp3, and Sp4 
are involved in the E2-mediated downregulation of VEGFR2 in MCF-7 cells, and 
ERα/Sp protein-promoter interactions are accompanied by recruitment of the 
corepressor SMRT using the ChIP assay.    
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CHAPTER I 
 
INTRODUCTION 
 
1.1. Cancer  
1.1.1. Statistics  
     According to estimates by the American Cancer Society, in 2002 there 
were almost 11 million new cases of cancer worldwide (Table 1).  There were 
approximately 6.7 million deaths and 24.6 million persons alive with cancer 
within three years of diagnosis (1).  Lung cancer is the most commonly 
diagnosed cancer with 1.35 million cases as well as the most common cause of 
cancer mortality with 1.18 million deaths (1).  Diagnosis of breast and colorectal 
cancers follow with 1.15 and 1 million cases, respectively (1).  Breast cancer is 
the most prevalent disease of women in the world with 4.4 million survivors up to 
5 years after diagnosis; however, approximately 411,000 women died from 
breast cancer in 2002 (1).  There were approximately 934,000 cases and 
700,000 deaths from stomach cancer, and 626,000 cases and 598,000 deaths 
from liver cancer (1).  Worldwide, there are 202,000 new cases of pancreatic 
cancer and nearly as many deaths from pancreatic cancer every year (2).   
 
This dissertation follows the style and format of Cancer Research.  
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Table 1. Incidence and mortality by sex and cancer site worldwide, 2002 
(Adapted from (1)). 
  
Incidence Mortality
Cancer Site Male Female Male Female
Bladder 273,858 82,699 108,310 36,699
Brain 108,221 81,264 80,034 61,616
Breast 1,151,298 410,712
Cervix uteri 493,243 273,505
Colon/rectum 550,465 472,687 278,446 250,532
Corpus uteri 198,783 50,327
Esophagus 315,394 146,723 261,162 124,730
Hodgkin disease 38,218 24,111 14,460 8,352
Kidney 129,223 79,257 62,696 39,199
Larynx 139,230 20,011 78,629 11,327
Leukemia 171,037 129,485 125,142 97,364
Liver 442,119 184,043 416,882 181,439
Lung 965,241 386,891 848,132 330,786
Melanoma of skin 79,043 81,134 21,952 18,829
Multiple myeloma 46,512 39,192 32,696 29,839
Non-Hodgkin lymphoma 175,123 125,448 98,865 72,955
Oral cavity 175,916 98,373 80,736 46,723
Ovary 204,499 124,860
Pancreas 124,841 107,465 119,544 107,479
Pharynx 162,015 48,324 102,877 31,448
Prostate 679,023 221,002
Stomach 603,419 330,518 446,052 254,297
Testis 48,613 8,878
Thyroid 37,424 103,589 11,297 24,078  
 
 
There are more than 100 distinct types of cancer in humans as well as 
subtypes of tumors within specific organs (3).  While there are many different 
types of cancers that are classified by tissue and cell type, cancer cells have two 
distinct properties: unregulated proliferation and the ability to invade and 
metastasize (4).  Development of cancer in humans occurs over long periods of 
time (from 5-20 years) and involves multiple changes in the genome of tumor 
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cells, conferring some growth advantage and/or defects in the regulatory 
mechanisms that govern cell proliferation and homeostasis.   
 
1.1.2. Stages of carcinogenesis 
Development of cancer is the result of several independent events that 
have a cumulative effect on a cell, and many carcinogenic agents significantly 
increase the likelihood of cancer cell formation.  There are three distinct stages 
in carcinogenesis: initiation, promotion, and progression (Figure 1).  Tumor 
initiation is often attributed to irreversible damage or mutation of DNA.  Most 
cancers are initiated by DNA damage induced by carcinogens, such as tobacco 
smoke, chemical carcinogens, ionizing radiation such as x-rays, and viruses. 
Various agents, which induce mutations in DNA, have been correlated with the 
cause of carcinogenesis and may be the result of environmental mutagens or 
defects in DNA processing including DNA excision and repair (4).  Mutations can 
occur spontaneously because of limitations of the accuracy of DNA replication 
and repair, and an increase in the frequency of mutations can influence both the 
incidence of tumors and the rate of progression.  Blocking normal maturation of 
cells toward a non-dividing state or preventing normal programmed cell death 
also play a role in tumor formation. 
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Figure 1. Stages of carcinogenesis (Adapted from (5)).  
 
 
 
Tumor promoters are not mutagenic but induce proliferation of damaged 
cells (i.e., reproductive hormones in women at different stages of life), and 
mutated cells survive to proliferate and avoid apoptosis (programmed cell 
death).  The promotion process can be stopped or interrupted and initiated cells 
seem to disappear.  However, when benign, initiated cells acquire additional 
permanent genetic mutations, they have reached the progression stage and 
have become sufficiently unstable genetically in order to invade and metastasize 
(6).   
Tumorigenesis is a multistep process involving genetic alterations that 
transform normal cells into cancer cells.  Mutations that result in gain of function 
of oncogenes or loss of function of tumor suppressor genes are common in most 
cancers.  Common alterations in cellular physiology lead to malignant growth 
and allow cancer cells to evade anticancer defense mechanisms of normal cells.  
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1.1.3. Acquired capabilities of cancer cells 
Cancer cells become self-sufficient in growth signals, insensitive to 
growth inhibitory signals, capable of evading apoptosis, sustaining angiogenesis, 
invading surrounding tissues, and undergoing metastasis, and they exhibit 
limitless replicative potential (3, 7).  Figure 2 shows these six acquired 
capabilities of cancer cells and an example of each mechanism. 
 
 
 
 
Figure 2. Acquired capabilities of cancer cells (Adapted from (3)). 
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Cells can acquire the ability to become self-sufficient in growth signals 
through oncogenes that mimic normal growth signals.  Tumor cells may 
generate their own growth factors, creating a positive feedback loop, in order to 
decrease dependence on growth factors from other cells.  For example, platelet-
derived growth factor (PDGF) and tumor growth factor alpha (TGFa) are 
overexpressed in glioblastomas and sarcomas respectively (3, 7).  Cell surface 
receptors that are involved in mediating growth stimulatory pathways are also 
targets of deregulation during tumor pathogenesis.  For example, growth factor 
receptors are overexpressed in many cancers, and this overexpression enables 
cancer cells to become hyperresponsive to levels of growth factors that would 
not normally trigger cell proliferation (7, 8).  Epidermal growth factor receptor 2 
(EGFR-2)/HER-2 is overexpressed in several cancers such as stomach, brain, 
and breast tumors (3).  Overexpression of growth factor receptors or structural 
alteration of receptors, such as mutations or truncations, can lead to ligand-
independent activation of growth stimulatory pathways (3, 7, 8).  
 Cancer cells can switch to expression of extracellular matrix receptors 
(integrins) that transmit growth signals, thus, influencing cell behavior such as 
motility, induction of apoptosis, and entrance into the cell cycle as well as 
activation of kinase pathways (9).  Alterations in downstream components of 
pathways involved in receiving and processing signals from ligand-activated 
growth factor receptors and integrins are targets of deregulation in many human  
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tumors (3, 10).  In fact, approximately 50% of all human colon carcinomas have 
mutant ras oncogenes, and the other half are suspected to have mutations in 
other components of growth signaling pathways (3, 11).  Growth of normal cells 
is influenced by paracrine signals from neighboring cells or systemic endocrine 
signals.  Cell to cell growth signaling in tumors also results in tumor cell 
proliferation, as evidenced in growth signals from stromal cells of a tumor that 
contribute to proliferation of neighboring cancer cells (12).  
 Normally, cells are maintained in homeostasis by multiple antigrowth 
signals such as soluble growth inhibitors or inhibitors embedded in the 
extracellular matrix or the surface of nearby cells which block cell proliferation 
(3).  Through intracellular signaling by cell surface receptors, these growth 
inhibitory signals block proliferation by either temporarily or permanently forcing 
cells out of the active proliferative cycle into G0 (the quiescent state) or into a 
postmitotic state (Figure 3) (3).   
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Figure 3. The cell cycle (Adapted from (13)). 
 
 
 
Cancer cells must become insensitive to growth inhibitory signals which 
block normal cell proliferation.  Many of these antigrowth signals are associated 
with the components of the cell cycle that govern the transition of the cell 
through G1 phase of the cell cycle (13).  When retinoblastoma protein (Rb) is 
hypophosphorylated, E2F transcription factors, which control the expression of 
many genes essential for G1 to S phase progression, are sequestered, and their 
function is decreased, resulting in inhibition of proliferation (14).  
Phosphorylation of Rb activates E2F protein and allows cancer cells to 
proliferate.  Transforming growth factor beta (TGFb) prevents phosphorylation of 
Rb, inactivating pRb, and blocking cells from progressing through G1 (14).  
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Some human tumors lose TGFb responsiveness through downregulation of the 
TGFb receptor or mutations in the TGFb receptor that render it dysfunctional, 
resulting in enhanced cell cycle progression (3).    
The ability of tumor cells to evade apoptosis contributes to the expansion 
of the tumor cell population.  Activation of apoptosis triggers disruption of cellular 
membranes, breakdown of cytoplasmic and nuclear skeletons, degradation of 
chromosomes, and nuclear fragmentation (3).  Certain cell surface receptors 
and their ligands are responsible for either survival or death signals.  The ligands 
insulin-like growth factor 1 and 2 (IGF-1/IGF-2) and their receptor, IGF-1R, or 
interleukin 3 (IL-3) and its receptor, IL-3R, are examples of survival signals for 
cells (15, 16).  Tumor cells often acquire the ability to evade apoptosis by 
overexpressing survival factors like IGF-1/IGF-2 (7, 15).  Conversely, apoptosis 
can be triggered by the p53 tumor suppressor protein that upregulates 
expression of Bax, a proapoptotic protein, in response to DNA damage (7, 17).  
Resistance to apoptosis by cancer cells can also result from loss of proapoptotic 
regulators through inactivating p53 mutations (15).  Inactivation of p53 is 
observed in more than 50% of human cancers, including pancreatic cancer (3, 
17).   
 Cells also have an intrinsic program that limits their ability to proliferate 
which must be disrupted in order for cells to acquire the limitless replicative 
potential needed to form a tumor (18).  Normally, cells go through a certain 
number of cell cycles where cells multiply and then stop growing or enter a 
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phase called senescence, G0 (3).  When pRb or p53 tumor suppressor proteins 
are inactivated, senescence is avoided and cells continue to multiply (19).  
When cells acquire the ability to multiply without limit, they are referred to as 
“immortal.”  Most types of tumor cells have this ability and cell immortality is 
essential for malignant growth of a tumor (20).   
The ends of chromosomes have telomeres made up of thousands of 
repeats of a short 6 base pair sequence element.  There is a loss of telomeric 
DNA from the ends of chromosomes during each cell cycle (18).  Continuous 
shortening of telomeric DNA from chromosomal ends is due to the inability of 
DNA polymerases to completely replicate the 3’ ends of DNA during S phase, 
and this leads to the eventual loss of protection of the ends of chromosomal 
DNA.  Chromosomal ends that are unprotected can result in cell death (3).   
Almost all types of malignant cells maintain their telomeres, mostly by 
upregulating telomerase, an enzyme that adds 6 base pair repeats to the ends 
of telomeric DNA (19).  By keeping telomeres above a critical length, cells can 
continue to multiply limitlessly. 
 Cells require oxygen and nutrients to function and survive.  Blood vessels 
supply cells within about 100 mm (21).  Angiogenesis, the growth of new blood 
vessels, is tightly regulated by balancing positive and negative cellular signals 
(7, 22).   Examples of angiogenesis initiating signals are vascular endothelial 
growth factor (VEGF) and fibroblast growth factors 1 and 2 (FGF1/2) which bind 
to transmembrane tyrosine kinase receptors on the surface of endothelial cells 
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(22, 23).  Thrombospondin-1 is a known inhibitor of angiogenesis (7, 21, 23).  
Cancer cells acquire the ability to induce and sustain angiogenesis during tumor 
development by expressing increased levels of angiogenic factors such as 
VEGF and FGFs compared to normal cells or by downregulating expression of 
inhibitors such as thrombospondin (7).  Thus, the normal balance of signals in 
the cell is altered and angiogenesis is sustained, allowing for further growth of 
tumor cells (23).   
 Primary human tumors often acquire the ability to invade other tissues 
and metastasize to form secondary tumors (3).  In cells that possess the ability 
to invade and metastasize, proteins involved in cell-to-cell and cell-to-
environment interactions are altered: cell-cell adhesion molecules (CAMs) and 
integrins which link cells to extracellular matrix substrates.  For example, E-
cadherin is a cell-to-cell interaction molecule ubiquitously expressed on epithelial 
cells which often lose their function in certain cancer cells (7).  E-cadherin acts 
as a suppressor of invasion and metastasis of cancer cells, and inactivation of 
E-cadherin is one way cells acquire the ability to invade and metastasize.   
 
1.1.4. Environmental and genetic factors 
Development of cancer results from a disturbance in the most 
fundamental rules of the behavior of cells and is a multistage process involving 
the accumulation of genetic damage and other factors, including interactions 
between genetics of an individual and the environment.  The sum of these 
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events is required to produce a malignant tumor (4, 24, 25).  In vitro models and 
studies using cultured cells from human tissues have facilitated research on 
causes of these events and have verified that the risk of developing cancer is 
the combination of genetics and interactions with an oncogenic agent (25).  
Environmental factors such as nutrition have an influence on health and 
disease risk, and it has been estimated that nutritional and dietary factors 
influence 20-60% of cancers worldwide (24, 26).  For example, dietary fiber and 
phytochemicals, such as indoles in cruciferous vegetables and allyl sulfides in 
garlic, are components in certain foods that have potentially important 
chemoprotective effects (24).  Subjects whose diets are high in certain fruits and 
vegetables that contain substances with potential anticarcinogenic activity, 
including folate, carotenoids, flavonoids, vitamins, isothiocyanates, 
dithiolthiones, glucosinolates, allium compounds, and limonene, have a lower 
risk of most cancers (26).  See Table 2 for the relationship of several dietary 
factors with the risk of major cancers.  Epidemiological, clinical, and laboratory 
studies provide substantial evidence suggesting that nutritional and dietary 
factors not only influence risk for development of cancer, but also prognosis after 
diagnosis and quality of life during cancer treatment (24).  
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Table 2. Relationship of dietary factors with risk of major cancers: (+) 
indicates an increased risk, (-) indicates a decreased risk (Data modified 
from (26)). 
 
Diet Breast Pancreatic Lung Colorectal Endometrial Prostate
Foods
Red or processed meat + + + +
Fruits - - - - - -
Vegetables - - - - -
Nutrients
Folate -- - --
Alcohol ++ ++
Calcium - +
Carotenoids
Vitamins - - -
Macronutrients/energy balance
Obesity ++ + ++ ++
Glycemic index/glycemic load + + ++ + +
Fat/refined carbohydrates + + +  
 
 
 
Furthermore, weight/obesity, exercise/physical inactivity, tobacco, 
alcohol, occupation/work environment, and exposure to estrogens also play an 
important role in cancer risk and prevention (26, 27).  For example, in the US, 
smoking is the cause of death in more than 440,000 smoking related diseases, 
30% of cancer deaths, and as many as 80% of lung cancers (27).  Positive 
associations have been reported between renal cell carcinoma (RCC) and 
cigarette smoking, obesity, diabetes, and hypertension (28).  There is convincing 
evidence of moderate to small protective effects of physical activity for colon 
cancer and breast cancer, respectively (27, 29), as well as evidence that obesity  
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has a large to moderate effect on various cancers and may account for about 
10% of breast and colorectal cancers, and 25-40% of kidney, esophageal, and 
endometrial cancer (27).  Lifetime exposure to both endogenous and exogenous 
estrogens increases the risk of hormone-dependent cancers such as breast, 
endometrial, and uterine cancer. 
There are important interactions between environmental and genetic 
factors that contribute to the risk of disease.  Gene variants may not cause 
disease, but they can make an individual more susceptible to carcinogenesis.  
Genes involved in metabolic activation, detoxification, or elimination of 
carcinogens, DNA repair, chromosome instability, activity of tumor suppressor 
genes or oncogenes, cell cycle control, signal transduction, hormone 
metabolism, vitamin metabolism, immune function, and receptor action can all 
potentially influence susceptibility to dietary and other environmental exposures 
(Figure 4) (24).   
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Figure 4. Biotransformation enzyme systems (Adapted from (24)). 
 
 
A balance of enzyme expression levels and potential gene polymorphism 
may account for propensity or sensitivity to carcinogens (30).  For example, 
polymorphisms exist in the genes for drug-metabolizing enzymes.  Phase I 
enzymes, such as cytochromes P450, which are coded by CYP genes, catalyze 
oxidation of endogenous compounds like steroid hormones and vitamin D 
metabolites and of exogenous xenobiotics such as drugs and carcinogens.   
Polymorphic CYP genes in the general population result in differences in 
the ability to oxidize substrates, resulting in enhanced metabolism of some 
carcinogens to more activated carcinogenic intermediates.  CYP1A1 
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metabolizes polycyclic aromatic hydrocarbons such as benzo[a]pyrene, a 
carcinogenic substance contained in tobacco smoke.  Increased lung cancer risk 
in smokers has been associated with certain CYP1A1 polymorphisms: the 
homozygous CYP1A1 MspI genotype and CYP1A1*2 alleles are associated with 
increased lung cancer risk (31).  A significant association of the CYP1A1*2C 
allele with esophageal cancer in smokers has been reported as well as 
CYP1A1*2A or CYP1A1*2B alleles with increased risk of developing leukemia 
(31). 
Diet also affects endogenous substrates of CYPs which may be a key to 
preventing some cancers (24).  The activities of CYPs can be inhibited by 
dietary constituents, such as naringenin, a dietary flavonoid in grapefruit juice 
(24).  CYP1A1 is induced by indole-3-carbinol found in many vegetables and 
results in increased estradiol 2-hydroxylase activity in humans.  2-Hydroxylation 
converts estradiol (E2) to less potent metabolites; 2-hydroxy-E2 (2-OH-E2) can 
subsequently be metabolized to 2-methoxyestradiol (2-MeO-E2) by catechol-O-
methyltransferase (COMT).  
2-MeO-E2 may reduce the risk for estrogen-related cancers, such as 
breast and endometrial cancer, due to its ability to inhibit proliferation of several 
cell types and because it has antitumorigenic and antiangiogenic properties.  
Furthermore, methoxyestrogens can inhibit CYP1B1 activity leading to 
decreased formation of 4-OH-derived quinones and semiquinones which have 
high carcinogenic potential.  Quinones are reactive metabolites capable of 
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forming DNA adducts, and redox cycling between quinones and semiquinones 
generates reactive oxygen species that can result in DNA damage (32).   
Phase II or conjugating enzymes, such as glutathione S-transferases 
(GSTs), N-acetyltransferases (NATs), microsomal epoxide hydrolase, 
sulfotransferases, and UDP-glucuronosyl-transferases, catalyze detoxification 
reactions.  GSTs play a crucial role in conjugation of reduced glutathione to 
electrophilic compounds formed by P450s.  Electrophiles can bind to DNA 
forming adducts which can potentially result in DNA mutations.  Thus, GSTs 
protect cells from these reactive compounds, and phytochemicals, including 
indole-3-carbinol and sulforaphane in cruciferous vegetables, that induce GST 
activity can result in overall decreased susceptibility to cancer.   
GSTs catalyze conjugation of GSH with epoxides, quinones, and 
polycyclic aromatic hydrocarbons, common carcinogens found in tobacco smoke 
and food.  However, impaired detoxification may increase susceptibility for 
development of cancer.  Genetic polymorphisms in GSTs have been identified, 
and some of these have been correlated with a higher risk for several types of 
cancer (24): GSTM1-null genotypes confer a higher risk of bladder and lung 
cancers (33).  Combination of high-risk alleles for GSTT1 and GSTM1 and 
heterozygous or homozygous for the GSTP1 valine substitution increase breast 
cancer risk almost four-fold (34).  
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1.2. Breast cancer 
1.2.1. Statistics/ risk factors/ genetics  
There are about 1.15 million new cases of breast cancer worldwide each 
year (1).  Breast cancer is not only the most common cancer in women but is 
also the most prevalent cancer in the world and accounts for more than 20% of 
cancers worldwide (1, 35).  In the last twenty years, the death rate from breast 
cancer in the US and Europe has declined due to advances in early detection, 
diagnosis, and treatment (1, 35, 36); however, about 411,000 women died from 
breast cancer in 2002 (1). 
Factors associated with the risk of breast cancer include weight/ obesity, 
lack of exercise, diet/ nutrients (phytoestrogens/ flaxseed), and alcohol intake 
(37).  Women reporting moderate to vigorous physical activity for 7 or more 
hours per week had a 20% lower risk of developing breast cancer than those 
who exercised less than 1 hour per week (38).  Increased risk for breast cancer 
is associated with alcohol use, intake of red meat, and an energy-dense diet rich 
in fat/ low complex carbohydrate, whereas intake of carotenoids, folate, soy 
(phytoestrogens), and other phytochemicals are associated with a decreased 
risk of breast cancer (29, 36, 37, 39-42).  Areas where the diet is high in 
consumption of soy and flaxseed show a lower breast cancer rate (37, 41, 42).  
Many foods in our diet, such as fruits, vegetables, and tea, contain compounds 
that prevent cancer.  For example, broccoli contains sulforaphane, grapes have 
resveratrol, soy has genistein, tumeric contains curcumin, and green tea 
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contains epigallocatechin-3-gallate (EGCG) (30), and all these compounds 
inhibit cancer formation/growth in animal models.   
Breast cancer is a hormone-dependent disease, and exposure to 
estrogens over a lifetime plays a role in breast cancer risk (36, 37).  It is well 
established that reproductive factors are associated with breast cancer risk, and 
these include early age at menarche, late age at menopause, and late first 
childbirth, as well as shorter duration of breast-feeding (36, 37, 43, 44).  The 
effect of using oral contraceptives on breast cancer risk is not yet clearly 
established.  One study showed a small increase in risk with long-term use of 
oral contraceptives; however, other studies have shown no association with 
breast cancer risk and oral contraceptive use (36).  In 1986, the Nurses’ Health 
Study showed no long-term adverse effect for past oral contraceptive users, but 
a modest risk increase for current users; over 50 separate epidemiological 
studies have confirmed this finding (29).   
Hormone replacement therapy has been associated with an increased 
risk of breast cancer, especially with long-term use (37, 45, 46).  In 1995, the 
Nurses’ Health Study published a report stating that the duration of 
postmenopausal hormone use was associated with increased breast cancer risk 
(29).  For current users with 5 years of use, the risk of using estrogen alone was 
1.2 versus 1.7 for using estrogen combined with progestin (29).  Several studies 
have confirmed that combined estrogen-progestin therapy increases the risk of 
breast cancer more than estrogen alone (Table 3) (29, 47).    
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Table 3. Relative risk of breast cancer associated with hormone 
replacement therapy (Adapted from (47)). 
 
 
 
Another risk factor for breast cancer is family history and genetics.  
Family history, specifically mutations in the BRCA1 and BRCA2 genes, accounts 
for about 5-10% of all human breast cancers (36).  BRCA1 suppresses 
estrogen-dependent transcriptional pathways that regulate the proliferation of 
breast epithelial cells.  Mutation of BRCA1 results in the loss of this ability to 
regulate proliferation, thus contributing to tumorigenesis (37, 48).  Other genes 
associated with a predisposition to breast cancer are CHEK-2, a gene involved 
in DNA repair, and ATM, a gene encoding a putative protein kinase.  Mutations 
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in CHEK-2 are found in 1% of breast cancers, and two mutations in ATM are 
associated with a 16-fold increased risk of breast cancer (36, 49).   
Furthermore, there is epidemiological evidence that indicates a role of 
metabolic factors in breast cancer risk.  Glucose metabolism, hyperinsulinemic 
insulin resistance, and insulin-like growth factor bioavailability may play a role in 
breast cancer (50).  Insulin is not only a strong mitogenic agent that induces 
growth of breast cancer cell lines, but it also stimulates production of androgens 
in ovarian tissue (50, 51).  IGF-1 is a mitogenic and anti-apoptotic protein that 
stimulates cellular responses related to growth, such as DNA, RNA, and protein 
synthesis (50, 52).  IGF-1 increases proliferation of breast epithelial cells, and 
both in vitro and animal data indicate a role for IGF-1 in breast cancer (29, 37).  
To further support the role of these metabolic factors in breast cancer, many 
breast cancer cell lines show increased expression of insulin and IGF-I 
receptors, and an increase in glucose metabolism/ utilization for proliferation is 
characteristic of malignant tissues compared to normal tissue (50).   
 
1.2.2. Role of hormones and growth factors in normal breast development 
Development of human mammary glands is a progressive process, 
involving changes in size, shape, and function that start during embryonic life.  
The main growth occurs with lobule formation at puberty, and only by the end of 
the first full term pregnancy is development and differentiation of the breast 
completed (53).  The ovarian steroids 17b-estradiol (E2) and progesterone (P) 
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are the most important in terms of biological activity and are synthesized from 
the onset of menarche until menopause (53).  These hormones play a significant 
role in breast development; the mammary epithelium undergoes extensive cell 
proliferation during puberty and again during early pregnancy.  During other 
stages, the mammary epithelium responds to ovarian hormone levels that 
fluctuate during the menstrual cycle (53).  These hormonal fluctuations cause 
small changes in proliferation and apoptosis in the mammary epithelium (54).  
See Figure 5 for a diagram of the human breast.  
 
 
 
 
Figure 5. Structure of the female breast (American Cancer Society, 2005). 
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The steroid hormones, E2 and P, promote proliferation and differentiation 
in normal breast epithelium through binding to their respective receptors and 
regulate target gene expression (54).  Through the estrogen receptor (ER), E2 
mediates transcription of various genes to modulate physiological processes, 
including development and function of reproductive organs, and bone density 
(55).  Classical targets for estrogens are organs that function in sex and 
reproduction such as the breast, uterus, vagina, and ovaries.  Endothelial cells 
have recently been identified as targets for estrogens; expression of low levels 
of functional ER have been shown in endothelial cells from vasculature, and 
expression of ER is upregulated upon treatment with E2 (56).  Furthermore, E2 
induces endothelial cell proliferation and migration mediated by the classical ER 
(57). 
Steroid hormone receptors can also integrate with other signaling 
pathways (Figure 6).  For example, the downstream effects of cell surface 
receptors can result in phosphorylation of ER, thus activating ER in the absence 
of ligand, or alternatively, steroid hormone receptors can modulate the activity of 
signaling proteins, such as c-src (54).  Most growth factors, including EGF, 
TGFa, and IGF, stimulate proliferation and differentiation of mammary epithelial 
cells (58), and they play pivotal roles in the growth and development of the 
mammary gland.  There is growing evidence of cross-talk between nuclear 
steroid hormone receptors such as ER and signaling pathways such as IGF in 
mammary gland cell proliferation (58).  Both E2 and IGF stimulate proliferation, 
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and E2 not only increases mRNA and protein expression of IGF-1 and IGF-1R, 
but E2 also enhances IGF signaling (58).  ER is transcriptionally activated by 
survival factors such as IGF and epidermal growth factor (EGF), and E2 in 
combination with IGF or EGF synergistically stimulate mammary cell proliferation 
(58).     
 
 
 
Figure 6. Crosstalk mechanisms between ERa , growth factor receptors 
and their intracellular kinase cascade signaling pathways. Membrane ER 
can interact with and activate intracellular signaling pathways, or nuclear 
ERa can be activated by growth factor signaling pathways.  
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Steroid hormone receptor expression in the normal human mammary 
gland has been primarily studied in women who are not pregnant or lactating.  
ERa is expressed in approximately 15-25% of luminal epithelial cells that are 
scattered throughout the mammary epithelium and are not expressed in other 
cell types (54, 59).  ERb is present in most luminal epithelial cells and 
myoepithelial cells and is detectable in fibroblasts and other stromal cells in the 
normal human mammary gland (60).  In the normal human breast, progesterone 
receptor (PR) is expressed in a small percentage of cells which are also 
scattered throughout the luminal epithelium in a pattern similar to that observed 
for ERa expression (54).  Immunofluorescence has been used to show that all 
the cells in the luminal epithelium that express PR also express ERa (54), and 
the two isoforms of PR, PR-A and PR-B, are expressed in comparable amounts 
in normal mammary epithelium (61).   
In the normal human breast, cells expressing ERa or PR are not actively 
proliferating cells although they are often adjacent to proliferating cells (54).  The 
separation of steroid hormone receptor-expressing cells from those cells that are 
proliferating has been confirmed in human breast and in mouse or rat mammary 
glands (62).  This implies that receptor containing cells act as “sensors” that 
respond to steroid hormone concentrations and induce secretion of growth 
factors that influence the activity of adjacent/ neighboring proliferating cells 
(Figure 7) (54).   
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Figure 7. Growth factor stimulation of proliferation (Adapted from (63)). 
 
 
To study the normal functions of ERa and ERb genes during 
development and maturation, knockout mouse models have been utilized.  
Knocking out either ERa and/or ERb in mice is not lethal (64).  ERa knockout 
mice (aERKO) do not exhibit abnormal external phenotypes, but defective 
phenotypes occur in the uterus and the mammary gland, and to a lesser extent 
in the ovary (64, 65).  aERKO mice also show altered sexual behavior and are 
infertile (64-66).  Adult aERKO mice have mammary glands that look similar to 
those of prepubescent female mice, indicating that for glands to become fully 
differentiated, ERa is required (67).   
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ERb knockout mice (bERKO) have the most obvious phenotype defects in 
the ovary, whereas mammary gland structure is normal (66).  Sexual behavior in 
bERKO mice appears normal (68).  However, bERKO females have fewer litters 
and fewer pups per litter, thus, knocking out ERb reduces fertility (64, 66).   Mice 
with both ERa and ERb knockouts (abERKO) also survive to adulthood and 
exhibit no abnormal external phenotypes; however, these mice are infertile (69).   
 
1.2.3. Role of hormones in breast cancer 
While many steroid hormones regulate breast development, these same 
hormones play a role in both development and growth of breast cancer, and an 
increase in breast cancer risk results from lifetime exposure to estrogens 
associated with early menarche, late pregnancy, late menopause or decreased 
with early menopause or late menarche (37).  Correlations between reproductive 
history and risk for breast cancer support the idea that female hormones act as 
tumor promoters.  Therefore, using drugs such as tamoxifen, an estrogen 
antagonist, prevents or delays recurrence of breast cancer (4).  Hormones 
presumably affect the incidence of breast cancer by influencing cell proliferation 
in the breast; estrogens promote the development of mammary cancer in 
rodents and have proliferative effects on cultured human breast cancer cells (37, 
70). 
High levels of both estrogens and androgens (i.e., testosterone) are 
positively associated with increased breast cancer risk (29, 71, 72).  Although 
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postmenopausal ovaries produce a small amount of estrogen, circulating 
estrogens may act directly on breast tissue and breast cancer cells, while serum 
androgens may be aromatized into estrogens within breast tissue and breast 
cancer cells (50, 73).  Prolactin, an endogenous hormone, may enhance breast 
cancer risk by increasing cell proliferation and survival as well as promoting cell 
motility (74). 
ER and PR expression in mammary tumors are predictive for their 
positive response to hormone therapy; they also can predict sensitivity or 
resistance to specific treatments.  For example, ER(+) tumors respond well to 
endocrine therapy with a good prognosis (75).  About 75% of primary human 
breast cancers are ER(+) when diagnosed (76), whereas only 7-17% of normal 
human breast epithelial cells are ER(+) (70).  Most proliferating cells in the 
normal breast are ER(-), and estrogen induces proliferation through paracrine 
pathways; however, many proliferating cells in ER(+) breast tumors express ER 
and estrogen directly induces proliferation (70).   
In the normal rat and human mammary gland, as well as in benign breast 
disease, ERb is predominant, but the ratio of ERa to ERb changes during 
carcinogenesis where ERb mRNA expression is downregulated and ERa mRNA 
is upregulated (77, 78).  Also, most breast tumors express lower ERb than 
ERa (78, 79) whereas animals with reduced breast cancer risk have higher 
levels of ERb in the mammary gland (77). 
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About 10-20% of epithelial cells of normal breast tissue express PR. 
However, in benign, premalignant, or malignant breast lesions, more than 70% 
of cells are PR(+) (61).  PR(+) breast cancers are usually smaller, less 
proliferative, more differentiated, and correspond to a more favorable prognosis 
and better response to endocrine therapy (61).  Furthermore, postmenopausal 
women with primary breast cancers that are PR(-) have tumors that are more 
likely to progress to secondary sites (61).  Although the PR-A and PR-B forms of 
PR are expressed in comparable amounts in normal mammary epithelium, in 
tumors, the ratio often favors PR-A (61).  
 
1.2.4. Treatment of breast cancer 
 More than 100 years ago, George Beatson showed that metastatic breast 
cancer could be forced into remission by removal of the ovaries in 1 out of 3 
women (59, 80).  In the mid-20th century, diethylstilbestrol (DES), a synthetic 
estrogen, was used as an effective treatment for breast cancer, especially in 
postmenopausal women where response rates were 20-40% (63, 80).  See 
Figure 8 for the chemical structures of selected ER ligands. 
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Figure 8. Chemical structures of selected ER ligands: E2, DES, raloxifene, 
4-OH-tamoxifen (Adapted from (55)). 
 
 
In the 1970s, the drug tamoxifen became the most widely prescribed 
endocrine treatment for breast cancer: tamoxifen is an antiestrogen, or selective 
estrogen receptor modulator (SERM) (Table 4), that decreases breast cancer 
proliferation rates and increases cell death in vivo for ER(+) cases, and this drug 
has decreased the rate of breast cancer mortality since the mid-1980s (63).  
Tamoxifen exhibits both antiestrogenic effects as well as partial agonist 
properties in the uterus resulting in increased risk of endometrial carcinoma 
which is a major adverse side-effect associated with prolonged treatment with 
tamoxifen (80).  Other side-effects of tamoxifen include increased risk of 
thrombosis, hot flashes, and depression, but because tamoxifen acts as an 
estrogen, it has beneficial effects on bone and lipid levels (80).  
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Table 4. Examples of breast cancer therapies and their mechanisms of 
action (Data modified from (81)). 
 
Breast cancer therapies Mechanism of action Direct result
SERMs block binding of E2 to ER attenuate transcription of 
some E2-sensitive genes
Aromatase inhibitors compete with androgen block synthesis of E2
for aromatase binding 
site on aromatase enzyme
Faslodex (ICI 182,780) bind to ER blocking E2 no ER dimer formed: 
target ER for degradation or 
abrogate transcription of
E2-sensitive genes
 
 
 
Research shows that 50-60% of women with ER(+) tumors responded to 
endocrine therapy, while only 5-10% of ER(-) tumors regressed with this 
treatment (75).  In a study comparing tamoxifen to placebo, tamoxifen increased 
survival in patients with ER(+) tumors, but had little benefit for patients with   
ER(-) breast cancer, while patients who had ER(-), PR(+) tumors benefited from 
tamoxifen treatment more than patients with ER(-), PR(-) tumors (82).  Also, in 
ER(+), PR(+) breast tumors, 70-80% regressed with endocrine therapy (75). 
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Unfortunately, most patients with a tumor that initially regresses after 
treatment with tamoxifen will eventually have a resistant tumor recur (55, 83).  
Loss of ER does not account for tamoxifen resistance because most of these 
tumors have a functional ER (55).   Levels of ERb mRNA are elevated in 
tamoxifen resistant tumors (83).  Resistance to tamoxifen could be explained by 
numerous potential mechanisms including increased local metabolism of 
tamoxifen to less potent or unstable metabolites, mutations in the ER, 
modulation of coregulator expression and recruitment, or interactions with other 
signaling pathways.  The precise mechanisms of tamoxifen resistance are 
unknown and require further investigation (55, 83, 84). 
2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-
dimethylethylamine citrate (toremifene), 3-OH-tamoxifen (droloxifene), and 
methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-
piperidinyl) ethoxy] phenyl]-, hydrochloride (raloxifene) represent a new 
generation of antiestrogens that have been developed to circumvent the adverse 
side effects of tamoxifen while retaining the benefits (80, 85, 86).  The pure 
antiestrogen ICI 182,780 (Faslodex) (Table 4) does not exhibit estrogenic 
activity and can be used in cases when tamoxifen has failed (80, 81).  Other  
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drugs that inhibit estrogen synthesis, such as specific aromatase inhibitors 
anastrozole and letrozole, have recently been shown to be more effective than 
tamoxifen in treating breast cancer (Table 4) (75, 87, 88).  For example, 
anastrozole and letrozole, as well as exemestane, a steroidal aromatase 
inactivator, are strong and highly specific inhibitors of the cytochrome P450 
enzyme, aromatase, resulting in efficient blockage of the conversion of 
androgens to estrogens in breast tissue (86).  These aromatase inhibitors offer a 
promising new therapeutic strategy for treatment of ER(+) breast cancer. 
Although endocrine therapy/antiestrogen treatment is well developed and 
successful for treating ER(+) breast tumors, endocrine therapy is not effective 
for treating ER(-) breast cancer.  Patients with ER(-) breast tumors are primarily 
treated with cytotoxic drugs and the overall prognosis is poor.  New mechanism-
based drugs, such as Herceptin for EGFR (74), may provide alternate strategies 
for future therapeutic treatment of human breast cancers.
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1.3. Pancreatic cancer 
1.3.1. Statistics/ genetics/ risk factors  
Approximately 202,000 new cases of pancreatic cancer occur worldwide 
every year and pancreatic cancer is the 4th most common cause of cancer 
deaths in the US (2, 89, 90).  In the US, there are nearly 30,000 newly 
diagnosed cases of pancreatic cancer every year and almost the same number 
of fatalities (2, 91, 92).  Pancreatic cancer is one of the most lethal human 
cancers (91) with a very low survival rate; about 99% of these cases will develop 
metastases and death (91, 93), and this cancer is the most lethal of the GI 
malignancies (2).  The overall one-year survival rate after diagnosis is less than 
20%, and after 5 years, only 1-3% (90, 93, 94). 
The incidence rate of pancreatic cancer has either remained constant or 
decreased slightly in the past 25 years in the US, while a rise in frequency has 
been seen in Japan and almost all European countries (93).  Although no 
specific industrial cause has been found, pancreatic cancer is still more common 
in Western industrialized countries than in less developed nations (93).  
Furthermore, pancreatic cancer incidence rates for Japanese emigrants to the 
US are higher than those in Japan and are even higher than among white 
Americans (93). 
There are a variety of risk factors associated with pancreatic cancer 
including genetics and medical history (2).  Of patients with primary cancer of 
the breast, colon, lung, kidney, and skin, 3-12% exhibit metastasis in the 
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pancreas (95).  Family history of pancreatic cancer, hereditary syndromes, such 
as pancreatitis, non-polyposis colorectal cancer, and familial breast cancer, as 
well as other genetic syndromes (i.e., Peutz-Jeghers syndrome (PJ), multiple 
colonic adenomas in familial adenomatous polyposis (FAP), and familial atypical 
multiple-mole melanoma (FAMMM)) are associated with an increased risk of 
pancreatic cancer (2, 91, 93, 96-99).  An estimated 10% of patients with 
pancreatic cancer have one or more first or second-degree relatives with 
pancreatic cancer (2).  There is an 18-fold increased risk of pancreatic cancer in 
families with at least 2 first-degree relatives with pancreatic cancer (100).  See 
Table 5 for examples of genetic disorders and their associated risk of pancreatic 
cancer. 
 
 
 
Table 5. Genetic disorders and germline genetic alterations associated 
with familial pancreatic cancer (Data modified from (100)). 
 
 36 
The role of diabetes in pancreatic cancer has been examined since 
diabetes mellitus frequently accompanies pancreatic cancer (93).  Up to 80% of 
pancreatic cancer patients are also diabetic or have impaired glucose tolerance 
at the time of diagnosis (2).  Recent research indicates diabetes is an indicator 
of pancreatic dysfunction and may be an underlying cause of pancreatic cancer 
in long term diabetics (93).  However, results from one study indicate that 
diabetes may play a role in non-familial pancreatic cancer but is less prevalent in 
cases of familial pancreatic cancer (93). 
Other risk factors for pancreatic cancer such as age and cigarette 
smoking are consistently reported (91).  Advanced age is a major risk factor for 
pancreatic cancer (onset of the disease within the seventh and eighth decades 
of life) (2, 101).   Eighty percent of diagnosed cases of pancreatic cancer are in 
people between the ages of 60 and 80; people under age 25 rarely have this 
disease, and it is relatively uncommon in those under age 45 (93).  Cigarette 
smoking is the most reproducible and significant environmental factor associated 
with a 1.5 to 5.5-fold increase in pancreatic cancer risk (2).  Often, interactions 
between two or more of these risk factors result in an even higher risk: studies 
have shown persons with pancreatitis who also smoke are 50 to 154 times more 
likely to have pancreatic cancer and the occurrence of this disease is 
approximately 20 years sooner than for individuals who do not smoke (2). 
There is also evidence that genetic variability in DNA repair and 
carcinogen metabolism genes affects susceptibility to carcinogen exposure and 
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risk for pancreatic cancer (91).  Studies involving polymorphisms in genes 
involved in metabolism and detoxification of carcinogens and DNA repair show 
an increase in risk of pancreatic cancer for smokers (91).  For example, 
significant association between cigarette smoking and the GSTT1 null genotype 
is reported in pancreatic cancer (102).   
Pancreatic cancer is more common in males than in females, is slightly 
more common in Jewish people, and mortality is highest in blacks (91, 93).  
Single rather than married individuals have a greater risk of developing 
pancreatic cancer, regardless of age or sex, although no definitive explanation 
has been found (93).  Also, as in breast cancer, environmental/ lifestyle factors, 
including diet, obesity, and physical activity and occupational exposures, are all 
associated with an increased risk of developing pancreatic cancer (91).   
Positive associations have been noted between pancreatic cancer and dietary 
intake of fat and oil, meat, and dairy products, as well as high intake of fried 
foods, carbohydrates, cholesterol, and salt (93).  Consumption of fresh fruits, 
vegetables, fiber, natural foods, and vitamin C is associated with a decreased 
risk of pancreatic cancer (93).   
 
1.3.2. Disease model involving stepwise gene mutations 
Pancreatic cancer is a multistage process resulting from the accumulation 
of genetic changes in the DNA of normal cells which lead to disturbance of cell 
cycle regulation and continuous growth (103).  In fact, most pancreatic cancers 
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have accumulated multiple mutations and abnormalities such as overexpression 
of receptor-ligand systems, oncogene activation, loss of tumor suppressor 
genes, and dysfunctional genomic maintenance genes (103, 104).  These 
multiple genetic changes and the functional consequences of these changes 
result in aggressive growth and rapid early spread of pancreatic cancer (92, 
105).  At a very early stage of development, 85 to 90% of pancreatic cancers 
have an activating point mutation at codon 12 in the K-ras oncogene (Figure 9) 
(91, 106, 107).   
 
 
 
 
Figure 9. Genetic profile of pancreatic intraepithelial neoplasia (PanIN) 
progression model. 
 
 
Frequent genetic alterations in pancreatic tumors include mutations in K-
RAS (oncogene), CDKN2A (Ink4A & ARF), TP53, and DPC4/SMAD4/MADH4 
(tumor suppressors), followed by less frequent/rare mutations in BRCA2 (tumor 
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suppressor), AKT2, and LKB1/STK11 (mismatch repair genes and serine-
threonine kinases) (103, 108).  The tumor suppressor gene most often 
inactivated in pancreatic cancers is p16 (inactivated in 90-95%) (91, 107).  TP53 
is the second most frequently inactivated tumor suppressor gene (inactivated in 
50-75%), followed by others such as DPC4/SMAD4/MADH4 gene (inactivated in 
55%), and BRCA2 (inactivated in about 7%) (Table 6) (91, 103, 107).  
 
 
 
Table 6. Genetic alterations in pancreatic cancer (Data modified from (103, 
107, 108)). 
 
Gene Frequency (%) Alteration Appearance
Oncogenes
K-ras 90-95 activation mutation early
AKT2 ~15 amplification
CDKN2A(Ink4A & ARF) 95 mutation, silencing middle
Tumor-suppressor genes
p16 95 inactivation mutation middle
p53 50-75 inactivation mutation late
DCP4/SMAD4/MADH4 55 inactivation mutation late
BRCA2 7 inactivation mutation late
LKB1/STK11 5 inactivation mutation
MKK4 4 inactivation mutation
ALK4 ~2 inactivation
Genome maintenance genes
MSH2 4 mutation
MLH1 ~3 silencing
Receptors/signaling genes
TGFBRs ~3 underexpression
ErbB2/Her2/neu 82 overexpression early  
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Recent research indicates that pancreatic cancer involves mutation and 
activation of oncogenes and inactivation of tumor suppressor genes as well as 
abnormalities in growth factors and their receptors affecting downstream signal 
transduction pathways that control growth and differentiation (91).  Pancreatic 
cancers overexpress several growth factors and receptors such as VEGF, FGF, 
EGFs, as well as many cytokines including TGFb, IL-1, IL-6, IL-8, and TNFa (91, 
109-111).  Upregulation of growth-promoting factors and decreased expression 
of growth-inhibitory factors results in decreased apoptosis and cells which 
exhibit upregulation of growth signals, angiogenesis, and metastasis (91). 
 
1.3.3. Treatment of pancreatic cancer 
Life expectancy for patients diagnosed with pancreatic cancer is usually 
in months.  This poor prognosis for pancreatic cancer patients is due to three 
main factors: namely metastasis of the tumor to distant sites, increased 
morbidity as the disease progresses, and resistance to most forms of cancer 
chemotherapy (91).  However, another complicating factor in treatment of 
pancreatic cancer is that reliable diagnosis of this disease is not possible based 
on signs or symptoms alone (2).  Many early symptoms are general complaints 
and are often confused with other illnesses, e.g., stomach pain, nausea, loss of 
appetite, insomnia, and overall poor health (2).  Therefore, most patients already 
have metastases when diagnosed due to the fact that early stages of pancreatic 
cancer are not readily detected or diagnosed (112). 
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Less than 20% of patients present early enough for curative surgical 
resection (2).  Prognostic factors for pancreatic cancer patients include surgical 
margin status, nodal status, and tumor size (91).  If angiogenesis, metastasis, or 
node involvement has occurred, patients usually have less than 1-year survival 
rate, and surgery alone provides no better prognosis (2).  Therefore, approaches 
such as surgery, radiation, chemotherapy, or combinations of these treatments, 
have had only a minor impact on the course of this disease (91).  Adjuvant 
fluorouracil-based chemoradiation is frequently recommended for resectable 
pancreatic cancer in the US (91).  The overall 5-year survival rate is around 20% 
after surgery (113), but in this subset of patients, survival can be increased to 
55% with an interferon-based adjuvant chemoradiation regimen (2, 114).  
Unfortunately, by the time of diagnosis, more than 80% of patients have 
tumors that are unresectable (2).  Few options exist for patients who present 
with locally advanced or metastatic pancreatic cancer.  However, recently, 
locally advanced, unresectable pancreatic cancers that do not show signs of 
distant metastasis are typically treated with fluorouracil-based chemoradiation 
(100).  Combining external-beam radiation with 5-fluorouracil (5-FU) doubles the 
survival time from about 23 weeks to 42-44 weeks compared to radiation alone 
(Figure 10) (91, 113, 115).   
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Figure 10. Schematic illustration contrasting preoperative and 
postoperative chemoradiation (115). 
 
 
To date no single-agent chemotherapy provides a substantial 
improvement in survival for patients with unresectable tumors; however, 
gemcitabine is currently the most promising chemotherapeutic agent for treating 
metastatic pancreatic cancer.  Although it only modestly improves survival, it is 
highly effective for improving the patient’s quality of life (2).  Patients treated with 
gemcitabine had a median survival time of 5.6 months, which is slightly longer 
than the 4.4 months for those patients treated with fluorouracil (91, 113).  More 
significantly, symptoms such as pain and weight were improved with 
gemcitabine vs fluorouracil (91).  Currently, gemcitabine is standard treatment 
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for patients with metastatic pancreatic cancer and is associated with a 1-year 
survival advantage of 18% vs 2% for fluorouracil (91).   
Preliminary data on the use of gemcitabine combined with radiation 
therapy look promising, and novel therapies such as tyrosine kinase inhibitors, 
antiangiogenic agents, farnesyl transferase inhibitors, and gene therapy are 
being developed (115-117).  New approaches in pancreatic cancer treatment 
are to target components of the tumor microenvironment and signaling pathways 
to specifically inhibit tumor growth and metastasis or to increase antitumor 
immunity to antigenic targets (100).  For example, targets in the tumor 
microenvironment include matrix metalloproteinases (MMP), which are 
overexpressed and facilitate early pancreatic tumor invasion and metastasis, 
and pancreatic cancer associated genes that are linked to angiogenesis, such 
as VEGF or K-ras (100).  Furthermore, identification of signaling pathways that 
are specifically upregulated in pancreatic cancer, such as the K-ras signaling 
pathway, could provide even more potential targets for pancreatic cancer 
therapy (100).  Clinical testing on vaccine and antibody therapies that target 
tumor antigens associated with pancreatic cancer produce minimal toxicity but 
minimal improvements in clinical response; yet synergistic activity between 
immune-based therapy and other cancer treatment strategies (surgery, 
radiation, and chemotherapy) has been noted (118).   
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1.4. Gene transcription 
1.4.1. Importance in cancer 
 Since cancer is a genetic disease that involves multiple steps in the 
process of tumorigenesis including alteration in activities of regulatory genes, 
cell cycle, and germline mutations, determining selected transcriptional 
mechanisms may facilitate understanding of cancer development and 
development of new and more effective treatment strategies.  For example, 
BRCA1 is involved in various transcriptional activation or repression processes, 
apoptosis, maintenance of genome stability, and interaction with complexes for 
DNA recognition and repair.  It is known that BRCA1 mutations are associated 
with breast and ovarian cancer and that many cancer therapies are based to 
some extent on inhibiting transcription of this and other specific genes (119).  
 
1.4.2. Gene promoters/ basal transcription machinery/ activation of transcription 
 The basic structure of eukaryotic promoters is divided into core elements 
and regulatory elements, and only minimal transcriptional activity is evident in 
the core promoter region.  In fact, DNA regions, at sites distant from the core 
promoter, regulate activity and provide binding sites for regulatory transcription 
factors (TFs) (120).  The core promoter includes the site for assembly of the 
preinitiation complex (PIC) and a TATA sequence, located upstream of the 
transcription start site.  The TATA sequence is the binding site for TATA binding 
protein (TBP).  TBP is a transcription factor required for initiation of transcription 
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by RNA polymerase II (RNAP II) and is required for expression of most, if not all, 
genes in vivo.  Some promoters have an initiator sequence (Inr), alone or along 
with a TATA element, which encompasses the start site (120, 121). Downstream 
promoter elements (DREs) often function in conjunction with the Inr in TATA-
less promoters (121).   
The regulatory elements are located upstream of the core promoter and 
are gene specific sequences that control the rate of transcription initiation.  
Regulatory elements include upstream activation sequences (UAS) and 
upstream repression sequences (URS), where transcriptional enhancers and 
repressors bind.  Regulatory DNA elements do not effect transcription by 
themselves, but serve as binding sites for a diverse group of DNA-binding 
proteins, TFs.  Numerous transcription factors binding together at the same time 
are believed to effect transcription (120).   
 General transcription factors (GTFs), including TBP, TFIIB, TFIIE, TFIIF, 
and TFIIH, are required for basal-level transcription initiation by RNAPII which 
requires the assembly of the GTFs at the promoter to form a PIC (Figure 11) 
(122).  At most promoters, TFIID binds to the TATA box.  TFIID is a multi-subunit 
factor composed of TBP and TBP-associated factors (TAFs).  TFIIA and TFIIB 
then join the complex providing a platform for recruitment of RNAPII and TFIIF.  
TFIIE and TFIIH join to complete the PIC (121, 122).   
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Figure 11.  Idealized model for transcription initiation from core promoters 
containing TATA or Inr elements (123). 
 
 
This large multisubunit enzyme, RNAPII, is responsible for transcribing 
nuclear genes encoding messenger RNAs and several other small nuclear 
RNAs but does not identify the promoter and begin transcription by itself (124).  
Instead, RNAPII relies on GTFs, transcriptional activators, and coactivators to 
regulate transcription.  Activators increase the rate and extent of PIC formation.  
Activation domains can interact with several target factors within the TFIID 
complex including TBP and TAFs (122).  These transcriptional activator proteins 
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act synergistically, thus, directing a greater level of transcription than would be 
expected from observing the activity of an individual activator (122). 
Coactivators are required for activation of transcription but are not part of 
the basal transcription machinery (Figure 12) (122).  Coactivators of the nuclear 
receptor (NR) superfamily (I) bind to target transcription factors in a ligand-
dependent manner, (II) many are capable of directly interacting with the basal 
transcription machinery, and (III) some exhibit enzymatic function intrinsically 
linked to gene regulation, such as histone acetyl-transferase (HAT) or 
deacetylase (HDAC) activities (125).  They often have transferable 
transactivation or repression domains, and thus, can function by remodeling 
chromatin structure and/or act as bridging molecules between nuclear receptors 
and the basal transcription machinery (125).  Basal transcription can be 
performed on the DNA template by the PIC.  In living cells, DNA is assembled 
into chromatin, impeding assembly of the PIC requiring chromatin to be modified 
before PIC can nucleate at the promoter (122). 
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Figure 12. Coregulators of transcription (125). 
 
 
  Proteins are essentially the functional end products of information stored 
in DNA.  Protein encoding genes are transcribed from DNA to RNA by RNAP; 
primary RNA-transcripts are processed into mRNA which is transported out of 
the nucleus into the cytoplasm where it is translated into a protein product.   
There are three primary domains required for site-specific transcription: a DNA-
binding domain, a nuclear localization signal, and a transcriptional regulatory 
domain (126).  Mechanisms of diseases such as cancer that exhibit deviant 
growth and differentiation patterns are most likely a result of these proteins 
affecting morphogenesis (126).   
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1.4.3. Transcription factors - Sp family 
There are several families of TFs which share the ability to bind specific 
sequences on DNA promoters or enhancers through the presence of a DNA 
binding domain (DBD) and have in common the presence of a transactivation 
domain involved in modulation of the transcriptional activity of the target 
promoter (120).  TFs interact directly with subunits of the transcription 
machinery, and this causes a conformational change, increases transcriptional 
initiation, and enhances recruitment of basal transcription factors to the 
promoter.  TFs can interact with different targets; therefore, simultaneous action 
of TFs can increase transcription synergistically (120).   
Specificity protein 1 (Sp1) is a general transcription factor that binds to 
GC-rich regions of many different gene promoters and activates transcription of 
these target genes.  Sp1 interacts with nuclear proteins including the basal 
transcription machinery (TBP and TAFs) as well as cell cycle regulating proteins, 
such as retinoblastoma-related protein p107, and transcription factors, such as 
YY1 and E2F (127).  Sp1 is implicated in the activation of a large number of 
genes involved in housekeeping, tissue-specific and cell cycle-regulated genes, 
and is required to prevent methylation of CpG islands (127).   
Sp1 is a member of the Sp family of proteins, including Sp2, Sp3, and 
Sp4, which all share similar domain structures, including the characteristic three 
zinc fingers on the C-terminal region that interact with DNA, activation domains, 
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and other common structural motifs (128).  Sp2 is the least well-studied protein 
in the family and is known to bind to GT-rich promoter elements in vitro (127).   
Reports on the transcriptional properties of Sp3 are contradictory.  Sp3 
acts as a transcriptional activator like Sp1 or remains as an inactive or very 
weak activator depending upon the gene promoter and cell context (127).  In 
some cases Sp3 competes for the same binding site as Sp1 and can decrease 
Sp1-mediated activation, and in others, Sp1 and Sp3 cooperatively activate 
expression of some genes.  Currently, it is not understood what experimental 
conditions are needed for Sp3 to act as a strong activator versus a 
transcriptionally inactive protein that represses Sp1-mediated activation.  It is 
possible that the arrangement of the GC-rich promoter sites may determine the 
activity of Sp3.  Promoters containing one GC-rich site are activated, whereas 
Sp3-dependent repression is often observed with promoters containing multiple 
binding sites, and this also is modulated by cell context (127).  Unlike the 
ubiquitously expressed Sp1 and Sp3 proteins, Sp4 expression is restricted 
mainly to the brain and central nervous system.  Furthermore, Sp4 exhibits 
specific functional properties distinct from Sp1 and Sp3 (127).    
 
1.4.4. Nuclear hormone receptors - ER 
The NR superfamily includes receptors for thyroid and steroid hormones, 
retinoids and vitamin D, as well as different “orphan” receptors.  NRs act as 
ligand-inducible transcription factors by directly interacting with DNA response 
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elements of target genes and by crosstalk to other signaling pathways (129).  
NRs are primarily classified by the type of hormone to which they bind.  NRs 
possess a highly conserved DNA binding region which separates the variable 
amino (N-) terminal from the conserved carboxy (C-) terminal region (Figure 13) 
(130).   
 
 
 
 
Figure 13. Nuclear receptor domains (129). 
 
 
NRs regulate transcription of target genes by binding to specific 
sequences of DNA known as hormone response elements (HREs) located in 
regulatory regions of gene promoters.  Two six base pair consensus sequences 
have been identified as the core motifs in HREs recognized by nuclear 
receptors: AGAACA is preferentially recognized by steroid class III receptors, 
and AGG/TTCA is recognized by the remainder of receptors in the superfamily 
(129).  These are idealized consensus sequences, and naturally occurring HREs 
can vary significantly from the consensus.  Most receptors bind as homo- or 
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heterodimers to two core HREs except in the case of steroid hormone receptors 
which predominantly bind as homodimers (129).   
Estrogens increase proliferation of target cells by transcriptional 
mechanisms involving the ER (131), and recent studies on the transcriptional 
regulation of target genes by the ER have identified the regulatory factors and 
molecular mechanisms of action.  Also of interest are the activity of various ER 
ligands, the identification of new ER subtypes, and the types of gene families 
regulated by estrogens during hormonally-induced increases in proliferation.  
The ER contains several domains that are involved in transcriptional regulation, 
and activation of these domains are dependent in part on ligand structure (131).   
ERa is a modular protein with 3 major functional domains: two activation 
function domains (AF-1 and AF-2) and a DNA binding domain (DBD) (132).    
AF-1 exhibits some transcriptional activity in certain cell contexts, and in most 
cells, AF-1 cooperatively interacts with ligand-activated AF-2 (133).  The AF-1 
domain interacts with components of basal transcription machinery and several 
different cofactors and is required for ligand-independent activation of ERa 
through several different kinase-signaling cascades.  The DBD is responsible for 
protein-DNA contacts with EREs on DNA and is important for dimerization and 
nuclear localization (132).  The AF-2 domain functions in receptor dimerization, 
ligand binding, nuclear localization, transcription activation, heat shock protein 
binding, and coactivator/ corepressor binding (132, 134).  
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1.4.5. Mechanisms of ER-activated gene transcription 
The ER is a member of the nuclear receptor superfamily and is a ligand-
induced nuclear transcription factor (129).  Overexpression of ERa can affect 
the rate of progression of several cancers, and ER interacts with a large number 
of other proteins to regulate transcription (131).  Nuclear factors such as 
coactivators and corepressors play important roles in ER mediated 
transcriptional events, and these factors can alter the magnitude of cellular 
responses to estrogens and other steroids.  For example, in breast 
tumorigenesis, ER coactivator expression is modified, and estrogen-dependent 
signaling may be modulated by relative expression of different cofactors that 
upregulate ER expression (70). 
Ligand bound ER activates transcription through several different 
mechanisms.  In the classical mechanism (Figure 14), E2 passively diffuses into 
the cell where it binds nuclear ER.  Ligand binding promotes a conformational 
change that dissociates heat shock proteins, and this facilitates formation of an 
ER homodimer (134, 135).  Estrogen-bound NRs bind to specific DNA 
sequences such as the estrogen-responsive element (ERE) at the promoter 
regions of target genes, and this results in activation of target gene expression 
(56).  Recruitment of coactivators, which perform a variety of functions including 
histone acetylation, mediate interactions of ER with the basal transcription 
machinery and are also required for gene transcription.   
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Figure 14. Classical mechanism of ER mediated transactivation (Adapted 
from (120)). 
 
 
 
Estrogens and antiestrogens also regulate expression of target genes 
that do not contain HREs, and this can occur through protein-protein interactions 
(131).  Surprisingly, very few E2-responsive genes have been identified that are 
strictly regulated by the classical mechanism described above.  An alternative 
DNA independent mechanism for ER involves interaction with other transcription 
factors, such as Jun/FOS, which bind DNA at activator protein 1 (AP-1) sites 
(Figure 15) (136).  The human collagenase gene promoter is regulated through 
ER-mediated induction at AP-1 sites (136, 137). 
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Figure 15.  ER/AP1: DNA independent mechanism (Adapted from (136)). 
 
 
 
Furthermore, several genes studied in this laboratory, including cathepsin 
D (138), Hsp 27 (139), and TGFa (140), and genes identified in other labs, such 
as C-myc (141), induce transactivation through nonclassical pathways involving 
interactions between ERa and Sp1.  This mechanism involves Sp1 binding to 
GC-rich elements, and ERa binds an ERE-halfsite and Sp1 in association with 
other factors (Figure 16).   
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Figure 16. ER/Sp1: DNA dependent mechanism (Adapted from (138, 140)). 
 
 
 
 
In contrast, a second ERa/Sp1 mechanism requires only ERa-Sp1 
(protein-protein) interactions at GC-rich sites, and ERa does not directly bind 
promoter DNA (Figure 17).  Sp1 plays an important role in the transcription of 
many different genes including various genes involved in the cell cycle, purine/ 
pyrimidine biosynthesis, and angiogenesis.  The ERa/Sp1 mechanism has been 
extensively investigated in our laboratory, and E2-responsive genes that are 
regulated via ER/Sp1 in breast cancer cell lines include cathepsin D (142), c-fos 
(143), retinoic acid receptor a1 (RARa1) (144), insulin-like growth factor binding 
protein 4 (IGFBP-4) (145), adenosine deaminase (ADA) (146), bcl-2 (147), E2F1 
(148), cad (149), cyclin D1 (150), rat creatine kinase B (CKB) (151), and 
deoxyribonucleic acid polymerase a (DNAPa) (152).  
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Figure 17. ER/Sp1: DNA independent mechanism (Adapted from (153)). 
 
 
 
 
Although interaction of ER/Sp1 with GC-rich elements is required for 
hormonal activation of these genes, there are important differences in their gene 
promoters as well as in their regulation in different cell lines.  ERa/Sp1 mediated 
gene expression through GC-rich promoters is observed in MCF-7, ZR-75, and 
Hec1A cells but not LnCaP cells, and ERb/Sp1 is not activated by hormones 
(153, 154).  The fact that only some genes containing GC-rich promoter 
elements are activated by ER/Sp1 and that only some GC-rich sites within the 
same promoter are E2-responsive, suggest that the promoter sequences and 
positioning of chromatin and nucleosomes also influence ERa/Sp1-mediated 
transactivation (155).   
The VEGF gene promoter contains multiple GC-rich elements.  In Hec1A 
human endometrial cancer cells treated with E2, VEGF mRNA expression was 
decreased, and deletion analysis of the VEGF gene promoter identified a 
specific GC-rich region of the promoter that was sufficient for decreased 
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transactivation by E2.  Further characterization of this region revealed a novel 
mechanism whereby ERa-Sp3 interactions mediated inhibition of VEGF gene 
expression (156).  In ZR-75 breast cancer cells, E2 induced VEGF expression 
through a GC-rich region in the promoter that interacts with both ER/Sp1 and 
ER/Sp3 and is required for transactivation (157).  Investigation of various 
pancreatic cancer cell lines revealed the importance of Sp1, Sp3, and Sp4 in 
regulating basal expression of VEGF (158).  These reports demonstrate the 
complexity of hormonal regulation of VEGF and the strong influence of cell 
context which may be related to differential expression of coregulatory factors.   
The VEGFR2 and VEGF promoters are similar and both contain some of the 
same motifs including GC-rich sequences that bind Sp1 protein (Figure 18).  
Preliminary data shows that the VEGF and VEGFR2 promoters both respond to 
E2 and other treatments in transient transfection studies in various cell lines. 
 
 
 
Figure 18. Schematic of the VEGF and VEGFR2 gene promoters (Adapted 
from (157)). 
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1.5. VEGF and VEGFRs 
1.5.1. Angiogenesis 
Angiogenesis, the process by which capillaries sprout from preexisting 
blood vessels, is a complex phenomenon requiring numerous biological steps 
including degradation of the endothelial cells underlying basement membranes 
and the interstitial matrix.  Injury to the vessel walls or disruption of basement 
membranes that surround the capillaries activates endothelial cells.  These cells 
subsequently secrete extracellular matrix proteases permitting them to migrate 
into the stromal space and to attach to other matrix molecules.  Proliferation and 
differentiation of endothelial cells yield a sufficient mass of cells to allow 
organization into new tubular structures, and with secretion and remodeling of a 
new basement membranes, mature capillaries are formed as part of the 
angiogenic process (56, 159). 
Physiological roles of angiogenesis include development of the embryonic 
cardiovascular system, wound healing/tissue repair, and the menstrual cycle in 
the adult.  Pathological roles for angiogenesis are seen in tumor progression and 
in a variety of disorders including the perpetuation of chronic inflammatory 
diseases such as rheumatoid arthritis and psoriasis (56, 160).  Mutated cells can 
develop into benign tumors when their proliferation is uncontrolled, and in a 
population of somatic cells, an individual mutant cell prospers while destroying 
neighboring cells, leading to development of cancer.  However, uncontrolled cell 
division is not the only characteristic necessary for tumor growth.  In order for a 
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tumor to continue to proliferate, invade surrounding tissue, and metastasize, 
angiogenesis must occur.  
 
1.5.2. Role of angiogenesis in tumor growth and metastasis 
Angiogenesis is important for neovascularization and growth of many 
different tumors.  Tumor cells also require oxygen and nutrients for growth.  The 
diffusion limit for oxygen is about 100-200 mm from blood vessels.  Solid tumors 
greater than 1-2 mm usually have many new vessels that satisfy the requirement 
for nutrients and oxygen which enable unlimited tumor growth.  Because tumors 
cannot grow beyond a critical size without blood vessels, tumor cells must 
stimulate the development and formation of new blood vessels to carry both 
oxygen and nutrients to support growth.  
In 1972, Judah Folkman recognized the importance of microvasculature 
in the growth of malignant tumors.  The connection between angiogenesis and 
tumor growth was originally theorized when transplanted tumors displayed 
unusual neovascularization (161).  Although an important feature of cancer is 
uncontrolled cell growth and proliferation, it is in latter stages when tumors 
become invasive and metastasize to other organs/ tissues that they become 
malignant (162).  
Angiogenesis is not only crucial for tumor growth but also for tumor 
metastasis.  The expression of angiogenic factors in tumors correlates with 
relapse, metastasis, and poor prognosis in human cancer patients, and thus, 
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angiogenesis is an indication of the metastatic potential of human tumors.  Many 
studies have shown that increased vascular density of a tumor correlates with 
increased metastasis, with the highly vascularized primary tumors having a 
higher incidence of metastases than poorly vascularized tumors; moreover, this 
increase in tumor vasculature correlates with decreased survival (21).  These 
observations are consistent with the role of angiogenesis in providing an efficient 
route for tumor cells to exit the site of the primary tumor into the blood stream 
and metastasize to different sites. 
When a tumor metastasizes, several steps occur.  Surrounding tissues, 
blood, and lymphatic vessels are invaded when tumor cells permeate tissue 
barriers.  There is also interaction of tumor cells with other tumor cells and/or 
with blood cells and stimulation of fibrin deposition resulting in local embolus. 
Another step in the process is the adhesion of tumor cells to endothelial cells. 
Finally, there is extravasation of tumor cells into organs/tissues (163).  Once 
established, these cells proliferate and form their own neovasculature (Figure 
19).   
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Figure 19. Vascular components of tumor metastasis.  The steps of 
metastatic pathways that involve interactions with blood vessels. (a) Small 
primary tumors (<2 mm) remain avascular until they (b) invade the local 
epithelial basement membrane.  If tumor cells produce angiogenic factors 
(c) angiogenesis will occur, allowing expansion of the primary tumor.  (d) 
New blood vessels then provide a route of entry into the bloodstream and 
the tumor cells circulate until they die or (e) attach specifically to 
endothelial cells in the vessels of downstream organs. (f) The tumor cells 
extravasate through the vessel wall and then (g) migrate to sites proximal 
to arterioles where their growth is enhanced.  (h) Micrometastases can 
remain dormant for extended time periods during which angiogenesis is 
suppressed.  (i) Initiation of angiogenesis at the secondary site releases 
the metastatic colonies from dormancy and allows rapid growth (21). 
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1.5.3. Regulation of angiogenesis 
Some triggers for angiogenesis are metabolic stress (low oxygen, pH, or 
hypoglycaemia), mechanical stress from pressure generated by proliferating 
cells, immune/inflammatory responses, and genetic mutations including 
activation of oncogenes or deletion of tumor suppressors that control expression 
of angiogenic regulators (164).  Angiogenesis is tightly regulated in normal and 
malignant tissues by the balance of a large number of proangiogenic and 
antiangiogenic factors that are produced in target tissues and at distant sites 
(22, 163).  Deregulation of cellular and molecular mechanisms, such as 
angiogenesis, motility, and invasiveness, lead to malignancy.  Tumor 
vasculature is disorganized, uneven, and chaotic compared to normal vessels, 
which is thought to be a result of an imbalance of angiogenic regulators (Figure 
20) (164).   
 
 
 
 
Figure 20. The balance hypothesis for the angiogenic switch  (Adapted 
from (23)). 
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1.5.4. Physiological and pathological roles of VEGF 
A large number of proangiogenic factors and receptors have been 
identified, including VEGF.  VEGF, also known as vascular permeability factor, is 
a prominent angiogenic factor and is a highly specific mitogen for vascular 
endothelial cells (165, 166).  VEGF is the most potent direct-acting angiogenic 
protein and induces angiogenic responses in a variety of in vitro and in vivo 
models (22).  
VEGF expression in normal cells is restricted to proliferating endothelial 
cells and stimulates a cascade of responses required for growth and 
angiogenesis including increased vascular leakage and protection of endothelial 
cells from cytotoxic drugs and other injuries (163, 167).  VEGF acts as a survival 
factor for endothelial cells (ECs) and prevents apoptosis induced by serum 
starvation in vitro (161).  Several studies have also reported the mitogenic 
effects of VEGF on certain non-EC types (161).  
VEGF plays a role in wound healing, cancer, rheumatoid arthritis, ocular 
and neovascular disorders, and cardiovascular disease (168).  Heterozygous 
mutations or deletion of one allele of the VEGF gene in mice is embryolethal due 
to impaired blood vessel formation (156, 169).  Neovascularization requires a 
coordination of complex processes in the activation of a number of receptors by 
various ligands; however, VEGF signaling is a key rate-limiting enzyme in 
angiogenesis (161).  
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VEGF is a diffusible glycoprotein that stimulates mitosis and migration of 
endothelial cells and increases vascular permeability which plays a significant 
role in inflammation as well as in other pathologies such as increasing 
metastatic potential of tumor cells (22, 161, 167).  VEGF and its receptors are 
important in angiogenic pathways associated with tumor growth in many solid 
tumors including breast cancer, colon cancer, hepatoma, bladder cancer, gastric 
cancer, and prostate cancer (22, 161).  VEGF not only stimulates angiogenesis 
in vitro and in vivo but also plays a major role in proliferation and maintenance of 
vascular endothelial cells and in development of new blood vessels in tumors 
(170). 
 
1.5.5. VEGF isoforms and receptors 
The VEGF family of proteins includes six members: VEGF-A, B, C, D, 
and E, as well as placental growth factor (PlGF) (165, 171).  VEGFs interact with 
three receptors which activate downstream signaling required for vascular and 
embryonic development.  VEGF receptors VEGFR1/flt-1, VEGFR2/flk-1/KDR, 
and VEGFR3/flt-4 are cell surface receptor tyrosine kinases which have a single 
transmembrane segment and are activated by ligand binding (172).  Activation 
of VEGFRs by VEGF results in receptor dimerization and autophosphorylation of 
cytoplasmic tyrosine residues resulting in either enhanced catalytic activity or 
enhanced interactions with other intracellular signaling proteins (22).  VEGFRs 
activate signaling pathways that are involved in cell proliferation, differentiation, 
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migration, and metabolism.  VEGF-A is the most important form of VEGF and 
interacts with both VEGFR1 and VEGFR2, although functionally, VEGFR2 is the 
most predominant receptor for VEGF (167).  VEGF-A has five known mRNA 
isoforms generated by alternative splicing of a single gene containing eight 
exons (Figure 21) (165, 171, 173, 174).  
 
 
 
 
 
Figure 21. VEGF and VEGFRs. 
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1.5.6. Function and expression of VEGFR  
Both VEGFR1 and VEGFR2 play a role in embryonic development as 
well as pathological angiogenesis.  Disruption of either VEGFR gene leads to 
embryonic lethality in mice (174).  However, embryonic lethality in homozygous 
VEGFR2 null mice resulted from the absence of endothelial cells, whereas 
deletion of VEGFR1 led to embryonic lethality due to endothelial cell overgrowth 
and disorganized blood vessels (175, 176).   
VEGFR1 and VEGFR2 differ considerably in their signaling properties.  
VEGFR2 positively regulates angiogenesis while VEGFR1 appears to negatively 
regulate this response (175).  VEGF does not induce autophosphorylation of or 
kinase activation of VEGFR1 in vivo and in vitro, nor does it stimulate EC 
migration or angiogenesis in vitro (175).  There are many conflicting reports 
about the role of VEGFR1 as a positive or negative regulator of angiogenesis 
primarily due to the fact that its functions and signaling properties are different 
depending on the developmental stage and cell type (160). 
VEGFR2 plays a role in endothelial cell differentiation and vasculogenesis 
and in tumor vascularization, growth, and metastasis (22).  Angiogenesis is 
primarily initiated by VEGFR2 yet VEGFR1 may inhibit angiogenesis in some 
tumors (163).  VEGFR1 has a higher affinity for VEGF than VEGFR2, and 
formation of a VEGF-VEGFR1 complex may decrease activation of VEGFR2 
(177). 
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VEGFR2 is expressed in all vessel-derived endothelial cells, is 
upregulated when tumors shift to an angiogenic phenotype, and is coexpressed 
with VEGF in primary breast cancers (167).  VEGF, VEGFR1, and VEGFR2 are 
colocalized by immunohistochemistry in many cancer cells within the tumor 
mass (178).  VEGF, VEGFR1, and VEGFR2 mRNA levels are elevated in 
pancreatic cancer tissues compared to the normal pancreas (178).  VEGFR1 
and VEGFR2 are mainly expressed in endothelial cells (Figure 22), and mRNAs 
for both receptors are expressed in a variety of breast cancer cell lines, including 
T-47D and MCF-7 cells, and VEGFR2 is enhanced in endothelial cells of 
malignant breast tissue compared to neighboring normal breast tissue (179).   
AsPC-1, Capan-1, and MiaPaCa-2 pancreatic cancer cells express VEGFR2 
mRNA and protein (178).  VEGFR3 is also upregulated in tumor angiogenesis 
such as breast carcinomas (174), and VEGFR3 expression is elevated in 
invasive breast cancer as compared to normal breast tissue (180).  
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Figure 22. Schematic of VEGF being secreted by tumor cells and binding 
to its receptors (R1 and R2) on the abluminal surface of tumor endothelial 
cells (171). 
 
 
 
 
 Overexpression of growth factors and downregulation of growth inhibiting 
factors in tumors result in evasion of apoptosis, increased angiogenesis, and 
metastasis (91).  For example, human pancreatic cancers overexpress many 
growth factors and their receptors such as VEGF, FGF, TNFa, TGFb, IL-1, etc 
(91).  VEGF may stimulate angiogenesis through both paracrine and autocrine 
effects on tumor cells (Figure 23).  Transcription and secretion of growth factors 
by tumor and stromal cells upregulates and activates growth factor receptors.   
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Figure 23. Paracrine and autocrine stimulation by angiogenic growth 
factors (22). 
 
 
1.5.7. Regulation of VEGF/VEGFR expression 
In vitro, many tumor cells express VEGF with no apparent external 
stimulation, supporting the idea that loss/ inactivation of tumor suppressor genes 
and activation of oncogenes is associated with this response (91).  The VEGF 
promoter contains binding sites for various transcription factors such as hypoxia 
inducible factor 1 (HIF-1), AP-1/2, and Sp1 (91), and multiple signal transduction 
pathways may be involved in regulation of VEGF transcription.  In human 
pancreatic cancer cells, basal expression of multiple-metastasis-related proteins, 
such as IL-8 and VEGF are regulated by transcription factors such as Sp1 and 
STAT3 (91).  
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Chronic pancreatitis with reduced blood flow, low tissue oxygenation, and 
low pH levels are common to pancreatic cancer (89).  The hypoxic conditions in 
pancreatic tumors may account for the aggressive nature of pancreatic cancer 
and its resistance to chemo and radiation therapies (181).  Hypoxia stabilizes 
and enhances the HIF-1 heterodimeric complex that activates many genes, such 
as VEGF and PDGF, which promote angiogenesis, tumor growth and metastasis 
(89).  The HIF system activates genes encoding angiogenic growth factors, such 
as VEGF, and metabolic enzymes responsible for growth under reduced oxygen 
conditions, thereby facilitating development of new blood vessels and growth in 
hypoxic tumors (89).  HIF-1 increases the rate of gene transcription and 
increases the mRNA stability.  VEGF enables endothelial cell migration by 
activating expression of tissue plasminogen activator, urokinase plasminogen 
activator, collagenases and matrix metalloproteases, which contribute to 
degradation of the extracellular matrix (172).  
HIF-1a and VEGF are overexpressed in patients with pancreatic 
carcinoma (92), and VEGF, VEGFR1, and VEGFR2 are upregulated by hypoxia 
in tumor endothelial cells (174).  As observed in ischemic regions of tumors, 
VEGFR1 and VEGFR2 genes are upregulated in lung vasculature in rats 
exposed to hypoxia (182).  This upregulation of VEGFR2 is interesting because, 
unlike the VEGFR1 gene promoter, the VEGFR2 gene promoter does not 
contain a putative HIF consensus binding sequence.  In vitro, conflicting findings 
have been observed.  Hypoxia induces VEGF and VEGFR1 in endothelial cells, 
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but VEGFR2 mRNA levels are unchanged in vitro.  This suggests the presence 
of additional components involved in the VEGFR2 upregulation observed in 
several in vivo models.  In vivo, VEGFR2 expression is increased in hypoxic 
conditions most likely through upregulation of hypoxia inducible VEGF which in 
turn upregulates VEGFR2.  Alternatively, a so far unidentified paracrine mediator 
released by ischemic tissues might be responsible for VEGFR2 upregulation in 
response to hypoxia.  Discrepancies between in vivo and in vitro findings might 
be partially explained by a soluble factor not present in endothelial cell 
supernatant (182). 
Acidosis (low extracellular pH) also upregulates VEGF expression, most 
likely through activation of the transcription factors nuclear factor kappa B 
(NFkB) and AP-1 (91).  For example, in human pancreatic cancer, constitutively 
activated NFkB and AP-1 are required for basal expression of both IL-8 and 
VEGF (91).  In areas of a tumor where hypoxia and acidosis are not detected, 
VEGF expression may still be elevated due to other activating factors such as 
hormones, growth factors, and cytokines such as TNFa, PDGF, EGF, TGFb1, 
IL-1b (91). 
 
1.5.8. Hormonal regulation of VEGF/VEGFR 
VEGFR2 was detected in ~65% of 141 invasive human breast 
carcinomas, and hypoxia induced expression of VEGF in tumors is enhanced by 
the presence of sex hormones (172, 183).  Estrogen is involved in angiogenesis 
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and promotion of new vessel formation both in vitro and in vivo (56, 159).  The 
molecular mechanisms through which estrogens induce angiogenesis are 
unknown and may involve activation of both genomic and non-genomic 
mechanisms.     
Hormonal regulation of angiogenesis is supported by findings that 
angiogenesis is impaired in aERKO mice, ER antagonists inhibit angiogenesis, 
and that there is a positive correlation between ER expression, angiogenesis, 
and breast tumor invasiveness (57).  In adults under normal conditions, the 
female reproductive tract is virtually the only location where angiogenesis occurs 
(57).  Neovascularization is required in the uterus as part of normal physiology, 
and estrogens plays a role in modulating this process (56, 57).  Throughout the 
normal menstrual cycle, sex hormones, estrogen and progesterone, control the 
recurrent cycle of uterine cell proliferation, vascular growth, and repair of 
damaged tissues (57).  This coordinated, complex cycle of neovascularization 
supports the theory that angiogenic growth factor expression is regulated by 
steroid hormones and influences blood vessel formation (57).   
The proangiogenic effects of estrogen include upregulation of both VEGF 
and its receptors, and these effects extend beyond the tissues involved in 
reproduction and are mediated by VEGF and other factors (159).  Several 
observations show that VEGF may be partially responsible for the angiogenic 
action of estradiol.  First, VEGF expression in uterine and vascular tissues is 
induced by estradiol.  Second, some estrogen-dependent tumors exhibit 
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increased expression of VEGF and its receptors, and finally, increased VEGF 
expression is associated with acceleration of endothelial recovery after estrogen 
treatment for arterial injury (57).   
Estrogen also increases VEGF and VEGFR2 mRNA and protein levels in 
retinal microvascular endothelial cells (184), stimulates VEGF production in rats 
and monkeys (159), and steroid hormones and antiestrogens regulate VEGF 
protein expression in breast cancer cells (185).  Both estrogens and growth 
factors enhance proliferation of human breast cancer cells and regulate 
secretion of VEGF to stimulate tumor-associated angiogenesis (76).  These 
studies indicate that at least one mechanism by which estrogen may stimulate 
angiogenesis is through upregulation of VEGF and VEGFR expression and that 
both VEGF and VEGFR are involved in estrogen-induced carcinogenesis.  
Human vascular endothelial cells (HUVECs) express both full length and 
soluble VEGFR1 (sVEGFR1) whereas normal mammary cells and breast cancer 
cells lines primarily express sVEGFR1.  In ER(+) but not ER(-) breast cancer 
cells treated with estrogen, sVEGFR1 expression is decreased and 
accompanied by increased angiogenesis, and pretreatment with an ER 
antagonist blocks the estrogen-induced responses (177).  In MCF-7 breast 
cancer cells treated with estrogen, sVEGFR1 mRNA levels are greatly 
decreased, and this response is inhibited by the ER antagonist ICI 182,780.  ER-
negative MDA-MB-231 breast cancer cells also express sVEGFR1, and E2 did 
not affect sVEGFR1 levels.  VEGFR1 expression is also not affected by E2 in 
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normal breast epithelial cells (7-17%) due to low levels of ER expression; 
however, in early stage ER-positive breast tumors, estrogen decreases VEGFR1 
and thereby increases the availability of VEGF to activate angiogenesis (177).  
This relationship is consistent with observations that patients with higher 
sVEGFR (and lower availability of VEGF) had a better prognosis than patients 
with low VEGFR1/VEGF ratios (177). 
Angiogenesis is also a prognostic marker in breast cancer (57, 167).  
Cells of large solid tumors release angiogenic factors such as bFGF and VEGF 
(167).  VEGF-A is upregulated when tumor growth exceeds 1-3 mm3 (167), and 
this overexpression in many solid tumors indicates poor prognosis because of 
increased microvascularization (172).  The degree of vascularization in tumors, 
angiogenesis, and expression of VEGF and VEGFR are negative prognostic 
factors for breast cancer patient survival (174).  Patients with ER(+) node 
negative breast cancer, a group usually associated with good prognosis, have 
significantly reduced survival rates when VEGF expression levels are high (186).  
In breast cancer, not only does expression of VEGF correlate with early relapse, 
but tumors that produce multiple angiogenic factors also show higher rates of 
tumor growth (21).   
 
1.5.9. Implications of angiogenesis in cancer treatment  
It is difficult to surgically remove every cancer cell, and treatment with 
cytotoxic chemicals or radiation is not specific for cancer cells and can also kill 
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normal cells.  Furthermore, conventional cancer therapies are often limited by 
their inability to effectively cause regression of tumors that have undergone 
metastasis.  One major problem with chemotherapeutic agents is that many 
tumors are genetically unstable and cancer cells may develop drug resistance.  
One aim is to combine cytotoxic therapy with antiangiogenic agents in order to 
target existing vascularized tumors as well as to prevent further 
neovascularization and growth (22).  Blocking angiogenesis could be an 
effective strategy for inhibiting tumor growth (187), and in animal studies, 
angiogenic inhibitors decrease tumor growth and metastasis (21).  Thus, a 
combination of conventional chemotherapy with antiangiogenic agents 
significantly reduces tumor metastases. 
There are several known angiogenic inhibitors and these include naturally 
occurring agents such as thrombospondin, interferon, metalloproteinase 
inhibitors, synthetic protease inhibitors and anti-adhesive peptides, tumor-
derived angiostatin, endostatin, and pharmacological agents such as 
AGM1470/TNP470, thalidomide, and carboxyamidotriazole (21).  Inhibition of 
tumor angiogenesis and VEGF has also been observed in cells/tumors treated 
with naturally occurring isoflavonoids (188), antisense oligo/ribosymes (22), and 
anti VEGF antibodies (22, 163).  Drugs acting directly on VEGFRs (172), anti 
VEGFR antibodies (163), soluble VEGFR constructs (90), and peptide/low 
molecular weight inhibitors of VEGFR have also been investigated (Table 7) (94, 
163, 189, 190).   
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Table 7. Antiangiogenic mechanisms, targets, and therapies (Data 
modified from (91, 164, 169, 172, 191, 192)). 
 
Mechanisms Target Therapy
Block proteolytic pathways occurring Metalloproteinases and their Metalloproteinase inhibitors
in the extracellular matrix substrates
Block proliferating endothelial cells Activated endothelium Specific growth inhibitors (i.e. TNP-470)
Gene therapy Thrombospondin-1, angiostatin, Transfection of neoplastic cells with 
and platelet-factor 4 genes encoding angiogenic inhibitors
Block angiogenic peptides VEGF, bFGF, and others Growth factor inhibitors;
neutralizing antibodies
Block angiogenic growth factor VEGFR Inhibitors; neutralizing antibodies; 
receptors soluble receptor constructs  
 
 
The naturally occurring isoflavonoid genistein has strong antiangiogenic 
activity and inhibits tyrosine kinases and hypoxic activation of HIF-1 in 
pancreatic carcinoma cells; VEGF mRNA expression is also decreased by 
treatment with genistein, and this phytochemical may be beneficial for pancreatic 
cancer patients (188).   
Anti-VEGF antibodies, such as 2C3, inhibit both angiogenesis and tumor 
growth in implanted tumors.  For example, 2C3 prevents binding of VEGF to 
VEGFR2 but allows VEGF to bind to VEGFR1.  2C3 also inhibited tumor growth 
in mice and in xenografts bearing MDA-231 human breast cancer and 
decreased VEGFR2 expression and tumor vascularization (163).  Over 90% of 
all human cancers are solid tumors which are resistant to current antibody-
based therapies.  This resistance stems from the inaccessibility of tumor cells in 
solid masses to these agents.  This problem can be alleviated, in part, by 2C3 
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which binds VEGF/VEGFR1 in vitro while blocking interactions between VEGF 
and VEGFR2.  Therefore, 2C3 combines vascular targeting and anti-
angiogenesis into one molecule suggesting possibilities that linkage to other 
drugs may enhance their effects on solid tumors (171). 
Results of clinical trials support the development of antiangiogenesis 
agents targeting VEGFR2.  For example, pancreatic cancer growth is inhibited 
using dominant negative VEGFR2 (92), and VEGFR tyrosine kinase inhibitors in 
conjunction with chemotherapy are highly effective for treating pancreatic cancer 
(94).  Soluble VEGFR2 mRNA is 2.3 KB and contains the secretory leader 
sequence and extracellular immunoglobulin-like domains of the receptor.  The 
cDNA is about 1034 bp with the first 3 immunoglobulin-like domains, without the 
4-7 immunoglobulin-like domains, transmembrane spanning sequence, or 
kinase domain.  Soluble VEGFR2 has a high binding affinity for VEGF but does 
not exhibit tyrosine kinase activity or induce endothelial proliferation.  Trapping 
VEGF with a soluble VEGFR chimer that binds VEGF with high affinity 
suppresses the growth and metastasis of pancreatic tumors as well as 
decreasing tumor microvessel density (90).  Soluble VEGFR2 can form a 
heterodimer with wild type VEGFR2 to block activation, and retroviruses that 
express soluble VEGFR2 inhibited pancreatic tumor growth but did not eliminate 
tumors from the animals (193).  
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1.6. Research objectives 
1.6.1. Objective 1 
Angiogenesis as well as VEGF and VEGFR expression are upregulated 
in pancreatic cancer tissues compared to normal pancreas.  Studies on various 
pancreatic cancer cell lines in this laboratory have revealed the importance of 
Sp1, Sp3, and Sp4 in regulating expression of VEGF (158).  The first objective 
of this research was to investigate VEGFR2 gene expression and to identify 
mechanisms of transcriptional regulation and the role of Sp proteins in mediating 
VEGFR2 expression in various pancreatic cancer cell lines.  
 
1.6.2. Objective 2 
Angiogenesis and expression of VEGF and VEGFR2 are negative 
prognostic factors for survival of breast cancer patients.  VEGF and VEGFR2 
are potential targets of E2-induced carcinogenesis, and VEGF gene expression 
is induced by E2 in some hormone-dependent cancer cell lines.  Data from this 
laboratory have confirmed that in Hec1A endometrial cancer cells treated with 
E2, VEGF mRNA and promoter-reporter gene expression was decreased.  It 
was shown that specific GC-rich regions of the VEGF gene promoter were 
required for decreased transactivation of VEGF by E2 in Hec1A cells, and the 
ERa-Sp3 complex was required for this novel mechanism (156).  However, in 
ZR-75 breast cancer cells, E2 induces VEGF mRNA and promoter-reporter gene 
expression.  This upregulation of VEGF expression was dependent on the same 
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GC-rich region in the VEGF promoter that was critical for E2-mediated inhibition 
in Hec1A cells, and interactions with both ERa/Sp1 and ERa/Sp3 mediated the 
induced response (157).  From these reports, the complexity of hormonal 
regulation of VEGF and the strong influence of cell context is apparent. VEGFR2 
expression levels are elevated in some hormone-dependent cancers compared 
to normal cells, but currently, the mechanisms of hormonal regulation of VEGFR 
are not well understood.  The VEGF and VEGFR2 gene promoters are similar 
and lack a consensus ERE but contain comparable proximal GC-rich sequences 
that bind Sp proteins.  The second objective of this research was to identify 
specific regions of the VEGFR2 gene promoter required for transactivation by E2 
and to determine the role of Sp proteins and other transcription factors required 
for upregulation of VEGFR2 by E2 in ZR-75 cells.   
 
1.6.3. Objective 3 
Global gene expression profiles of E2-responsive genes in breast cancer 
and other cell lines have been widely investigated.  Although expression of many 
genes is regulated by E2, expression of a large percentage of these genes is 
decreased.  The mechanisms of E2-dependent inhibition of gene expression are 
not well characterized and are dependent on gene and cell context.  The third 
objective of this research was to investigate downregulation of VEGFR2 by E2 in 
MCF-7 breast cancer cells as a model for understanding the mechanisms of E2-
mediated downregulation of gene expression. 
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CHAPTER II 
 
 
REGULATION OF VASCULAR ENDOTHELIAL GROWTH 
FACTOR RECEPTOR-2 EXPRESSION IN PANCREATIC CANCER 
CELLS BY Sp PROTEINS 
 
 
2.1. Introduction 
 
Pancreatic cancer ranks fourth among cancer deaths in the United 
States, and it is estimated that approximately 32,000 new pancreatic cancer 
cases were diagnosed in 2004 (194).  Since diagnosis of this disease usually 
occurs at a late stage, the prognosis for patient survival is low, and the five-year 
survival rate is < 5% (195).  Successful management of pancreatic cancer 
requires more sensitive methods for early diagnosis, the development of 
improved surgical and chemotherapies, and a more comprehensive 
understanding of the underlying biological basis for pancreatic tumor 
development and metastasis (91).  A number of genetic determinants and 
medical conditions have been identified as risk factors for this disease (91, 108, 
196-198).  For example, several heritable gene mutations such as Peutz-
Jeghers, hereditary pancreatitis, hereditary non-polyposis colorectal cancer 
syndromes, familial breast cancer, and familial atypical multiple-mole melanoma 
(FAMMM) are associated with increased risks for pancreatic cancer (108, 196-
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198).  In addition, medical conditions such as chronic pancreatitis gastrectomy, 
diabetic mellitus, and certain polymorphisms associated with DNA repair and 
drug/carcinogen metabolism are also associated with increased risks for 
pancreatic cancer (93, 102, 199-206).  Epidemiology studies also show that 
several environmental and lifestyle factors such as cigarette smoking, intakes of 
red and processed meats and their methods of preparation, and low dietary 
intakes of fruits and vegetables are correlated with increased incidence of 
pancreatic cancer (207-212).  Many of these same factors are associated with 
increased risks for other cancers; however, identification of specific substances 
that modulate these risks have not been determined. 
  Development of pancreatic cancer is also accompanied by several 
acquired mutations of both oncogenes and tumor suppressor genes (213-222).  
K-ras oncogene mutations are observed in > 85% of pancreatic tumors and are 
generally detected during the early stages of cancer development.  In contrast, 
the tumor suppressor genes p16, p53, and SMAD4 are detected in up to 95%, 
98%, and 75% of pancreatic cancer cases respectively and are generally 
observed in later stages of tumor development (197).  Mutations of these and 
other genes contribute to the high proliferative rates and metastases of 
pancreatic cancers.  Current chemotherapies commonly used for treatment of 
pancreatic cancer involve cytotoxic drugs such as gemcitabine alone or in 
combination with radiation or other drugs; therapies that inhibit k-ras, receptor 
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tyrosine kinases, and matrix metalloproteinases are promising new approaches 
for treatment of this disease (91, 223, 224).   
 Research in our laboratory has focused on expression and regulation of 
the important angiogenic factor vascular endothelial growth factor (VEGF) in 
cancer cell lines (156-158, 225, 226).  Several studies show that VEGF 
expression is due, in part, to specificity protein 1 (Sp1) expression in pancreatic 
and other cancer cell lines (109, 158, 225-227).  However, using RNA 
interference, it has recently been shown that VEGF regulation in pancreatic 
cancer cell lines is due to Sp1, Sp3, and Sp4 (158).  In this study, using Real-
time PCR, we have identified VEGFR2 expression in Panc-1, AsPC-1, Panc-28, 
HPAFII, BxPC-3, and MiaPaCa-2 pancreatic cancer cells, and this has been 
confirmed by immunofluorescent staining for VEGFR2 protein in Panc-1 cells.  
Analysis of the VEGFR2 promoter shows that two proximal GC-rich sites at -58 
and -44 are important for expression of VEGFR2, and RNA interference studies 
show that Sp proteins (Sp1, Sp3, and Sp4) are critical transcription factors that 
mediate expression of VEGFR2 in pancreatic cancer cells.   
 
2.2. Materials and methods 
2.2.1. Chemicals, plasmids, and gifts 
Phosphate buffered saline (PBS) and 100X antibiotic/ antimycotic solution 
were purchased from Sigma Chemical Company (St. Louis, MO); 5X lysis buffer, 
luciferase reagent, restriction enzymes (XhoI and HindIII), and ligase were 
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purchased from Promega (Madison, WI).  b-galactosidase reagents were 
purchased from Tropix (Bedford, MA).  Taq polymerase and other PCR reagents 
were purchased from Perkin Elmer (Boston, MA).  pCDNA3.1-His-LacZ 
expression plasmid was obtained from Invitrogen (Carlsbad, CA).  VEGFR2 
promoter luciferase constructs pVEGFR2A, pVEGFR2B, and pVEGFR2C 
(previously named pKDR-716/+268, pKDR-225/+268, and pKDR-95/+268) were 
provided by Dr. Arthur Mu-EnLee (deceased) and Dr. Koji Maemura 
(Cardiovascular Biology Laboratory, Boston, MA).  pGL2 basic luciferase 
reporter vector was purchased from Promega.  
 
2.2.2. Cell lines and tissue culture 
The human pancreatic cancer cell lines Panc-1, AsPC-1, MiaPaCa-2, 
HPAFII, and BxPC-3 were obtained from American Type Culture Collection 
(ATCC, Manassas, VA), and Panc-28 cells were obtained from Dr. J. 
Abbruzzese, M.D. Anderson Cancer Center (Houston, Tx).  Panc-1, MiaPaCa-2, 
and Panc-28 cells were cultured in Dulbecco’s modified Eagle’s medium/F12 
(Sigma) supplemented with 5 or 10% fetal bovine serum (FBS) (Summit 
Biotechnology, Fort Collins, CO; Intergen, Des Plains, IA; JRH Biosciences, 
Lenexa, KS; or Atlanta Biologicals, Inc., Norcross, GA).  Medium was further 
supplemented with 2.2 g/L sodium bicarbonate and 100X antibiotic/ antimycotic 
solution (Sigma).  AsPC-1 and BxPC-3 cells were maintained in RPMI 1640 
media (Sigma) supplemented with 10% FBS (Summit Biotechnology; Intergen; 
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JRH Biosciences; or Atlanta Biologicals, Inc.).  Medium was further 
supplemented with 1.5 g/L sodium bicarbonate, 2.38 g/L HEPES, 0.11 g/L 
sodium pyruvate, and 100X antibiotic/ antimycotic solution (Sigma).  HPAFII 
cells were cultured in Eagle’s Minimal Essential medium (Sigma) supplemented 
with 10% FBS (Summit Biotechnology; Intergen; JRH Biosciences; or Atlanta 
Biologicals, Inc.).  Medium was further supplemented with 1.5 g/L sodium 
bicarbonate and 100X antibiotic/antimycotic solution (Sigma).  Cells were 
maintained at 37 ºC with a humidified CO2:air (5:95) mixture.  
 
2.2.3. Cloning and oligonucleotides  
VEGFR2 promoter-derived oligonucleotides, PCR primers, and primers 
employed in plasmid construction were synthesized by Genosys/Sigma (The 
Woodlands, TX) or Integrated DNA Technologies (IDT) (Coralville, IA).  VEGFR2 
promoter deletion constructs pVEGFR2D, pVEGFR2E, pVEGFR2F, and 
pVEGFR2G were created by PCR amplification using pVEGFR2A as the 
template.  Forward primers were designed with XhoI restriction enzyme sites at 
the 5’ end.  A reverse luciferase primer was used for PCR.  PCR products were 
digested with XhoI and HindIII, and subsequently ligated into the pGL2 basic 
vector.  All constructs are in pGL2 basic luciferase reporter vector, and all 
constructs were sequenced to verify their identity.  Mutation constructs 
pVEGFR2Em1, pVEGFR2Em2, and pVEGFR2Em3 were constructed by PCR 
amplification using the reverse luciferase primer paired with the forward primer 
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containing the desired mutations.  Forward primers are as follows: (mutated 
bases are underlined) 
XhoI      -60 
M1=5’-GAT GAT CTC GAG CCA AGC CCC GCA TGG CCC CGC C-3’ 
    
M2=5’-GAT GAT CTC GAG CCC CGC CCC GCA TGG CCA AGC CTC CGC  
GC-3’ 
 
M3=5’-GAT GAT CTC GAG CCA AGC CCC GCA TGG CCA AGC CTC CGC  
GC-3’ 
 
 
 
2.2.4. Transient transfection assays 
Cells were seeded in 12-well plates at a concentration of 1.5-3.0 x 105 
cells per well in phenol red-free DME/F12 media supplemented with 2.5% 
charcoal-stripped FBS.  Panc-1, AsPC-1, and MiaPaCa-2 cells were transiently 
cotransfected with 500 ng of the appropriate VEGFR2 luciferase reporter 
plasmid and 250 ng of pCDNA3.1-His-LacZ.  Four to eight hr after transfection, 
cells were shocked with 25% glycerol in PBS to increase transfection efficiency, 
washed with PBS, and fresh serum-free DME/F12 medium was replaced.  Cells 
were harvested by scraping the plates in 100-200 mL of 1X lysis buffer 
(Promega).  An aliquot of soluble protein was obtained by one cycle of 
freezing/thawing the cells, vortexing (30 s), and centrifuging at 12,000 x g (1 
min).  Cell lysates (30 mL) were assayed for luciferase activity using Luciferase 
Assay Reagent (Promega) and b-galactosidase activity using Tropix Galacto-
Light Plus assay system (Tropix) in a Lumicount micro-well plate reader 
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(Packard Instrument Co., Downers Grove, IL).  Relative luciferase activity was 
normalized to relative b-galactosidase units for each transfection experiment.  
 
2.2.5. Transient transfection of siRNA  
Cells were cultured in phenol red-free DME/F12 medium supplemented 
with 2.5% charcoal stripped FBS in 12-well plates until 50-70% confluent.  Cells 
were washed once with serum free, antibiotic free, phenol red-free DME/F12 
media.  The amount of siRNA to give a maximal decrease of each target protein 
was determined experimentally (5-20 nM final concentration in the well). 
Pancreatic cancer cells were co-transfected with siRNA, 400 ng of the 
appropriate VEGFR2 luciferase reporter plasmid and 200 ng of pCDNA3.1-His-
LacZ using Lipofectamine 2000 reagent (Invitrogen) according to the 
manufacturer’s protocol.  Cells were harvested ~48 hr later.  Cell lysates were 
assayed for luciferase and b-galactosidase activity as described above.   
The Lamin A/C duplex (target sequence: 5’-CTG GAC TTC CAG AAG 
AAC A-3’) and the Luciferase GL2 duplex RNA (target sequence: 5’-CGT ACG 
CGG AAT ACT TCG A-3’) from Dharmacon (Lafayette, CO) were used for 
controls in siRNA transfections.  The siRNA oligonucleotides for Sp1, Sp3, and 
Sp4 were also ordered from Dharmacon as follows:    
Sp1: 5’-AUC ACU CCA UGG AUG AAA UGA dTdT-3’ 
Sp3: 5’-GCG GCA GGU GGA GCC UUC ACU dTdT-3’ 
Sp4: 5’-GCA GUG ACA CAU UAG UGA GCdT dT-3’ 
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2.2.6. Western blot analysis  
Cells were seeded into 6-well plates in DME/F12 medium supplemented 
with 2.5% charcoal stripped FBS.  The next day, cells were transfected with 
siRNA as described above.  Cellular protein was obtained by harvesting cells in 
a high salt lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10% (v/v) 
glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, 10 mg/mL aprotinin, 50 
mM phenylmethylsulphonylflouride, 50 mM sodium orthovanadate) on ice for 45-
60 min and centrifugation at 20,000 x g for 10 min at 4ºC.  Thirty to sixty mg of 
protein was diluted with Laemmli’s loading buffer, boiled, and loaded onto a 
7.5% SDS-polyacrylamide gel.  Samples were resolved using electrophoresis at 
150-180 V for 3-4 hr and transferred (transfer buffer: 48 mM Tris-Hcl, 29 mM 
glycine, and 0.025% SDS) to a PVDF membrane (BioRad, Hercules, CA) by 
electrophoresis at 0.2 A for ~12-16 hr.   
Membranes were blocked with excess protein and then probed with 
polyclonal primary antibodies for Sp1 (PEP2), Sp3 (D20), and Sp4 (V20) from 
Santa Cruz Biotechnology Inc (Santa Cruz, CA).  Sp1 and Sp3 were each 
diluted 1:1000 and incubated overnight.  Sp4 was diluted 1:250 or 1:500 and 
incubated overnight as well.  Membranes were probed with a horseradish 
peroxidase conjugated secondary antibody (1:5000) for 3-6 hr.  Blots were 
visualized using the chemiluminescent substrate ECL detection system (NEN-
DuPont, Boston, MA) and exposure on Kodak X-O Mat autoradiography film 
(Eastman Kodak Co., Rochester, NY).  Band intensity values were obtained by 
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scanning the film on a Sharp JX-330 scanner (Sharp Electronics, Mahwah, NJ) 
and by densitometry using the Zero-D Scanalytics software package 
(Scanalytics, Sunnyvale, CA).  
 
2.2.7. Real-time PCR  
For experiments involving siRNA, pancreatic cancer cells were 
transfected as described previously.  Total RNA was isolated using the RNeasy 
Protect Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol.  
RNA was eluted with 30 mL RNase-free water and stored at -80ºC.  RNA was 
reverse transcribed using Superscript II reverse transcriptase (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s protocol.  PCR was carried out 
using SYBR Green PCR Master Mix from PE Applied Biosystems (Warrington, 
UK) on an ABI Prism 7700 Sequence Detection System (PE Applied 
Biosystems).  The 25 mL final volume contained 0.5 mM of each primer and 2 mL 
of cDNA template.  TATA binding protein (TBP) was used as an exogenous 
control to compare the relative amount of target gene in different samples.  The 
PCR profile was as follows:  1 cycle of 95°C for 10 minutes, then 40 cycles of 
95°C for 15 s and 60°C for 1 min.  The comparative CT method was used for 
relative quantitation of samples.  Primers were purchased from Integrated DNA 
Technologies (Coralville, IA).   
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The following primers were used:   
KDR (F): 5’- CAC CAC TCA AAC GCT GAC ATG TA -3’  
KDR (R): 5’- CCA ACT GCC AAT ACC AGT GGA T -3’  
TBP (F): 5’- TGC ACA GGA GCC AAG AGT GAA -3’    
TBP (R): 5’- CAC ATC ACA GCT CCC CAC CA -3’   
 
2.2.8. Preparation of nuclear extracts  
Cells were cultured in medium without phenol red, supplemented with 
2.5% charcoal stripped FBS.  The next day, cells were switched to serum free 
media without phenol red for 1-3 days.  Cells were washed in PBS (2X), scraped 
in 1 ml of 1X lysis buffer, incubated at 4ºC for 15 min, and centrifuged 1 min at 
14,000 x g.  Cell pellets were washed in 1 ml of lysis buffer (3X).  Lysis buffer 
supplemented with 500 mM KCl was then added to the cell pellet and incubated 
for 45 min at 4ºC with frequent vortexing.  Nuclei were pelleted by centrifugation 
at 14,000 x g for 1 min at 4ºC, and aliquots of supernatant were stored at -80°C 
until needed. 
 
2.2.9. Electrophoretic Mobility Shift Assays (EMSA)   
VEGFR2 oligonucleotide (-64 5’-CCG GCC CCG CCC CGC ATG GCC 
CCG CCT CCG-3’ -35) was synthesized and annealed, and 5 pmol aliquots 
were [32P] labeled at the 5’-end using T4 polynucleotide kinase (Invitrogen) and 
[g32P]ATP (NEN-Dupont, Boston, MA).  A 30 ml EMSA mixture contained ~100 
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mM KCl, 3 mg of crude nuclear protein, 1 mg poly(dI-dC) (Roche Molecular 
Biochemicals, Basel, Switzerland), with or without unlabeled competitor 
oligonucleotide, and ~10 fmol of radiolabeled probe.  After incubation for 20 min 
on ice, antibodies against Sp1, Sp3, or Sp4 proteins were added and incubated 
another 20 min on ice.  Protein-DNA complexes were resolved by 5% 
polyacrylamide gel electrophoresis as previously described (Stoner et al., 2004; 
Abdelrahim et al., 2004).  Specific DNA-protein and antibody-supershifted 
complexes were observed as retarded bands in the gel, and were visualized by 
exposure to a phosphor-storage screen, followed by scanning on a STORM 860 
(Molecular Dynamics, Sunnyvale, CA).   
 
2.2.10. Chromatin Immunoprecipitation (ChIP) assay  
MiaPaCa-2, Panc-1, and AsPC-1 cells (1x107 each) were fixed with 1.5% 
formaldehyde, and the cross-linking reaction was stopped by addition of 0.125 M 
glycine.  Cells were scraped, pelleted, and hypotonically lysed, and nuclei were 
collected.  Nuclei were then sonicated to desired chromatin length (~500bp).  
The chromatin was precleared by addition of protein A-conjugated beads (Pierce 
Biotechnology, Rockford, IL).  The precleared chromatin supernatants were 
immunoprecipitated with antibodies specific to IgG, TFIIB, Sp1, Sp3, and Sp4 
(Santa Cruz Biotechnology) at 4°C overnight.  The protein-antibody complexes 
were collected by addition of protein A-conjugated beads for 1 hr, and the beads 
were extensively washed.  The protein-DNA crosslinks were eluted and 
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reversed.  DNA was purified by Qiaquick Spin Columns (Qiagen) and followed 
by PCR amplification. The VEGF primers are: 5’ - GGT CGA GCT TCC CCT 
TCA - 3’ (forward) and 5’ - GAT CCT CCC CGC TAC CAG - 3’ (reverse), which 
amplify a 202-bp region of human VEGF promoter containing GC-rich/Sp1 
binding sites.  The VEGFR2/KDR primers are: 5’ - GTC CAG TTG TGT GGG 
GAA AT - 3’ (forward) and 5’ - GAG CTG GAG CCG AAA CTC TA - 3’ (reverse), 
which amplify a 169-bp region of human VEGFR2/KDR promoter containing GC-
rich/Sp1 binding sites.  The positive control primers are: 5’ - TAC TAG CGG TTT 
TAC GGG CG - 3’ (forward) and 5’ - TCG AAC AGG AGG AGC AGA GAG CGA 
- 3’ (reverse), which amplify a 167-bp region of human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene.  The negative control primers are: 5’ 
- ATG GTT GCC ACT GGG GAT CT - 3’ (forward) and 5’ - TGC CAA AGC CTA 
GGG GAA GA - 3’ (reverse), which amplify a 174-bp region of genomic DNA 
between the GAPDH gene and the CNAP1 gene.  PCR products were resolved 
on a 2% agarose gel in the presence of 1:10,000 SYBR gold (Molecular Probes-
Invitrogen, Carlsbad, CA). 
 
2.2.11. Immunofluorescence  
Rabbit polyclonal antibody for VEGFR2/KDR was purchased from Santa 
Cruz Biotechnology. Fluorescein isothiocyanate (FITC)-conjugated goat anti-
rabbit immunoglobulin G (IgG) was purchased from Jackson ImmunoResearch 
Laboratories (West Grove, PA) or Santa Cruz Biotechnology.  Panc-1 cells were 
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seeded in Lab-Tek chamber slides (Nalge Nunc International, Naperville, IL) at 
100,000 cells/well in phenol red-free DME/F12 medium supplemented with 5% 
charcoal-stripped FBS.  Cells were then transfected with iRNAs as described 
previously and, after 48 hr, were fixed with cold methanol at -20°C for 5 min.  
After washing with PBS, cells were blocked with 4% goat serum at 4°C overnight 
and incubated with the primary rabbit polyclonal antibody against VEGFR2 
(1:25) at 37°C for 1 hr.  After washing with PBS/0.1% Tween 3 x 10 min, the 
samples were incubated with FITC-conjugated goat anti-rabbit IgG (1:500) at 
room temperature for 1 hr.  After PBS/Tween rinsing, glass coverslips were 
mounted over the samples with mounting medium containing 4’,6-diamidino-2-
phenylindole (Vector Laboratories, Burlingame, CA), and cells were examined 
with a fluorescence microscope.  
 
2.2.12. Statistical analysis  
Results of transient transfection studies are presented as means (+/-)  
standard error (S.E.) for at least three replicates for each treatment group.  All 
other experiments were carried out at least two times to confirm a consistent 
pattern of responses. Significant statistical differences between treatment 
groups were determined by analysis using SuperANOVA and Scheffe’s test or 
Fisher’s Protected LSD (p < 0.05).  
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2.3. Results 
2.3.1. VEGFR2 expression in human pancreatic cancer cells 
Several studies have reported expression of VEGF in pancreatic tumors 
and cancer cells and have identified a role for this protein and other angiogenic 
factors in tumor growth and metastasis (109, 226, 228, 229).  A recent study did 
not detect expression of VEGFR2 in pancreatic cancer cells using reverse 
transcriptase-PCR (230).  Real-time PCR was used in this study to analyze 
expression of VEGFR2 mRNA in several pancreatic cancer cell lines including 
Panc-1, AsPC-1, Panc-28, HPAFII, BxPC-3, and MiaPaCa-2 cells.  VEGFR2 
mRNA was detected in all cell lines tested, and the relative expression levels 
between cell lines were determined by comparison with TATA binding protein 
(TBP) (Table 8).  Relatively high VEGFR2 expression was observed in Panc-1 
and AsPC-1 cells, lower levels of VEGFR2 mRNA were detected in Panc-28 and 
HPAFII cells, and among these six cell lines, the lowest levels were observed in 
BxPC-3 and MiaPaCa-2 cells.  Subsequent transfection studies have used 
Panc-1, AsPC-1, and MiaPaCa-2 cells as models since they express both high 
and low VEGFR2 mRNA levels and are readily transfectable.  
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  Table 8. VEGFR2 expression in pancreatic cancer cellsa. 
 
    a - Expression of VEGFR2 mRNA detected by Real-time  
   PCR in pancreatic cancer cell lines relative to TATA  
   binding protein (TBP). 
 
 
 
 
2.3.2. Analysis of VEGFR2 gene promoter constructs in Panc-1, AsPC-1, and 
MiaPaCa-2 pancreatic cancer cells 
The proximal region of the VEGFR2 promoter contains multiple cis-
elements (170, 231, 232), and the relative contributions of these motifs to 
expression of VEGFR2 were investigated in transient transfection studies.  
Panc-1 human pancreatic cancer cells were transiently transfected with 
pVEGFR2A which contains the -716 to +268 promoter insert and also a series of 
5’ deletion constructs including pVEGFR2B, pVEGFR2C, pVEGFR2D, and  
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pVEGFR2E (Figure 24).  Luciferase activity was comparable even after deletion 
of the -716 to -78 region of the VEGFR2 promoter; however, activity was 
significantly decreased by approximately 35% in Panc-1 cells after deletion of 
the promoter region between -77 to -61.  This suggests that overlapping GC-
rich/ AP-2 motifs may contribute to the basal activity of VEGFR2.  Upon further 
deletion of the two GC-rich sites between -60 to -37, basal activity was 
decreased by > 80%.  Mutation analysis of the proximal GC-rich motifs shows 
that basal activity was also decreased in cells transfected with constructs 
containing single mutations of each of these sites (pVEGFR2Em1 and 
pVEGFR2Em2), and a further decrease was observed in cells transfected with 
the double mutant (pVEGFR2Em3).  Thus, results of deletion/mutation analysis 
of the VEGFR2 promoter in Panc-1 cells show that basal activity is primarily due 
to two proximal GC-rich motifs between -60 to -37. 
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Figure 24. Deletion and mutation analysis of the VEGFR2 gene promoter in 
Panc-1 cells.  Panc-1 cells were transiently transfected with 500 ng of each 
pVEGFR2 reporter construct (or pGL2 empty vector), and luciferase 
activity was determined as described in the Materials and methods.  
Significantly (p < 0.05) decreased activity compared to that observed for 
pVEGFR2A is indicated by an asterisk.  Results are presented as means +/- 
S.E. for at least 3 determinations for each treatment group.  
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The pattern of activity of the VEGFR2 deletion and mutated constructs 
was also investigated in two additional pancreatic cancer cell lines which are 
also known to express Sp proteins that bind GC-rich motifs (158).  The results 
obtained in AsPC-1 cells are illustrated in Figure 25.  There was a significant 
45% decrease in activity after deletion of the -95 to -78 region of the promoter, 
and further deletion of the overlapping GC-rich/AP-2 motifs (-77 to -61) did not 
significantly result in further decreased luciferase activity.  Thus, in contrast to 
Panc-1 cells, the AP-2/NFkB sites (-95 to -78) contribute to basal activity of the 
VEGFR2 promoter constructs in AsPC-1 cells; however, analysis of the proximal 
-60 to -37 region of the promoter shows that both proximal GC-rich sites are the 
major cis-elements required for basal activity in both AsPC-1 (Figure 25) and 
Panc-1 (Figure 24) cells. The role of the proximal GC-rich motifs in modulating 
basal activity of VEGFR2 constructs in MiaPaCa-2 cells which express lower 
levels of the VEGFR2 mRNA transcript (Table 8) was also investigated.  The 
results of transfection studies (Figure 26) show that the loss of activity in 
MiaPaCa-2 cells is only observed after deletion of the -60 to -38 GC-rich sites. 
Mutation analysis shows that both the -58 and -44 GC-rich motifs are required 
for maximal activity suggesting cooperative interactions between Sp proteins 
bound in this region of the VEGFR2 promoter in MiaPaCa-2 cells.  These results 
(Figures 24-26) indicate that the proximal GC-rich sites at -58 and -44 are critical 
cis-elements for constitutive expression of VEGFR2 in pancreatic cancer cells. 
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Figure 25. Deletion and mutation analysis of the VEGFR2 gene promoter in 
AsPC-1 cells.  AsPC-1 cells were transiently transfected with 500 ng of 
each pVEGFR2 reporter construct (or pGL2 empty vector), and luciferase 
activity was determined as described in the Materials and methods.  
Significantly (p < 0.05) decreased activity compared to that observed for 
pVEGFR2A is indicated by an asterisk.  Results are presented as means +/- 
S.E. for at least 3 determinations for each treatment group.  
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Figure 26. Deletion and mutation analysis of the VEGFR2 gene promoter in 
MiaPaCa-2 cells. MiaPaCa-2 cells were transiently transfected with 500 ng 
of each pVEGFR2 reporter construct (or pGL2 empty vector), and 
luciferase activity was determined as described in the Materials and 
methods.  Significantly (p < 0.05) decreased activity compared to that 
observed for pVEGFR2A is indicated by an asterisk.  Results are presented 
as means +/- S.E. for at least 3 determinations for each treatment group.  
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2.3.3. Role of Sp proteins in regulating VEGFR2 expression in pancreatic cancer 
cells  
 Results in Figure 27A summarize the Western blot analysis of whole cell 
lysates from MiaPaCa-2, Panc-1, and AsPC-1 cells and show that Sp1, Sp3, 
and Sp4 are expressed in all three cell lines. The role of Sp proteins in mediating 
regulation of VEGFR2 expression in pancreatic cancer cells was investigated by 
RNA interference in Panc-1, AsPC-1, and MiaPaCa-2 cells using small inhibitory 
RNAs (siRNAs) for Sp1 (iSp1), Sp3 (iSp3), and Sp4 (iSp4).  Initial studies on the 
effectiveness of these siRNAs were carried out in Panc-1 cells transfected with 
different amounts of iSp1 (Figure 27B).  The results showed that 20 nM iSp1 
decreased Sp1 protein expression by 45-58% based on Western blot analysis of 
whole cell lysates.  Since transfection efficiencies vary from 60-95% in this cell 
line, the results represent a relatively high percentage of Sp1 protein knockdown 
in the transfected cells.  In this study, expression of Sp3 and Sp4 proteins were 
unaffected by iSp1 (data not shown), and this has previously been observed with 
this same siRNA oligonucleotide in Panc-1 cells (158).  Using a comparable 
approach, 20 nM iSp3, 20 nM iSp4, and iLamin (control) were also transfected 
into Panc-1 cells, and protein levels relative to those in iLamin transfected cells 
were determined by Western blot analysis (Figure 27C).  Both iSp3 and iSp4 
were highly effective in decreasing expression of Sp3 and Sp4 proteins, 
respectively.  Protein expression was decreased using 5-20 nM of the siRNAs, 
and higher levels of siRNAs appeared to be less effective (data not shown).  A 
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similar approach was used for MiaPaCa-2 (Figure 27D) and AsPC-1 cells 
(Figure 27E), and the results show the iSp1, iSp3, and iSp4 specifically 
knockdown Sp1, Sp3, and Sp4 proteins respectively as determined by Western 
blot analysis of whole cell lysates.  
 
 
 
 
Figure 27. Sp protein expression and Sp protein knockdown in pancreatic 
cancer cells by RNA interference. A. Sp protein expression. Whole cell 
lysates from Panc-1, AsPC-1, and MiaPaCa-2 cells were analyzed for Sp1, 
Sp3, and Sp4 by Western blot analysis as described in the Materials and 
methods. 
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Figure 27. (Continued) B. Effects of iSp1 in Panc-1 cells. Different amounts 
of iSp1 were transfected in Panc-1 cells, and protein levels were 
determined by Western blot analysis as described in the Materials and 
methods.  C. Effects of iSp3 and iSp4 in Panc-1 cells.  Panc-1 cells were 
transfected with 20 nM iSp3 or iSp4, and protein levels were determined by 
Western blot analysis as described in the Materials and methods.  Protein 
expression was quantitated relative to levels in cells treated with iLamin 
(control), and results are expressed as means +/- S.E. for at least 3 
determinations for each treatment group.  A significant (p < 0.05) decrease 
in protein expression level is indicated by an asterisk. 
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Figure 27. (Continued) Knockdown of Sp proteins in MiaPaCa-2 (20 nM) (D) 
and AsPC-1 cells (5 nM) (E) by RNA interference. Cells were transfected 
with iLamin, iSp1, iSp3, or iSp4, and whole cell lysates were analyzed by 
Western blot as described in the Materials and methods.  
 
 
The relative contributions of Sp1, Sp3, and Sp4 proteins in regulating 
VEGFR2 expression was investigated in pancreatic cancer cells cotransfected 
with the pVEGFR2A or pVEGFR2E constructs and iSp1, iSp3, or iSp4.  Panc-1 
cells were cotransfected with pVEGFR2A (Figure 28A) and pVEGFR2E (Figure 
28B) and iLamin (non-specific control), iGL2 (positive control), iSp1, iSp3, and 
iSp4.  The results show that all three siRNAs for Sp proteins decreased 
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luciferase activity in Panc-1 cells transfected with either construct.  Transfection 
with iGL2 decreased luciferase activity by > 90-95% and served as a control 
showing the effectiveness of RNA interference in the transfected cells.  The 
effects of iSp1, iSp3, and iSp4 were also investigated in AsPC-1 and MiaPaCa-2 
cells transfected with pVEGFR2A and pVEGFR2E (Figures 28C-F).  The results 
showed that all three siRNAs decreased activity in AsPC-1 (Figures 28C & 28D) 
and MiaPaCa-2 (Figures 28E & 28F) cells transfected with pVEGFR2A or 
pVEGFR2E and confirm a role for Sp1, Sp3, and Sp4 proteins in regulating 
VEGFR2 expression in pancreatic cancer cells.  The results are similar to those 
observed for Sp-dependent regulation of VEGF in pancreatic cancer cells (158) 
and suggest an important role for Sp1, Sp3, and Sp4 proteins in mediating 
expression of two critical angiogenic factors in pancreatic cancer cells.   
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Figure 28. Effects of Sp proteins on regulation of VEGFR2 in pancreatic 
cancer cells.  pVEGFR2A or pVEGFR2E constructs were transfected in 
Panc-1 (A, B), AsPC-1 (C, D), or MiaPaCa-2 (E, F) cells, cotransfected with 
iLamin, iGL2, iSp1, iSp3, or iSp4, and luciferase activity was determined as 
described in the Materials and methods.  Results are expressed as means 
+/- S.E. for three replicate determinations for each treatment group, and 
significant (p < 0.05) inhibition of luciferase activity is indicated by an 
asterisk.  iLamin serves as a non-specific control plasmid, and iGL2 is a 
positive control siRNA that targets the luciferase mRNA as described 
(158). 
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The effects of Sp proteins on VEGFR2 mRNA expression were also 
determined in Panc-1 and AsPC-1 cells transfected with a combination of 
siRNAs for Sp1, Sp3, and Sp4 (Figures 29A & 29B).  These cells were used in 
this study because of their relatively high expression of VEGFR2 mRNA (Table 
8).  Real-time PCR analysis of mRNA from both cell lines show that knockdown 
of Sp1, Sp3, and Sp4 resulted in a significant decrease in VEGFR2 mRNA 
expression in both cell lines.  These results complement the VEGFR2 promoter 
studies and confirm that VEGFR2 expression in pancreatic cancer cells is 
regulated by Sp1, Sp3, and Sp4.  The role of Sp proteins in VEGFR2 expression 
was also investigated in Panc-1 cells by immunofluorescent staining (Figure 
29C).  Cytoplasmic green staining for VEGFR2 was observed in cells 
transfected with iScr (non-specific) (panel a), and intensity of this staining was 
decreased after transfection of iSp1 (panel b) or iSp4 (panel c).  Nuclei are 
stained blue with DAPI.  These data confirm expression of VEGFR2 protein in 
this cell line and the role of Sp proteins in mediating VEGFR2 expression.   
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Figure 29. Decreased VEGFR2 expression by RNA interference in 
pancreatic cancer cells. Downregulation of VEGFR2 mRNA by siRNA for 
Sp-proteins in Panc-1 (A) and AsPC-1 (B) human pancreatic cancer cells.  
Panc-1 cells were transfected with siRNA for Sp1 (10 nM), Sp3 (20 nM), and 
Sp4 (20 nM) or iLamin (50 nM) (control), and AsPC-1 cells were transfected 
with siRNA for Sp1 (5 nM), Sp3 (5 nM), and Sp4 (5 nM) or iLamin (15 nM) 
(control).  After 48 hr, RNA was isolated using the RNeasy Protect Mini Kit 
(Qiagen), and samples were analyzed by Real-time PCR as described in the 
Materials and methods (A, B). Results are presented as means +/- S.E. for 
at least 3 determinations for each treatment group.  Significant (p < 0.05) 
inhibition of VEGFR2 mRNA levels (relative to iLamin) is indicated by an 
asterisk (*).  Immunofluorescence detection of VEGFR2 in Panc-1 cells 
transfected with siRNA for Sp proteins (C). Panc-1 cells were transiently 
transfected with iScr (a), iSp1 (b), and iSp4 (c), and stained for VEGFR2 
(green) and nucleus with 4',6-Diamidino-2-phenylindole–stained (blue) as 
described in the Materials and methods. Photographs were taken at the 
magnification of X400.  
 
 109 
The direct binding of Sp proteins to the proximal region of the VEGFR2 
promoter was initially investigated in electrophoretic mobility shift assays using 
an oligonucleotide (VEGFR2-32P) derived from the -64 to -35 region of the 
VEGFR2 promoter (Figure 30A).  Extracts from Panc-1, MiaPaCa-2, and AsPC-
1 cells (lanes 2-4) gave a pattern of protein-DNA complexes in which the least 
mobile band contains Sp1, Sp3, and Sp4 as previously reported (158), and the 
more mobile band contains Sp3 protein.  These assignments were confirmed in 
supershift experiments with antibodies for Sp1 (lane 5), Sp3 (lane 6), and Sp4 
(lane 7).  Non-specific IgG (lane 8) did not affect the pattern of retarded bands, 
and in the absence of cell extracts [lane 1, free probe (FP)], only the 
radiolabeled oligonucleotide probe was observed.  Interactions of Sp proteins 
with the GC-rich region of the VEGFR2 promoter was further investigated in a 
ChIP assay using primers that target the proximal region of the VEGFR2 
promoter (Figures 30B & 30C).  The results show that Sp1, Sp3, and Sp4 bind to 
the VEGFR2 promoter in MiaPaCa-2, AsPC-1, and Panc-1 cells, and we also 
show that these Sp proteins bind to the corresponding GC-rich region of the 
VEGF promoter (Figures 30B & 30C).  As a control for the ChIP assay, we show 
that TFIIB binds to the proximal region of the GAPDH promoter but not exon-1 of 
CNAP1 (Figure 30D) as previously described (233).  The ChIP assay confirms 
that Sp1, Sp3, and Sp4 bind to the VEGFR2 promoter, and this is consistent 
with the role of these transcription factors in mediating the expression of 
VEGFR2 in pancreatic cancer cell lines.  
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Figure 30. Sp protein binding to the VEGFR2 promoter in pancreatic 
cancer cells.  A. Electrophoretic mobility shift assay.  Nuclear extracts 
from Panc-1, AsPC-1, and MiaPaCa-2 cells were incubated with 
radiolabeled VEGFR2-32P alone or in the presence of unlabeled 
oligonucleotides and/or antibodies, and DNA-protein complexes were 
separated by EMSA as described in the Materials and methods. Arrows 
indicate various retarded and supershifted complexes. 
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Figure 30. (Continued) B. Summary of primers (Æ  ¨) and targeted regions 
of the VEGF and VEGFR2 promoters used in ChIP assays.  C. Analysis of 
protein interactions with the VEGF and VEGFR2 promoter by ChIP.  
MiaPaCa-2, Panc-1, and AsPC-1 cells were harvested and analyzed in a 
ChIP assay as described in the Materials and methods. D. Binding of TFIIB 
to the GAPDH promoter. The ChIP assay was also used to examine binding 
of TFIIB to the GAPDH promoter (positive control) and to exon 1 of CNAP1 
(negative control) as described in the Materials and methods. 
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2.4. Discussion 
 Angiogenesis is a key process in both physiologic and carcinogenic 
pathways where angiogenic factors play a critical role in tumor cell growth and 
metastasis (21, 23, 164).  VEGF proteins and related placental growth factors 
regulate angiogenesis through interactions with the transmembrane receptors 
VEGFR1, VEGFR2, VEGFR3, neurophilins, and a soluble form of VEGFR1 
which does not express the transmembrane or tyrosine kinase domains (161, 
234, 235).  VEGF is overexpressed in multiple tumors and cancer cells, and for 
some cancers, VEGF is a negative prognostic factor (236, 237).  VEGFR1 and 
VEGFR2 are also expressed in tumors and cancer cells, but their prognostic 
significance and function have not been extensively investigated.  VEGFR2 was 
expressed in over 64% of a set of breast tumors, and expression was highly 
correlated with proliferation indices (183).  Also, in another mammary tumor 
study, there was a correlation between VEGF and VEGFR2 expression (167).  
VEGFR1 and VEGFR2 are expressed in other tumors and cancer cell lines (167, 
179, 183, 238-240), and VEGFR2 expression increases while VEGFR1 
decreases during prostate tumor progression (240).   
 The molecular mechanism of VEGFR2 expression has primarily been 
investigated in endothelial cells using various constructs containing VEGFR2 
promoter inserts.  The VEGFR2 promoter is highly complex and contains 
multiple cis-elements including GATA, E-box, GC-rich, NFkB, and AP-2 motifs 
(170, 231, 232).  However, deletion analysis and DNA footprinting studies in 
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endothelial cells indicate that interactions of Sp1 protein with proximal GC-rich  
(-110 to -25) are important for basal and sheer-stress-induction of transactivation 
in cells transfected with pVEGFR2 constructs (161, 170, 231, 232).  These 
results are similar to those observed for VEGF expression in breast, colon, and 
pancreatic cancer cells where proximal GC-rich sites in the VEGF promoter are 
required for basal and hormone-induced transactivation (109, 156-158).  Real-
time PCR showed that VEGFR2 mRNA is expressed in a series of pancreatic 
cancer cell lines (Table 8), and we also detected VEGFR2 by immunostaining 
(Figure 29C).  In addition, we investigated the molecular biology of VEGFR2 
regulation in three cell lines that are readily transfected and express high (Panc-
1, AsPC-1) and low (MiaPaCa-2) VEGFR2 mRNA levels (Table 8).  In cells 
transfected with a series of deletion constructs (Figures 24-26), basal luciferase 
activity was primarily dependent on two GC-rich sites at -58 and -44 in Panc-1 
and MiaPaCa-2 cells, and in AsPC-1 cells there was also a significant 
contribution from the -95 to -78 region of the promoter which also contains AP-
2/NFkB sites.  These results illustrate that the proximal GC-rich sites at -58 and  
-44 in the VEGFR2 promoter are important for transactivation, and this parallels 
results obtained for regulation of VEGF in Panc-1 cells where proximal GC-rich 
sites were also critical for expression (158).   
 Several studies show that Sp1 is overexpressed in tumors, and this 
transcription factor regulates expression of VEGF and other genes associated 
with cancer cell proliferation (226-229).  Our results show that Sp1 is expressed 
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in Panc-1, AsPC-1, and MiaPaCa-2 cells and that these cells also contain Sp3 
and Sp4 proteins (Figure 27A).  Sp1 and Sp3 are often coexpressed in cancer 
cell lines and cooperatively activate some GC-rich promoters, although Sp3 also 
inhibits other Sp1-dependent genes.  For example, Sp3 attenuated Sp1-
mediated activation of VEGFR2 in endothelial cells (231).  Electrophoretic 
mobility shift and ChIP assays (Figure 30) show that Sp1, Sp3, and Sp4 are 
expressed in these pancreatic cancer cell lines and bind to proximal GC-rich 
motifs in the VEGFR2 promoter.  RNA interference studies with inhibitory RNAs 
for Sp1, Sp3, and Sp4 demonstrate that all three proteins not only regulate 
transactivation in cells transfected with pVEGFR2 constructs (Figure 28) but are 
also important for VEGFR2 mRNA (Figures 29A & 29 B) and protein (Figure 
29C) expression.  These results demonstrate that, like VEGF (158), VEGFR2 
expression is regulated by multiple Sp transcription factors in pancreatic cancer 
cell lines.   
Chemotherapies targeting the tyrosine kinase domains of VEGFR2 are 
currently being developed for inhibiting tumor angiogenesis and metastasis 
(241-244).  Results of this study also suggest that drugs such as mithramycin 
that target GC-rich promoters or cyclooxygenase inhibitors that induce Sp 
protein degradation will also exhibit antiangiogenic activity in pancreatic and 
other cancer cells through their effects on VEGF/VEGFR2 expression (225, 245, 
246).  Current studies in this laboratory are investigating chemotherapies that 
specifically target Sp transcription factors alone or in combination with other 
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agents such as gemcitabine or tyrosine kinase inhibitors as novel drug 
combinations for treatment of pancreatic cancer and for inhibition of 
angiogenesis through downregulation of Sp-dependent genes such as VEGFR2.  
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CHAPTER III 
 
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 
EXPRESSION IS INDUCED BY 17b-ESTRADIOL IN ZR-75 
BREAST CANCER CELLS BY ESTROGEN RECEPTOR a/Sp 
PROTEINS 
 
3.1. Introduction 
 Angiogenesis involves formation of blood vessels from vascular 
endothelial cells and pre-existing vessels and is a critical process required for 
neovascularization in normal and cancerous tissues (21, 23, 247).  New blood 
vessel formation is necessary for diverse biological processes including 
numerous steps in embryogenesis and wound repair, and several diseases 
including diabetes, cancer, and inflammation are also dependent on angiogenic 
pathways.  Although angiogenesis is dependent on the interplay of many cellular 
factors, key mediators of this response include vascular endothelial growth 
factor (VEGF) and its cognate receptors, VEGF receptor (VEGFR) (161, 234, 
235).  VEGF or vascular permeability factor belongs to the VEGF-platelet-
derived growth factor gene family.  Several major forms of VEGF are expressed 
in different tissues and cells based on alternative splicing.  VEGFRs are 
transmembrane tyrosine kinase receptors that are expressed as three major 
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forms, namely VEGFR1 (Flt-1)/soluble VEGFR1 (sFlt-1), VEGFR2 (KDR/Flk-1), 
and VEGFR3 (Flt-4).   Among these three receptors, VEGFR2 is generally 
recognized as the major form that mediates VEGF-induced responses (235). 
 VEGFR2 is highly expressed in endothelial cells and has also been 
detected in tumors and cancer cell lines derived from multiple tissues (163, 167, 
179, 183, 238-240, 248-250).  For example, VEGFR2 expression is increased in 
prostate cancer samples compared to normal prostate, and there is a switch 
from VEGFR1 expression to VEGFR2 expression during prostate tumor 
progression (240).  This switch is important because VEGFR1 and VEGFR2 
differ considerably in their signaling properties: VEGFR2 is the primary initiator 
of angiogenesis, while VEGFR1 may be an inhibitor of angiogenesis in some 
tumors (239).  VEGFR2 and VEGF are co-expressed in primary breast 
carcinomas, and their expression is increased when tumors shift to an 
angiogenic phenotype.  In addition, VEGFR2 is constitutively expressed in 
breast tumor epithelial cultures but exhibits decreased expression in stromal cell 
cultures (163).  Angiogenesis is hormonally regulated in breast cancer cells and 
other estrogen-responsive tissues, and E2 induces VEGF expression in many of 
these cells and tissues (157, 185, 251-260).  Hormonal regulation of VEGFR2 
has previously been observed in bovine retinal capillary endothelial cells where 
E2 induces expression of both VEGFR2 and VEGF (184).    
Although VEGFR2 is expressed in many different tumor types and has 
been detected in various cancer cell lines, to our knowledge, little is known 
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about the mechanism of regulation of VEGFR2 in hormonally regulated tissues/ 
cells including various cancer cell lines.  The VEGFR2 gene promoter is highly 
complex with multiple cis-elements; however, consensus or non-consensus ERE 
motifs have not been identified in the 5'-promoter region of this gene (170).  In 
this study, we show that VEGFR2 is expressed in estrogen receptor (ER)-
positive ZR-75 breast cancer cells and that gene expression is increased after 
treatment of these cells with E2.  Analysis of the VEGFR2 gene promoter shows 
hormone responsiveness is primarily due to two proximal GC-rich motifs (-60 to -
37) that bind Sp proteins, and hormonal activation of VEGRF2 is associated with 
ERa/Sp protein-mediated transactivation.  These results are similar to those 
previously observed for hormonal activation of VEGF in the same cell line (157) 
and suggest a common induction mechanism for both angiogenic factors.  
However, in contrast to previous reports showing that ERa/Sp1 is important for 
activation of hormone-responsive genes in breast cancer cells (143, 146, 149, 
152, 153, 261), VEGFR2 is primarily regulated by ERa/Sp3 and ERa/Sp4. 
 
3.2. Materials and methods 
3.2.1. Chemicals and plasmids   
Dimethyl sulfoxide (Me2SO), E2, 4'-hydroxytamoxifen, 100X 
antibiotic/antimycotic solution, and phosphate buffered saline (PBS) were 
purchased from Sigma Chemical Company (St. Louis, MO).  ICI 182,780 was 
kindly provided by Dr. Alan Wakeling (AstraZeneca, Macclesfield, UK).  Lysis 
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buffer, luciferase reagent, restriction enzymes (XhoI and HindIII), and ligase 
were purchased from Promega (Madison, WI).  b-galactosidase reagents were 
purchased from Tropix (Bedford, MA). Taq polymerase and other PCR reagents 
were purchased from Perkin Elmer (Boston, MA). Progesterone and other 
chemicals of the highest quality possible were obtained from commercial 
sources.  
Human ERa expression plasmid was provided by Dr. Ming-Jer Tsai 
(Baylor College of Medicine, Houston, TX).  ERa deletion constructs HE11C 
(DBD of ERa deleted) and HE19C (AF-1 domain of ERa deleted) were originally 
obtained from Dr. Pierre Chambon (Instutut de Genetique et de Biologie 
Moleculaire et Cellulaire, Illkirch, France) and inserted into vectors pCDNA3 and 
pCDNA3.1/His C.  pCDNA3.1-His-LacZ expression plasmid was obtained from 
Invitrogen (Carlsbad, CA).  VEGFR2 promoter luciferase constructs pVEGFR2A, 
pVEGFR2B, and pVEGFR2C (previously named pKDR-716/+268, pKDR-
225/+268, and pKDR-95/+268) were provided by Dr. Arthur Mu-EnLee 
(deceased) and Dr. Koji Maemura (Cardiovascular Biology Lab, Boston, MA).  
pGL2 basic luciferase reporter vector was purchased from Promega. 
 
3.2.2. Cell lines and tissue culture 
The human breast cancer cell line ZR-75 was obtained from American 
Type Culture Collection (ATCC, Manassas, VA).  Cells were maintained in RPMI 
1640 media (Sigma) supplemented with 10% Fetal Bovine Serum (FBS) 
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(Summit Biotechnology, Fort Collins, CO; Intergen, Des Plains, IA; JRH 
Biosciences, Lenexa, KS; or Atlanta Biologicals, Inc., Norcross, GA).  Medium 
was further supplemented with 1.5 g/L sodium bicarbonate, 2.38 g/L HEPES, 
0.11 g/L sodium pyruvate, and 100X antibiotic/antimycotic solution (Sigma).  
Cells were maintained at 37ºC with a humidified CO2:air (5:95) mixture.  
 
3.2.3. Cloning and oligonucleotides 
VEGFR2 promoter-derived oligonucleotides, PCR primers, and primers 
employed in plasmid construction were synthesized by Genosys/Sigma (The 
Woodlands, TX) or Integrated DNA Technologies (IDT) (Coralville, IA).  VEGFR2 
promoter deletion constructs pVEGFR2D, pVEGFR2E, pVEGFR2F, and 
pVEGFR2G were created by PCR amplification using pVEGFR2A as the 
template.  Forward primers were designed with XhoI restriction enzyme sites at 
the 5'-end.  A reverse luciferase primer was used for PCR.  PCR products were 
digested with XhoI and HindIII, and subsequently ligated into the pGL2 basic 
vector.  All constructs are in pGL2 basic luciferase reporter vector, and all 
constructs were sequenced to verify their identity.  Mutation constructs 
pVEGFR2Em1, pVEGFR2Em2, and pVEGFR2Em3 were constructed by PCR 
amplification using the reverse luciferase primer paired with the forward primer 
containing the desired mutations.  Forward primers are as follows: (mutated 
bases are underlined) 
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   XhoI      -60 
M1=5’-GAT GAT CTC GAG CCA AGC CCC GCA TGG CCC CGC C-3’ 
    
M2=5’-GAT GAT CTC GAG CCC CGC CCC GCA TGG CCA AGC CTC CGC  
GC-3’ 
 
M3=5’-GAT GAT CTC GAG CCA AGC CCC GCA TGG CCA AGC CTC CGC  
GC-3’ 
 
 
 
3.2.4. Transient transfection assays   
Cells were seeded in 12-well plates at a concentration of 1.5-3.0 x 105 
cells per well in phenol red-free DME/F12 media supplemented with 2.5% 
charcoal-stripped FBS.  After 18-24 hr, the appropriate VEGFR2 luciferase 
reporter plasmid (500 ng), ERa or ERa deletion construct expression plasmid 
(500 ng), and pCDNA3.1-His-LacZ expression plasmid (250 ng) (for 
normalization of transfection efficiency) were transiently cotransfected into ZR-
75 cells using the calcium phosphate-DNA co-precipitation method.  pCDNA3.1 
empty vector was transfected to maintain DNA mass balance among different 
transfection groups.  An estrogen-responsive pC3-Luc construct, containing the 
mouse complement-3 (C3) gene promoter insert, was kindly provided by Dr. 
Donald P. McDonnell (Duke University Medical School, Durham, NC) and was 
used as a positive control in most experiments to confirm hormone 
responsiveness of the transfected cells.   
After transfection (4-8 hr), cells were shocked with 25% glycerol in PBS to 
increase transfection efficiency.  Then cells were washed with PBS and treated 
 122 
for 24-48 hr with fresh serum-free DME/F12 medium containing 10 nM E2, 10 
nM progesterone (P), 10 nM E2 + 1 mM ICI 182,780, 1 mM !ICI 182,780 dissolved 
in Me2SO, or Me2SO alone as a solvent control.  Cells were harvested by 
scraping the plates in 100-200 mL of 1X lysis buffer (Promega).  An aliquot of 
soluble protein was obtained by one cycle of freezing/thawing the cells, 
vortexing (30 s), and centrifuging at 12,000 x g (1 min).  Cell lysates (30 mL) 
were assayed for luciferase activity using Luciferase Assay Reagent (Promega) 
and b-galactosidase activity using Tropix Galacto-Light Plus assay system 
(Tropix) in a Lumicount micro-well plate reader (Packard Instrument Co., 
Downers Grove, IL).  Relative luciferase activity was normalized to relative b-
galactosidase units for each transfection experiment.  
 
3.2.5. Transient transfection of siRNA   
Cells were cultured in phenol red-free DME/F12 medium supplemented 
with 2.5% charcoal stripped FBS in 12-well plates until 50-70% confluent.  Cells 
were washed once with serum free, antibiotic free, phenol red-free DME/F12 
media.  The amount of siRNA to give a maximal decrease of each target protein 
was determined experimentally (50 nM final concentration in the well).  
Oligofectamine reagent (Invitrogen, Carlsbad, CA) was used to transfect ZR-75 
cells with siRNA according to the manufacturer’s protocol.  The next day, 
following the manufacturer’s instructions, Lipofectamine 2000 reagent 
(Invitrogen) was used to transfect cells with 500 ng of the appropriate VEGFR2 
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luciferase reporter plasmid, 200 ng of pCDNA3.1-His-LacZ expression plasmid, 
and 500 ng ERa expression plasmid.  Four to eight hr later, cells were treated 
with 10 nM E2 or Me2SO in serum free, antibiotic free, phenol red-free DME/F12 
media.  Cells were harvested 24-48 hr after treatment.  Cell lysates were 
assayed for luciferase and b-galactosidase activity as described earlier.   
The Lamin A/C duplex (target sequence: 5’-CTG GAC TTC CAG AAG 
AAC A-3’) and the Luciferase GL2 duplex (target sequence: 5’-CGT ACG CGG 
AAT ACT TCG A-3’) RNA from Dharmacon (Lafayette, CO) were used for 
controls in siRNA transfections.  The siRNA oligonucleotides for Sp1, Sp3, and 
Sp4 were also ordered from Dharmacon as follows:    
Sp1: 5’-AUC ACU CCA UGG AUG AAA UGA dTdT-3’ 
Sp3: 5’-GCG GCA GGU GGA GCC UUC ACU dTdT-3’ 
Sp4: 5’-GCA GUG ACA CAU UAG UGA GCdT dT-3’ 
 
3.2.6. Western blot analysis   
Cells (3.0 x 105) were seeded into 6-well plates in DME/F12 medium 
supplemented with 2.5% charcoal stripped FBS.  The next day, cells were 
transfected with siRNA as described above.  Protein was extracted from the 
tissue culture cells by harvesting in a high salt lysis buffer (50 mM HEPES, pH 
7.5, 150 mM NaCl, 10% (v/v) glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM 
EGTA, 10 mg/mL aprotinin, 50 mM phenylmethylsulphonylflouride, 50 mM 
sodium orthovanadate) on ice for 45-60 min and centrifugation at 20,000 x g for 
 124 
10 min at 4ºC.  Sixty mg of protein was diluted with Laemmli’s loading buffer, 
boiled, and loaded onto a 7.5% SDS-polyacrylamide gel.  Samples were 
resolved using electrophoresis at 150-180 V for 3-4 hr and transferred (transfer 
buffer: 48 mM Tris-HCl, 29 mM glycine, and 0.025% SDS) to a PVDF membrane 
(BioRad, Hercules, CA) by electrophoresis at 0.2 A for ~12-16 hr.   
Membranes were blocked with excess protein and then probed with 
polyclonal primary antibodies for Sp1 (PEP2), Sp3 (D20), and Sp4 (V20) from 
Santa Cruz Biotechnology Inc (Santa Cruz, CA).  Sp1 and Sp3 were each 
diluted 1:1000 and incubated overnight.  Sp4 was diluted 1:250 and incubated 
overnight as well.  Membranes were probed with a horseradish peroxidase 
conjugated secondary antibody (1:5000) for 3-6 hr.  Blots were visualized using 
the chemiluminescent substrate ECL detection system (NEN-DuPont, Boston, 
MA) and exposure on Kodak X-O Mat autoradiography film (Eastman Kodak 
Co., Rochester, NY).  Band intensity values were obtained by scanning the film 
on a Sharp JX-330 scanner (Sharp Electronics, Mahwah, NJ) and by 
densitometry using the Zero-D Scanalytics software package (Scanalytics, 
Sunnyvale, CA).  
 
3.2.7. Real-time PCR   
For experiments involving hormonal regulation, ZR-75 cells were cultured 
in serum-free DME/F12 media for 1-3 days before treatment with 10 nM E2 or 
Me2SO as a solvent control for 6-24 hr.  For experiments involving siRNA, ZR-75 
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breast cancer cells were transfected as described previously.  Total RNA was 
isolated using the RNeasy Protect Mini Kit (Qiagen, Valencia, CA) according to 
the manufacturer’s protocol.  RNA was eluted with 30 mL RNase-free water and 
stored at -80ºC.  RNA was reverse transcribed using Superscript II reverse 
transcriptase (Invitrogen) according to the manufacturer’s protocol.   
PCR was carried out using SYBR Green PCR Master Mix from PE 
Applied Biosystems (Warrington, UK) on an ABI Prism 7700 Sequence 
Detection System (PE Applied Biosystems).  The 25 mL final volume contained 
0.5 mM of each primer and 2 mL of cDNA template.  TATA binding protein (TBP) 
was used as an exogenous control to compare the relative amount of target 
gene in different samples.  The PCR profile was as follows:  1 cycle of 95°C for 
10 minutes, then 40 cycles of 95°C for 15 s and 60°C for 1 min.  The 
comparative CT method was used for relative quantitation of samples.  Primers 
were purchased from Integrated DNA Technologies.   
The following primers were used:   
KDR (F): 5’- CAC CAC TCA AAC GCT GAC ATG TA -3’  
KDR (R): 5’- CCA ACT GCC AAT ACC AGT GGA T -3’  
TBP (F): 5’- TGC ACA GGA GCC AAG AGT GAA -3’    
TBP (R): 5’- CAC ATC ACA GCT CCC CAC CA -3’   
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3.2.8. Preparation of nuclear extracts   
Cells were cultured in phenol red-free medium supplemented with 2.5% 
charcoal stripped FBS.  The next day, cells were switched to serum free, phenol 
red-free media for 1-3 days.  Cells were treated with Me2SO or 10 nM E2 for 30 
min before harvesting.  Cells were washed in PBS (2X), scraped in 1 ml of 1X 
lysis buffer, incubated at 4ºC for 15 min, and centrifuged 1 min at 14,000 x g.  
Cell pellets were washed in 1 ml of lysis buffer (3X).  Lysis buffer supplemented 
with 500 mM KCl was then added to the cell pellet and incubated for 45 min at 
4ºC with frequent vortexing.  Nuclei were pelleted by centrifugation at 14,000 x g 
for 1 min at 4ºC, and aliquots of supernatant were stored at -80°C until needed. 
 
3.2.9. Electrophoretic Mobility Shift Assay (EMSA)  
VEGFR2 oligonucleotide (-64 5’-CCG GCC CCG CCC CGC ATG GCC 
CCG CCT CCG-3’ -35) was synthesized and annealed, and 5-pmol aliquots 
were 5'-end-labeled using T4 kinase and [g-32P]ATP.  A 30-mL EMSA reaction 
mixture contained ~100 mM KCl, 3 mg of crude nuclear protein, 1 mg poly(dI-dC), 
with or without unlabeled competitor oligonucleotide, and 10 fmol of radiolabeled 
probe.  After incubation for 20 min on ice, antibodies against Sp1, Sp3, or Sp4 
proteins were added and incubated another 20 min on ice.  Protein-DNA 
complexes were resolved by 5% polyacrylamide gel electrophoresis.  Specific 
DNA-protein and antibody-supershifted complexes were observed as retarded 
bands in the gel.   
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3.2.10. Immunofluorescence   
Rabbit polyclonal antibodies for VEGFR2/KDR, Lamin, Sp1, Sp3, Sp4, 
and normal rabbit IgG were purchased from Santa Cruz Biotechnology. 
Fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit immunoglobulin G 
(IgG) was purchased from Jackson ImmunoResearch Laboratories (West Grove, 
PA) or Santa Cruz Biotechnology.  ZR-75 cells were seeded in Lab-Tek 
chamber slides (Nalge Nunc International, Naperville, IL) at 0.75-1.0 x 105 
cells/well in phenol red-free DME/F12 medium supplemented with 2.5 or 5% 
charcoal-stripped FBS.  The next day, cells were either washed with PBS, 
changed to serum free medium and incubated for 24 hr or were transfected with 
siRNAs as described previously.  For experiments involving E2 treatment, ZR-75 
cells were treated with 10 nM E2 or Me2SO in serum free media for 7 hr and 
fixed with cold methanol at -20°C for 5 min.  After washing with PBS, cells were 
blocked with 4% goat serum at room temperature for 1 hr and incubated with the 
primary rabbit polyclonal antibodies against VEGFR2/KDR (1:25), Lamin (1:200), 
Sp1 (1:200), Sp3 (1:200), Sp4 (1:100), or normal rabbit IgG (1:1000) at 4°C 
overnight.  After washing with PBS/0.3% Tween 3 x 10 min, the samples were 
incubated with FITC-conjugated goat anti-rabbit IgG (1:500 or 1:1000) at room 
temperature for 1 hr.  After PBS/Tween rinsing, glass coverslips were mounted 
over the samples with mounting medium (Vector Laboratories, Burlingame, CA) 
or ProLong Gold (Invitrogen), and cells were examined with a fluorescence 
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microscope.  In some experiments, ZR-75 cells were stained with propidium 
iodide for nuclear counter-staining. 
  
3.2.11. Chromatin Immunoprecipitation (ChIP) assay   
ZR-75 cells (1.0 x 107) were treated with Me2SO (time 0) or 10 nM E2 for 
15, 60, and 120 min.  Cells were then fixed with 1.5% formaldehyde, and the 
cross-linking reaction was stopped by addition of 0.125 M glycine.  Cells were 
scraped, pelleted, and hypotonically lysed, and nuclei were collected.  Nuclei 
were then sonicated to desired chromatin length (~500bp).  The chromatin was 
precleared by addition of protein A-conjugated beads (Pierce Biotechnology, 
Rockford, IL).  The precleared chromatin supernatants were immunoprecipitated 
with antibodies specific to IgG, TFIIB, Sp1, Sp3, Sp4, and ERa (Santa Cruz 
Biotechnology) at 4°C overnight.  The protein-antibody complexes were 
collected by addition of protein A-conjugated beads for 1 hr, and the beads were 
extensively washed.  The protein-DNA crosslinks were eluted and reversed.  
DNA was purified by Qiaquick Spin Columns (Qiagen) and followed by PCR 
amplification.  The pS2 primers are: 5’ - CTA GAC GGA ATG GGC TTC AT - 3’ 
(forward) and 5’ - ATG GGA GTC TCC TCC AAC CT - 3’ (reverse), which 
amplify a 209-bp region of the human pS2 promoter containing estrogen 
response element (ERE).  The VEGF primers are: 5’ - GGT CGA GCT TCC 
CCT TCA - 3’ (forward) and 5’ - GAT CCT CCC CGC TAC CAG - 3’ (reverse), 
which amplify a 202-bp region of human VEGF promoter containing GC-rich/Sp1 
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binding sites.  The VEGFR2/KDR primers are: 5’ - GTC CAG TTG TGT GGG 
GAA AT - 3’ (forward) and 5’ - GAG CTG GAG CCG AAA CTC TA - 3’ (reverse), 
which amplify a 169-bp region of human VEGFR2/KDR promoter containing GC-
rich/Sp1 binding sites.  The positive control primers are: 5’ - TAC TAG CGG TTT 
TAC GGG CG - 3’ (forward) and 5’ - TCG AAC AGG AGG AGC AGA GAG CGA 
- 3’ (reverse), which amplify a 167-bp region of human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene.  The negative control primers are: 5’ 
- ATG GTT GCC ACT GGG GAT CT - 3’ (forward) and 5’ - TGC CAA AGC CTA 
GGG GAA GA - 3’ (reverse), which amplify a 174-bp region of genomic DNA 
between the GAPDH gene and the CNAP1 gene.  PCR products were resolved 
on a 2% agarose gel in the presence of 1:10,000 SYBR gold (Molecular Probes-
Invitrogen, Carlsbad, CA). 
  
3.2.12. Statistical analysis  
Results of transient transfection studies are presented as means (+/-)  
standard error (S.E.) for at least three replicates for each treatment group.  All 
other experiments were carried out at least two times to confirm a consistent 
pattern of responses. Significant statistical differences between treatment 
groups were determined by analysis using SuperANOVA and Scheffe’s test or 
Fisher’s Protected LSD (p < 0.05).  
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3.3. Results 
3.3.1. Induction of VEGFR2 by E2 in ZR-75 cells   
The effect of E2 on VEGFR2 mRNA expression in ZR-75 human breast 
cancer cells was investigated using Real-time PCR.  VEGFR2 mRNA 
expression was significantly upregulated by E2 in ZR-75 cells 6 hr after 
treatment but decreased to background levels 12 and 24 hr after treatment 
(Figure 31A).  We also investigated the effects of E2 on VEGFR2 expression by 
immunofluorescent staining.  ZR-75 cells were treated with Me2SO or 10 nM E2 
for 7 hr.  IgG (non-specific) and VEGFR2 antibodies were used to visualize 
protein expression (green), and nuclei were stained with propidium iodide 
(Figure 31B).  The results show that in Me2SO-treated cells, weak VEGFR2 
staining was observed (e, f), and after treatment with 10 nM E2, there was 
enhanced cytoplasmic VEGFR2 staining (green).  Thus, both VEGFR2 mRNA 
and protein are induced by E2 in ZR-75 cells.   
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Figure 31. Upregulation of VEGFR2 by E2 in ZR-75 cells. A. Upregulation of 
VEGFR2 mRNA by E2 in ZR-75 human breast cancer cells.  ZR-75 cells 
were treated with Me2SO or 10 nM E2 for 6, 12, or 24 hr.  RNA was isolated 
using the RNeasy Protect Mini Kit (Qiagen), and samples were analyzed by 
Real-time PCR as described in the Materials and methods.  Significant (p < 
0.05) induction of VEGFR2 mRNA levels by E2 are indicated by an asterisk.  
Results are presented as means ±  S.E. for at least three determinations for 
each treatment group.  B. Immunofluorescence detection of VEGFR2/KDR 
in ZR-75 cells treated with E2.  ZR-75 cells were treated with 10 nM E2 (a, b, 
c, g, h, i) or Me2SO (d, e, f) for 7 hr and incubated with normal rabbit IgG (a, 
b, c) or rabbit anti-KDR (d, e, f, g, h, i) and FITC (green)-conjugated 
secondary antibody as shown in b, e, and h.  Nuclei were counterstained 
with propidium iodide (red) as shown in a, d, and g.  Photographs were 
taken at the magnification of X200.  Two respective photos were merged 
and shown in c, f, and i.  VEGFR2/KDR staining (green) was increased in 
ZR-75 cells treated with E2. 
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3.3.2. Hormonal regulation of VEGFR2 promoter constructs:  deletion and 
mutation analysis   
The VEGFR2 promoter does not contain EREs although there are 
multiple cis-elements within the -716 to +268 region of the promoter.  The results 
in Figure 32A show that E2 induced activity in ZR-75 cells transfected with 
pVEGFR2A, pVEGFR2B, and pVEGFR2C which contain -716 to +268, -225 to 
+268, and -95 to +268 VEGFR2 promoter inserts.  Basal activity was essentially 
unchanged in the transfected cells, and hormone inducibility ranged from 2.4- to 
4.5-fold.  Further deletion of the -95 to -78 and -77 to -61 sequences resulted in 
lower (~35%) basal activity (i.e., after transfection of pVEGFR2C, pVEGFR2D 
and pVEGFR2E), and hormone inducibility was slightly enhanced in cells 
transfected with these VEGFR2 deletion constructs (Figure 32B).  In contrast, 
both basal and hormone-induced activity decreased dramatically in ZR-75 cells 
transfected with pVEGFR2F, suggesting that the two GC-rich sites between -60 
and -38 were critical elements for regulating VEGFR2 expression.  Fold-
inducibility was also increased in cells transfected with pVEGFR2F; however, 
since absolute activity was low, the fold-inducibility was highly variable, thus 
hormone-responsive elements in the -37 to +268 region of the VEGFR2 
promoter were not further investigated.  Mutation of one or both GC-rich sites at 
-58 and -44 in the VEGFR2 promoter resulted in loss of basal and hormone-
induced activity (Figure 32C).  These results demonstrate the importance of the 
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two proximal GC-rich motifs in mediating hormonal activation of VEGFR2 in ZR-
75 cells. 
 
 
 
 
Figure 32. Deletion analysis of the VEGFR2 gene promoter and effects of 
E2 on luciferase activity in ZR-75 cells.  ZR-75 human breast cancer cells 
were transiently transfected with 500 ng of pVEGFR2A, pVEGFR2B or 
pVEGFR2C (A), and pVEGFR2C, pVEGFR2D, pVEGFR2E, or pVEGFR2F (B), 
250 ng pCDNA3.1-His-LacZ, and 500 ng ERa .  Cells were treated for 36-48 
hr with Me2SO or 10 nM E2, and luciferase activity was determined as 
described in the Materials and methods.  Significant (p < 0.05) induction of 
luciferase reporter activity by E2 is indicated by an asterisk, (a) indicates 
no significant difference from E2-treated pGL2 (control), and (b) indicates 
no significant difference from Me2SO-treated pGL2 (control).  Results are 
expressed as means ±  S.E. for at least three determinations for each 
treatment group. 
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Figure 32. (Continued) C. Mutation analysis of pVEGFR2E in ZR-75 cells.  
ZR-75 human breast cancer cells were transiently transfected with 500 ng 
of pVEGFR2E, pVEGFR2Em1 (mutation of the 5' GC-rich element), 
pVEGFR2Em2 (mutation of the 3' GC-rich element), pVEGFR2Em3 
(mutation of both GC-rich elements), or pVEGFR2F, cells were treated for 
36-48 hr with Me2SO or 10 nM E2, and luciferase activity was determined 
as described in the Materials and methods.  Significant (p < 0.05) induction 
of luciferase reporter activity by E2 is indicated by an asterisk, (a) 
indicates no significant difference from E2-treated pGL2 (control), and (b) 
indicates no significant difference from Me2SO pGL2 (control).  Results are 
expressed as means ±  S.E. for at least three determinations for each 
treatment group. 
 
 
 Previous studies have demonstrated that ER/Sp1-mediated 
transactivation of E2-responsive GC-rich promoter did not require the DNA 
binding domain (DBD) of ERa (143, 146, 149, 152, 153, 261).  In ZR-75 cells 
transfected with wild-type ERa and variants containing deletions in the DBD 
(HE11C) or AF-1 (HE19C), E2 induced transactivation in cells cotransfected with 
the two former expression plasmids (Figure 33A).  These results demonstrate 
the requirement of the AF-1 but not the DBD of ERa for transactivation, and 
these results are similar to those observed for other hormone-induced genes 
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activated by ERa/Sp proteins (143, 146, 149, 152, 153, 261).  The results in 
Figure 33B demonstrate the hormone receptor specificity of hormonal activation 
of VEGFR2.  E2 induced activity in ZR-75 cells transfected with ERa and 
pVEGFR2C, and the antiestrogen ICI 182,780 inhibited hormone-induced 
transactivation.  In contrast, progesterone did not affect activity in ZR-75 cells 
transfected with PR-B, and similar results on the hormone receptor specificity of 
this response were observed in studies with VEGF in the same cell line (157). 
 
 
 
 
Figure 33. ER domain requirements and hormone specificity. A. 
Comparative effects of wild-type and variant ERa  on E2-induced 
transactivation in ZR-75 cells transfected with pVEGFR2C.  ZR-75 cells 
were transiently transfected with 500 ng of pVEGFR2C and 500 ng of ERa  
or variant (HE11C and HE19C) ERa .  Cells were treated with Me2SO or 10 
nM E2, and luciferase activity was determined as described in the 
Materials and methods.  Significant (p < 0.05) induction of luciferase 
activity is indicated by an asterisk.  Results are presented as means ±  S.E. 
for at least three determinations of each treatment group. 
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Figure 33. (Continued) B. Hormone and antiestrogen responsiveness of 
pVEGFR2C in ZR-75 cells.  ZR-75 cells were transiently transfected with 
500 ng of pVEGFR2C and 500 ng ERa  or PR-B.  Cells were treated with 
Me2SO, 10 nM E2, 10 nM E2 + 1 mM ICI 182,780, 1 mM ICI 182,780 alone, or 
10 nM progesterone.  Luciferase activity was determined as described in 
the Materials and methods.  Significant (p < 0.05) induction of luciferase 
activity (*) and inhibition of induced activity by the antiestrogen ICI 182,780 
are indicated (**).  Results are presented as means ± S.E. for at least three 
determinations for each treatment group. 
 
 
 
 
3.3.3. ERa and Sp protein interactions with the VEGFR2 promoter   
Interaction of Sp proteins with the proximal GC-rich sequences in the 
VEGFR2 promoter were investigated using EMSA with nuclear extracts from 
ZR-75 cells and VEGFR2-32P which contain the -64 to -35 proximal GC-rich 
sequence from the VEGFR2 promoter (Figure 34A).  The results show a pattern 
of retarded bands comparable to those observed using cancer cell nuclear 
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extracts and other GC-rich oligonucleotides (149, 152, 261).  Sp1 and Sp4 
complexes form an overlapping retarded band, and a more mobile Sp3-DNA 
complex is also observed (lane 2).  Coincubation with antibodies for Sp1, Sp3, 
and Sp4 results in formation of supershifted complexes (lanes 3 - 5, 
respectively), and coincubation with 100-fold excess of unlabeled 
oligonucleotide decreases intensity of all the retarded bands (lane 7).  However, 
non-specific IgG did not affect retarded band intensities (lane 6).  These results 
clearly show that Sp1, Sp3, and Sp4 are expressed in ZR-75 cells, and all three 
proteins bind the GC-rich VEGFR2 oligonucleotide.  We did not observe direct 
interactions of ERa with the Sp1-DNA complex in the EMSA, and this was 
consistent with results of previous studies with GC-rich oligonucleotides which 
did not observe formation of a ternary ERa/Sp1-DNA complex (153). 
Interactions of ERa, Sp1, Sp3, and Sp4 with the proximal GC-rich region 
of the VEGFR2 promoter in ZR-75 cells were also investigated using a ChIP 
assay (Figures 34B & 34C).  In untreated cells (0-time), Sp1, Sp3, Sp4, and 
ERa were bound to the VEGFR2 promoter, and similar results were observed 
for binding to the E2-responsive GC-rich region of the VEGF promoter.  VEGF 
was used as a comparative reference for studying the VEGFR2 promoter since  
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both proteins/genes are induced by E2 in ZR-75 cells (157).  The pS2 gene was 
also used as a control since previous studies show that treatment of MCF-7 cells 
with E2 enhances binding of ERa to the nonconsensus ERE in the pS2 
promoter (262-265).  The results obtained in this study also show that E2 
induces ERa binding to the pS2 promoter and that Sp1, Sp3, and Sp4 are 
constitutively bound to the promoter in the presence or absence of E2.  GC-rich 
sites that bind Sp proteins have previously been identified in the ERE region of 
the pS2 promoter (266).  After treatment of ZR-75 cells with E2 for 15, 60, or 120 
min, there were minimal changes in ERa or Sp protein binding to the VEGF or 
VEGFR2 promoter.  Thus, in contrast to the results obtained for protein 
assembly on the pS2 promoter, ERa and Sp1, Sp3, and Sp4 are constitutively 
bound to the VEGFR2 (and VEGF) promoter.  Results in Figure 34D show that 
TFIIB binds to the GAPDH promoter (positive control) but not to exon 1 of the 
CNAP1 promoter (negative control). 
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Figure 34. Sp protein binding to the VEGFR2 promoter in ZR-75 cells.  A. 
Electrophoretic mobility shift assay.  Nuclear extracts from ZR-75 cells 
were incubated with radiolabeled VEGFR2-32P alone or in the presence of 
unlabeled oligonucleotides and/or antibodies, and DNA-protein complexes 
were separated by EMSA as described in the Materials and methods.  
Arrows indicate various retarded and supershifted complexes. 
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Figure 34. (Continued) B. Summary of primers (Æ  ¨) and targeted regions 
of the pS2, VEGF, and VEGFR2 promoters used in ChIP assays.  C. 
Analysis of protein interactions with the pS2, VEGF, and VEGFR2 promoter 
by ChIP.  ZR-75 cells were treated with Me2SO (control) or 10 nM E2, and 
cells were harvested after treatment with hormone for up to 2 hr and 
analyzed in a ChIP assay as described in the Materials and methods. D. 
Binding of TFIIB to the GAPDH promoter. The ChIP assay was also used to 
examine binding of TFIIB to the GAPDH promoter (positive control) and to 
exon 1 of CNAP1 (negative control) as described in the Materials and 
methods. 
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3.3.4. RNA interference studies   
Sp proteins play a critical role in regulating genes involved in growth and 
angiogenesis.  Recent RNA interference studies in pancreatic cancer cells 
showed that Sp1, Sp3, and Sp4 are important for VEGF expression (157, 158).  
Initial studies showed that after transfection of ZR-75 cells with small inhibitory 
RNAs for Sp1 (iSp1), Sp3 (iSp3), and Sp4 (iSp4), there was 35-50% knockdown 
of Sp proteins as determined by Western blot analysis of whole cell lysates 
(Figure 35A).  Transfection efficiencies were 40-60%, indicating that the siRNAs 
were highly active, and this was confirmed in immunostaining of transfected cells 
which indicated that in transfected cells, >90% of the targeted protein was 
degraded (Figure 35B).  In panels a - d, cells were stained for Lamin, and 
decreased staining was observed in cells transfected with iLamin (a); Lamin 
staining was observed in cells transfected with small inhibitory RNAs for Sp 
proteins (b - d).  Sp1 (e), Sp3 (g), and weak Sp4 (i) immunostaining was 
observed in ZR-75 cells transfected with iLamin (non-specific control), but 
transfection with iSp1 (f), iSp3 (h), and iSp4 (j) decreased staining of Sp1, Sp3, 
and Sp4 proteins, respectively.  Staining with IgG or the secondary antibody (k, 
l) is also shown.  The decreases observed with iSp1 and iSp3 are consistent 
with results of previous studies (158); the antibody available for Sp4 was less 
efficient, but iSp4 decreased the overall immunostaining for this protein.  Results 
in Figures 35C and 35D show that iGL2 (siRNA for luciferase) decreased activity 
by >90% in ZR-75 cells transfected with pVEGFR2A and pVEGFR2E; however, 
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the effects of RNA interference of Sp protein expression were surprising.  iSp3 
and iSp4 significantly decrease hormone-responsiveness, yet iSp1 did not affect 
basal or inducible luciferase activity.  These results suggest that hormonal 
regulation of VEGFR2 in ZR-75 cells is primarily due to ERa/Sp3 and ERa/Sp4 
but not ERa/Sp1.  
 
 
 
 
Figure 35. Role of Sp proteins in hormonal regulation of VEGFR2 in ZR-75 
cells.  A. Sp protein knockdown – Western blot analysis.  ZR-75 cells were 
transfected with iSp1, iSp3, or iSp4, and whole cell lysates were analyzed 
by Western blot analysis as described in the Materials and methods.  The 
experiments were repeated (3X), and the Sp protein levels were 
significantly (p < 0.05) decreased by RNA interference (relative to iLamin) 
as indicated by an asterisk. 
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Figure 35. (Continued) B. Sp protein knockdown -  analysis by 
immunostaining.  ZR-75 cells were transfected with iLamin (control) (a, e, 
g, i), iSp1 (b, f), iSp3 (c, h), or iSp4 (d, j) and immunostained for Lamin (a - 
d), Sp1 (e, f), Sp3 (g, h), or Sp4 (i, j) as described in the Materials and 
methods.  IgG (k) and mouse secondary antibody (l) served as controls. 
Photographs were taken at the magnification of X60. 
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Figure 35. (Continued) Effects of iSp1, iSp3, and iSp4 on basal and E2-
dependent activity in ZR-75 cells transfected with pVEGFR2A (C) and 
VEGFR2E (D).  ZR-75 human breast cancer cells were transiently 
transfected with 500 ng of pVEGFR2A or VEGFR2E and 50 nM of each 
siRNA, treated with Me2SO or 10 nM E2, and luciferase activity was 
determined as described in the Materials and methods.  Significantly (p < 
0.05) decreased basal reporter activity by siRNAs (*) and decreased 
activity after treatment with E2 (**) compared to non-specific control (iNS) 
are indicated.  Results are presented as means ±  S.E. for at least three 
determinations for each treatment group. 
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3.4. Discussion 
 VEGFR2 is a key mediator of angiogenesis in normal and cancerous 
tissues, and this receptor is upregulated in many cancer cell lines and tumors 
(163, 167, 179, 183, 235, 238-240, 248-250).  Tyrosine kinases such as 
VEGFR2 are targets for development of antiangiogenic drugs, and several 
studies have characterized VEGFR inhibitors that block tyrosine kinase activities 
(241-244).  For example, CEP-7055 or N,N-dimethylglycine 3-[5,6,7,18-
tetrahydro-9-[(1-methyleneoxy)methyl]-5-oxo-12H-indeno(2,1-9)pyrrolo(3,4-
c)carbazol-12-yl] propyl ester is a pan-VEGFR inhibitor which inhibits 
angiogenesis in both in vitro and in vivo models (242).  Moreover, in athymic 
nude mouse xenograft studies, CEP-7055 inhibits growth of multiple tumor types 
including tumors in mice bearing MCF-7 breast cancer cell xenografts where a 
dose of 23.8 mg/kg/d (for 26 days) resulted in a 65% inhibition of tumor growth.  
Previous reports also showed that VEGFR2 was expressed in mammary tumors 
and both ER-negative and ER-positive breast cancer cells lines including T47D 
and MCF-7 cells (238).  Results of this study confirm that VEGFR2 is also 
expressed in ZR-75 cells (Figure 31). 
 Regulation of VEGFR2 expression is dependent on a number of factors 
including cell context.  Initial studies by Patterson and coworkers using VEGFR2 
promoter constructs showed that basal activity in bovine aortic endothelial cells 
was primarily associated with the GC-rich -95 to -60 region of the promoter 
which contains Sp, AP-2 and NFkB motifs (170).  This analysis was also 
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supported by DNA footprinting studies showing protected sequences between    
-110 and -25 in human umbilical vein endothelial cells (HUVECs).  Interestingly, 
comparable interactions were not observed in fibroblasts or HeLa cells (232).  
Hata and coworkers also showed that the GC-rich -79 to -68 region of the 
promoter was essential for activity in endothelial cells.  This region bound both 
Sp1 and Sp3; however, their results suggested that Sp1 expression enhanced 
VEGFR2 expression, but that Sp3 attenuated this response (231).  In contrast, 
Urbich and coworkers showed that basal and shear stress-induced activation of 
VEGFR2 promoter constructs in HUVECs was primarily dependent on two more 
proximal GC-rich sites at -58 and -44 bp (267).  Results of this study using 
epithelial-derived ZR-75 cells show a remarkable similarity to the results 
reported for shear stressed HUVECs where the -58 and -44 sites in VEGFR2 
are essential for high basal expression of VEGFR2 (Figure 32).  In ZR-75 cells, 
we have also confirmed, by both EMSA and ChIP assays, that Sp1, Sp3, and 
Sp4 constitutively bind regions of the VEGFR2 promoter encompassing the two 
proximal GC-rich sites (Figure 34).  The potential role of Sp3 in activating VEGF 
(157) and VEGFR2 expression in ZR-75 cells is in contrast to the inhibitory 
effects of the protein in endothelial cells, and this illustrates the important cell 
and promoter context-dependent effects of Sp3 on transactivation observed in 
other studies (268-270). 
 Hormone-dependent activation of VEGFR2 also primarily involves the 
proximal GC-rich sites in the VEGFR2 promoter (Figure 32), and the results with 
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PR and ERa variants (Figure 33) are similar to those observed for other 
hormone-responsive genes activated through interactions of ERa/Sp with GC-
rich cis-elements (270).  Most previous studies have assumed that hormonal 
activation of GC-rich promoters are dependent on ERa/Sp1 interactions with E2-
responsive GC-rich sites; however, RNA interference studies and selective 
knockdown of Sp1, Sp3, and Sp4 demonstrate that ERa/Sp1 plays a minimal 
role in activation of VEGFR2 and that both ERa/Sp3 and ERa/Sp4 are the 
critical factors required for this response (Figure 35).  Moreover, unlike the pS2 
gene where E2 enhances recruitment of ERa to the ERE promoter site (262-
266), ERa and the Sp proteins are constituitively bound to the proximal GC-rich 
VEGFR2 and VEGF promoters (Figure 34), and treatment with hormone has 
minimal effects on these interactions.  Previous studies have confirmed that 
ERa interacts with Sp proteins in the absence of ligand (153, 156), and the ChIP 
results suggest that in ZR-75 cells unliganded ERa is associated with Sp protein 
bound to E2-responsive GC-rich promoters and that addition of E2 does not 
significantly alter Sp or ER promoter interactions.  Presumably, hormone 
induces recruitment of coregulatory proteins required for transactivation, and 
current studies in this laboratory are focused on identification and 
characterization of ERa/Sp coactivators. 
 In summary, our results show that ERa/Sp3 and ERa/Sp4 are involved in 
hormone-dependent activation of VEGFR2 in ZR-75 cells.  Studies in several 
laboratories have demonstrated an important role for DNA-independent 
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activation of genes through nuclear receptor interactions with DNA-bound Sp 
transcription factors (271-280).  In contrast to results of this study, PPARg 
differentially activated VEGFR2 through Sp1 but not Sp3 in retinal capillary 
endothelial cells (279).  PPARa agonists inhibited VEGFR2 in HUVECs, and this 
response was linked to interactions with Sp1 bound to the proximal -58 and -44 
GC-rich sites (280).  Thus, expression of VEGFR2 and other genes with GC-rich 
promoters can be up- or downregulated by ER and other nuclear receptors, and 
current studies in this laboratory are focused on further understanding this 
pivotal gene regulatory pathway involving nuclear receptors and Sp proteins in 
breast cancer cells and other hormone-responsive tissues. 
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CHAPTER IV 
 
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 
EXPRESSION IS DOWNREGULATED BY 17b -ESTRADIOL IN 
MCF-7 BREAST CANCER CELLS BY ESTROGEN  
RECEPTOR a/Sp PROTEINS 
 
4.1. Introduction 
 Angiogenesis is a complex biological function that is required for new 
blood vessel formation and is essential for embryogenesis, wound healing, and 
many other physiological processes (161, 234, 247).  In addition, angiogenic 
pathways also contribute to disease states including inflammation, diabetes, and 
cancer where both tumor growth and metastasis are dependent on development 
of new vasculature in the parent tumor and in distal sites of metastasis (21, 23).  
Vascular permeability factor or vascular endothelial growth factor (VEGF) is a 
key angiogenic protein and is a critical activator of this pathway.  Several 
different splice-variant forms of VEGF (or VEGF-A) have been characterized 
along with VEGF-B, VEGF-C, VEGF-D, VEGF-E, and platelet-induced growth 
factor (234, 235).  The expression of these mitogens is tissue/cell specific, and 
there is also some specificity in their interactions with VEGF receptors 
(VEGFRs) which are protein tyrosine kinase transmembrane receptors.   
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 The expression of VEGFRs is cell-type specific: the major VEGFRs 
include VEGFR1(flt-1), soluble VEGFR1(sflt-1), VEGFR2(KDR/flk-1), and 
VEGFR3(flt-4) (161, 234, 235).  Soluble VEGFR1 (sVEGFR1) is a truncated 
form of VEGFR1 which does not contain the tyrosine kinase domain but 
expresses the extracellular ligand binding function of VEGFR1.  There is some 
evidence that sVEGFR1 exhibits anti-angiogenic activity by interacting with 
extracellular VEGF thereby inhibiting its interactions with other VEGFRs (234, 
235).  For example, a recent study (177) showed that 17b-estradiol (E2) induced 
sVEGFR1 (but not VEGFR1) in estrogen receptor a (ERa)-positive MCF-7 
breast cancer cells, the antiestrogen ICI 182 780 inhibited the E2-induced 
response, and sVEGFR1 levels were increased by the antiestrogen alone.  Also, 
evidence from xenograft studies with MCF-7 cells showed decreased expression 
of sVEGFR1 after treatment with E2 correlated with a less than 2-fold increase 
in vessel density. 
 Among the VEGFRs, VEGFR2 is the predominant form that regulates 
angiogenesis.  VEGFR2 is overexpressed in some tumor types (163, 167, 179, 
183, 238, 239, 249, 250), and tyrosine kinase inhibitors that block VEGFR 
signaling have been developed for cancer chemotherapy (241-244).  Regulation 
of VEGFR2 expression has been investigated in several different cell lines, and 
analysis of the VEGFR2 promoter has identified several important transacting 
factors/cis-elements (170, 231, 232, 267).  The proximal region of the VEGFR2 
promoter contains E-boxes, GC-rich, AP-2, and NFkB motifs which are 
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important for VEGFR2 expression in several cell lines, and a recent study 
showed that TFII-I also modulates endothelial cell expression of VEGFR2 (281).  
Studies in this laboratory recently showed that E2 induced VEGFR2 expression 
in ERa-positive ZR-75 breast cancer cells, and this was due to a non-classical 
mechanism involving ERa/Sp protein interactions with proximal GC-rich motifs 
at -58 and -44 (282).  Surprisingly, we observe that E2 decreases VEGFR2 
mRNA levels in MCF-7 cells, and analysis of this response also showed that the 
GC-rich sites at -58 and -44 are critical for the decreased response in MCF-7 
cells.  Results of RNA interference, chromatin immunoprecipitation, 
electrophoretic mobility shift, and transient transfection assays suggest that 
hormone-dependent downregulation is primarily dependent on ERa/Sp1 and 
ERa/Sp3 promoter interactions which are accompanied by recruitment of the 
corepressor silencing mediator for retinoid and thyroid hormone receptors 
(SMRT).  This novel mechanism for downregulation must also involve other 
factors which include cell context-dependent factors which govern the E2-
dependent up or downregulation in ZR-75 and MCF-7 cells respectively. 
 
4.2. Materials and methods 
4.2.1. Chemicals, plasmids, and gifts  
Dimethyl sulfoxide (Me2SO), 17b-estradiol (E2), 4’-hydroxytamoxifen, 
100X antibiotic/antimycotic solution, and phosphate buffered saline (PBS) were 
purchased from Sigma Chemical Company (St. Louis, MO).  ICI 182,780 was 
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kindly provided by Dr. Alan Wakeling (AstraZeneca, Macclesfield, UK).  5X lysis 
buffer, luciferase reagent, restriction enzymes (XhoI and HindIII), and ligase 
were purchased from Promega (Madison, WI).  b-galactosidase reagents were 
purchased from Tropix (Bedford, MA).  Taq polymerase and other PCR reagents 
were purchased from Perkin Elmer (Boston, MA).  Progesterone and other 
chemicals of the highest quality possible were obtained from commercial 
sources.  
Human ERa expression plasmid was provided by Dr. Ming-Jer Tsai 
(Baylor College of Medicine, Houston, TX).  ERa deletion constructs HE11C 
(DBD of ERa deleted) and HE19C (AF-1 domain of ERa deleted) were originally 
obtained from Dr. Pierre Chambon (Instutut de Genetique et de Biologie 
Moleculaire et Cellulaire, Illkirch, France) and inserted into vectors pCDNA3 and 
pCDNA3.1/His C.  pCDNA3.1-His-LacZ expression plasmid was obtained from 
Invitrogen (Carlsbad, CA).  VEGFR2 promoter luciferase constructs pVEGFR2A, 
pVEGFR2B, and pVEGFR2C (previously named pKDR-716/+268, pKDR-
225/+268, and pKDR-95/+268) were provided by Dr. Arthur Mu-EnLee 
(deceased) and Dr. Koji Maemura (Cardiovascular Biology Lab, Boston, MA).  
pGL2 basic luciferase reporter vector was purchased from Promega. 
 
4.2.2. Cell lines and tissue culture 
The human breast cancer cell line MCF-7 was obtained from American 
Type Culture Collection (ATCC, Manassas, VA).  Cells were cultured in 
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Dulbecco’s modified Eagle’s medium/F12 (Sigma) supplemented with 5 or 10% 
fetal bovine serum (FBS) (Summit Biotechnology, Fort Collins, CO; Intergen, 
Des Plains, IA; JRH Biosciences, Lenexa, KS; or Atlanta Biologicals, Inc., 
Norcross, GA).  Medium was further supplemented with 2.2 g/L sodium 
bicarbonate and 100X antibiotic/antimycotic solution (Sigma).  Cells were 
maintained at 37 ºC with a humidified CO2:air (5:95) mixture.  
 
 
4.2.3. Cloning and oligonucleotides  
VEGFR2 promoter-derived oligonucleotides, PCR primers, and primers 
employed in plasmid construction were synthesized by Genosys/Sigma (The 
Woodlands, TX) or Integrated DNA Technologies (IDT) (Coralville, IA).  VEGFR2 
promoter deletion constructs pVEGFR2D, pVEGFR2E, pVEGFR2F, and 
pVEGFR2G were created by PCR amplification using pVEGFR2A as the 
template.  Forward primers were designed with XhoI restriction enzyme sites at 
the 5’-end.  A reverse luciferase primer was used for PCR.  PCR products were 
digested with XhoI and HindIII, and subsequently ligated into the pGL2 basic 
vector.  All constructs are in pGL2 basic luciferase reporter vector and all 
constructs were sequenced to verify their identity.  Mutation constructs 
pVEGFR2Em1, pVEGFR2Em2, and pVEGFR2Em3 were constructed by PCR 
amplification using the reverse luciferase primer paired with the forward primer 
containing the desired mutations.  Forward primers are as follows: (mutated 
bases are underlined) 
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  XhoI      -60 
M1= 5’-GAT GAT CTC GAG CCA AGC CCC GCA TGG CCC CGC C-3’ 
    
M2= 5’-GAT GAT CTC GAG CCC CGC CCC GCA TGG CCA AGC CTC CGC  
GC-3’ 
 
M3= 5’-GAT GAT CTC GAG CCA AGC CCC GCA TGG CCA AGC CTC CGC  
GC-3’ 
 
 
 
4.2.4. Transient transfection assays 
Cells were seeded in 12-well plates at a concentration of 1.5-3.0 x 105 
cells per well in phenol red-free DME/F12 media supplemented with 2.5% 
charcoal-stripped FBS.  After 18-24 hr, the appropriate VEGFR2 luciferase 
reporter plasmid (500 ng), 250 or 500 ng ERa or ERa deletion constructs 
expression plasmid, and 250 ng pCDNA3.1-His-LacZ expression plasmid (for 
normalization of transfection efficiency) were transiently cotransfected into MCF-
7 cells using the calcium phosphate-DNA co-precipitation method.  pCDNA3.1 
empty vector was transfected to maintain DNA mass balance among different 
transfection groups.  An estrogen-responsive pC3-Luc construct, containing the 
mouse complement-3 (C3) gene promoter insert, was kindly provided by Dr. 
Donald P. McDonnell (Duke University Medical School, Durham, NC) and was 
used as a positive control in most experiments to confirm hormone 
responsiveness of the transfected cells.   
After transfection (4-8 hr), cells were shocked with 25% glycerol in PBS to 
increase transfection efficiency.  Then cells were washed with PBS and treated 
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for 24-48 hr with fresh serum-free DME/F12 medium containing 10 nM E2, 10 
nM progesterone (P), 10 nM E2 + 1 mM ICI 182,780, 1 mM ICI 182,780 dissolved 
in Me2SO, or Me2SO alone as a solvent control.  Cells were harvested by 
scraping the plates in 100-200 mL of 1X lysis buffer (Promega).  An aliquot of 
soluble protein was obtained by one cycle of freezing/thawing the cells, 
vortexing (30 s), and centrifuging at 12,000 x g (1 min).  Cell lysates (30 mL) 
were assayed for luciferase activity using Luciferase Assay Reagent (Promega) 
and b-galactosidase activity using Tropix Galacto-Light Plus assay system 
(Tropix, Bedford, MA) in a Lumicount micro-well plate reader (Packard 
Instrument Co., Downers Grove, IL).  Relative luciferase activity was normalized 
to relative b-galactosidase units for each transfection experiment.  
 
4.2.5. Transient transfection of siRNA 
 Cells were cultured in phenol red-free DME/F12 medium supplemented 
with 2.5% charcoal stripped FBS in 12-well plates until 50-70% confluent.  Cells 
were washed once with serum free, antibiotic free, phenol red-free DME/F12 
media.  The amount of siRNA to give a maximal decrease of each target protein 
was determined experimentally (50 nM final concentration in the well).  
Oligofectamine reagent (Invitrogen) was used to transfect MCF-7 cells with 
siRNA according to the manufacturer’s protocol.  The next day, following the 
manufacturer’s instructions, Lipofectamine 2000 reagent (Invitrogen) was used 
to transfect cells with 400 ng of the appropriate VEGFR luciferase reporter 
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plasmid and 200 ng of pCDNA3.1-His-LacZ, as well as 400 ng ERa.  Four to 
eight hr later, cells were treated with 10 nM E2 or Me2SO in serum free, 
antibiotic free, phenol red-free DME/F12 media.  Cells were harvested 24 hr 
after treatment.  Cell lysates were assayed for luciferase and b-galactosidase 
activity as described above.   
The Lamin A/C duplex (target sequence: 5’-CTG GAC TTC CAG AAG 
AAC A-3’) and the Luciferase GL2 duplex RNA (target sequence: 5’-CGT ACG 
CGG AAT ACT TCG A-3’) from Dharmacon (Lafayette, CO) were used for 
controls in siRNA transfections.  The siRNA oligonucleotides for Sp1, Sp3, Sp4, 
NCoR, and SMRT were also ordered from Dharmacon as follows:    
Sp1: 5’-AUC ACU CCA UGG AUG AAA UGA dTdT-3’ 
Sp3: 5’-GCG GCA GGU GGA GCC UUC ACU dTdT-3’ 
Sp4: 5’-GCA GUG ACA CAU UAG UGA GCdT dT-3’ 
NCoR: 5’-AAG AAG GAU CCA GCA UUC GGA dTdT-3’ 
SMRT: 5’-AAA GUC UAA ACU GAG CUC GCA dTdT-3’ 
 
4.2.6. Western blot analysis 
 Cells were seeded into 6-well plates in DME/F12 medium supplemented 
with 2.5% charcoal stripped FBS.  The next day, cells were transfected with 
siRNA as described earlier.  Protein was extracted from the tissue culture cells 
by harvesting in a high salt lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 
10% (v/v) glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, 10 mg/mL 
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aprotinin, 50 mM phenylmethylsulphonylflouride, 50 mM sodium orthovanadate) 
on ice for 45-60 min and centrifugation at 20,000 x g for 10 min at 4ºC.  Thirty to 
sixty mg of protein was diluted with Laemmli’s loading buffer, boiled, and loaded 
onto a 7.5% SDS-polyacrylamide gel.  Samples were resolved using 
electrophoresis at 150-180 V for 3-4 hr and transferred (transfer buffer: 48 mM 
Tris-Hcl, 29 mM glycine, and 0.025% SDS) to a PVDF membrane (BioRad, 
Hercules, CA) by electrophoresis at 0.2 A for ~12-16 hr.   
Membranes were blocked with excess protein and then probed with 
polyclonal primary antibodies for Sp1 (PEP2), Sp3 (D20), and Sp4 (V20) from 
Santa Cruz Biotechnology Inc (Santa Cruz, CA).  Sp1 and Sp3 were each 
diluted 1:1000 and Sp4 was diluted 1:250 or 1:500 and incubated overnight. 
Membranes were probed with a horseradish peroxidase conjugated secondary 
antibody (1:5000) for 3-6 hr.  Blots were visualized using the chemiluminescent 
substrate ECL detection system (NEN-DuPont, Boston, MA) and exposure on 
Kodak X-O Mat autoradiography film (Eastman Kodak Co., Rochester, NY).  
Band intensity values were obtained by scanning the film on a Sharp JX-330 
scanner (Sharp Electronics, Mahwah, NJ) and by densitometry using the Zero-D 
Scanalytics software package (Scanalytics, Sunnyvale, CA).  
 
4.2.7. Real-time PCR 
For experiments involving hormonal regulation, MCF-7 cells were cultured 
in serum-free DME/F12 media for 1-3 days before treatment with 10 nM E2 or 
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Me2SO as a solvent control for 6-48 hr.  For experiments involving siRNA, MCF-
7 breast cancer cells were transfected as described above.  Total RNA was 
isolated using the RNeasy Protect Mini Kit (Qiagen, Valencia, CA) according to 
the manufacturer’s protocol.  RNA was eluted with 30 mL RNase-free water and 
stored at -80ºC.  RNA was reverse transcribed using Superscript II reverse 
transcriptase (Invitrogen) according to the manufacturer’s protocol.   
PCR was carried out using SYBR Green PCR Master Mix from PE 
Applied Biosystems (Warrington, UK) on an ABI Prism 7700 Sequence 
Detection System (PE Applied Biosystems).  The 25 mL final volume contained 
0.5 mM of each primer and 2 mL of cDNA template.  TATA binding protein (TBP) 
was used as an exogenous control to compare the relative amount of target 
gene in different samples.  The PCR profile was as follows:  1 cycle of 95°C for 
10 minutes, then 40 cycles of 95°C for 15 s and 60°C for 1 min.   The 
comparative CT method was used for relative quantitation of samples.  Primers 
were purchased from Integrated DNA Technologies (Coralville, IA).  
KDR (F): 5’- CAC CAC TCA AAC GCT GAC ATG TA -3’  
KDR (R): 5’- CCA ACT GCC AAT ACC AGT GGA T -3’  
TBP (F): 5’- TGC ACA GGA GCC AAG AGT GAA -3’  
TBP (R): 5’- CAC ATC ACA GCT CCC CAC CA -3’   
 
 
 
 159 
4.2.8. Preparation of nuclear extracts   
Cells were cultured in phenol red-free medium supplemented with 2.5% 
charcoal stripped FBS.  The next day, cells were switched to serum free, phenol 
red-free media for 1-3 days.  Cells were treated with Me2SO or 10 nM E2 for 30 
min before harvesting.  Cells were washed in PBS (2X), scraped in 1 ml of 1X 
lysis buffer, incubated at 4ºC for 15 min, and centrifuged 1 min at 14,000 x g.  
Cell pellets were washed in 1 ml of lysis buffer (3X).  Lysis buffer supplemented 
with 500 mM KCl was then added to the cell pellet and incubated for 45 min at 
4ºC with frequent vortexing.  Nuclei were pelleted by centrifugation at 14,000 x g 
for 1 min at 4ºC, and aliquots of supernatant were stored at -80°C until needed. 
 
4.2.9. Electrophoretic Mobility Shift Assay (EMSA) 
VEGFR2 oligonucleotide (-64 5’-CCG GCC CCG CCC CGC ATG GCC 
CCG CCT CCG-3’ -35) was synthesized and annealed, and 5-pmol aliquots 
were 5'-end-labeled using T4 kinase and [g-32P]ATP.  A 30-mL EMSA reaction 
mixture contained ~100 mM KCl, 3 mg of crude nuclear protein, 1 mg poly(dI-dC), 
with or without unlabeled competitor oligonucleotide, and 10 fmol of radiolabeled 
probe.  After incubation for 20 min on ice, antibodies against Sp1, Sp3, or Sp4 
proteins were added and incubated another 20 min on ice.  Protein-DNA 
complexes were resolved by 5% polyacrylamide gel electrophoresis.  Specific 
DNA-protein and antibody-supershifted complexes were observed as retarded 
bands in the gel.   
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4.2.10. Chromatin Immunoprecipitation (ChIP) assay 
 
MCF-7 cells (1.0 x 107) were treated with Me2SO (time 0) or 10 nM E2 for 
15, 60, and 120 min.  Cells were then fixed with 1.5% formaldehyde, and the 
cross-linking reaction was stopped by addition of 0.125 M glycine.  Cells were 
scraped, pelleted, and hypotonically lysed, and nuclei were collected. Nuclei 
were then sonicated to desired chromatin length (~500bp).  The chromatin was 
precleared by addition of protein A-conjugated beads (Pierce Biotechnology, 
Rockford, IL).  The precleared chromatin supernatants were immunoprecipitated 
with antibodies specific to IgG, TFIIB, Sp1, Sp3, Sp4, ERa, SRC-1, SRC-3, 
NCoR, and SMRT (Santa Cruz Biotechnology) at 4°C overnight.  The protein-
antibody complexes were collected by addition of protein A-conjugated beads for 
1 hr, and the beads were extensively washed.  The protein-DNA crosslinks were 
eluted and reversed.  DNA was purified by Qiaquick Spin Columns (Qiagen) and 
followed by PCR amplification.  The pS2 primers are: 5’ - CTA GAC GGA ATG 
GGC TTC AT - 3’ (forward) and 5’ - ATG GGA GTC TCC TCC AAC CT - 3’ 
(reverse), which amplify a 209-bp region of the human pS2 promoter containing 
estrogen response element (ERE).  The VEGFR2/KDR primers are: 5’ - GTC 
CAG TTG TGT GGG GAA AT - 3’ (forward) and 5’ - GAG CTG GAG CCG AAA 
CTC TA - 3’ (reverse), which amplify a 169-bp region of human VEGFR2/KDR 
promoter containing GC-rich/Sp1 binding sites.  The positive control primers are: 
5’ - TAC TAG CGG TTT TAC GGG CG - 3’ (forward) and 5’ - TCG AAC AGG 
AGG AGC AGA GAG CGA - 3’ (reverse), which amplify a 167-bp region of 
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human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene.  The 
negative control primers are: 5’ - ATG GTT GCC ACT GGG GAT CT - 3’ 
(forward) and 5’ - TGC CAA AGC CTA GGG GAA GA - 3’ (reverse), which 
amplify a 174-bp region of genomic DNA between the GAPDH gene and the 
CNAP1 gene.  PCR products were resolved on a 2% agarose gel in the 
presence of 1:10,000 SYBR gold (Molecular Probes-Invitrogen, Carlsbad, CA). 
 
 
4.2.11. Immunofluorescence  
Rabbit polyclonal antibody for Lamin, Sp1, Sp3, Sp4, and normal rabbit 
IgG were purchased from Santa Cruz Biotechnology. Fluorescein isothiocyanate 
(FITC)-conjugated goat anti-rabbit immunoglobulin G (IgG) was purchased from 
Jackson ImmunoResearch Laboratories (West Grove, PA) or Santa Cruz 
Biotechnology.  MCF-7 cells were seeded in Lab-Tek chamber slides (Nalge 
Nunc International, Naperville, IL) at 75,000 -100,000 cells/well in phenol red-
free DME/F12 medium supplemented with 2.5 or 5% charcoal-stripped FBS.  
The next day cells were either washed with PBS, changed to serum free 
medium and incubated for 24 hr or were transfected with siRNAs as described 
above.  For experiments involving E2 treatment, MCF-7 cells were treated with 
10 nM E2 or Me2SO in serum free media for 4-7 hr and fixed with cold methanol 
at -20°C for 5 or 10 min.  After washing with PBS, cells were blocked with 4% 
goat serum at room temperature for 1 hr and incubated with the primary rabbit 
polyclonal antibodies against Lamin (1:200), Sp1 (1:200), Sp3 (1:200), Sp4 
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(1:100) or normal rabbit IgG (1:1000) at 4°C overnight.  After washing with 
PBS/0.3% Tween 3 x 10 min, the samples were incubated with FITC-conjugated 
goat anti-rabbit IgG (1:500 or 1:1000) at room temperature for 1 hr.  After 
PBS/Tween rinsing, glass coverslips were mounted over the samples with 
mounting medium (Vector Laboratories, Burlingame, CA) or ProLong Gold 
(Invitrogen), and cells were examined with a fluorescence microscope.  
 
 
4.2.12. Statistical analysis 
 Results of transient transfection studies are presented as means (+/-)  
standard error (S.E.) for at least three replicates for each treatment group.  All 
other experiments were carried out at least two times to confirm a consistent 
pattern of responses. Significant statistical differences between treatment 
groups were determined by analysis using SuperANOVA and Scheffe’s test or 
Fisher’s Protected LSD (p < 0.05). 
 
4.3. Results 
4.3.1. Downregulation of VEGFR2 by E2 in MCF-7 cells 
 Studies in this laboratory showed that E2 induced VEGFR2 expression in 
ZR-75 breast cancer cells (282); however, after treatment of MCF-7 cells with 10 
nM E2, there was a significant decrease in VEGFR2 mRNA levels 12 hr after 
treatment, and this persisted for up to 48 hr (Figure 36A).  These results were 
observed in replicate experiments and represents an example of hormone-
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induced downregulation of gene expression in ER-positive breast cancer cells.  
pVEGFR2A is a construct containing the -716 to +268 region of the VEGFR2 
promoter, and E2 induced transactivation in ZR-75 cells transfected with 
pVEGFR2A (282).  In contrast, E2 decreased luciferase activity in MCF-7 cells 
transfected with pVEGFR2A (Figure 36B).  Transfection of a series of 5’-deletion 
constructs into MCF-7 cells showed that basal activity was similar after 
transfection with pVEGFR2A, pVEGFR2B (-225 to +268), pVEGFR2C (-95 to 
+268), and pVEGFR2D (-77 to +268); A 20-30% loss of activity was observed in 
cells transfected with pVEGFR2E, suggesting that the GC-rich/AP-2 sites at -77 
to -60 play a role in basal expression of VEGFR2 in MCF-7 cells.  Furthermore, 
deletion of the proximal GC-rich sites at -58 and -44 resulted in the loss of >90% 
of basal activity, demonstrating the important role for these elements in VEGFR2 
expression.  E2-dependent downregulation of luciferase activity was observed in 
MCF-7 cells transfected with pVEGFR2A, pVEGFR2B, pVEGFR2C, 
pVEGFR2D, and pVEGFR2E, and deletion of the proximal GC-rich sites 
(pVEGFR2F) resulted in loss of hormone-responsiveness.  Thus, the -60 to -37 
region of the promoter was critical for both basal and hormone-induced activity.  
Transfection of a series of constructs containing mutations of a single GC-rich 
site (pVEGFR2Em1/ pVEGFR2Em2) or mutation of both sites (pVEGFR2Em3) 
showed that both sites contributed to E2-induced downregulation of 
transactivation (Figure 36C).  Hormone-responsiveness was lost only in cells 
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transfected with pVEGFR2Em3 (mutation of both GC-rich motifs) or pVEGFR2F 
(deletion of -60 to -37 region of the promoter).   
 
 
 
Figure 36. Downregulation of VEGFR2 by E2 in MCF-7 cells.  A. 
Downregulation of VEGFR2 mRNA by E2 in MCF-7 human breast cancer 
cells.  MCF-7 cells were treated with Me2SO or 10 nM E2 for 12, 24, or 48 hr.  
RNA was isolated using the RNeasy Protect Mini Kit (Qiagen), and samples 
were analyzed by Real-time PCR as described in the Materials and 
methods.  Significant (p < 0.05) downregulation of VEGFR2 mRNA levels 
by E2 are indicated by an asterisk.  Results are presented as means ±  S.E. 
for at least three determinations for each treatment group. 
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Figure 36. (Continued) B. Deletion analysis of the VEGFR2 gene promoter 
and effects of E2 on luciferase activity in MCF-7 cells.  MCF-7 human 
breast cancer cells were transiently transfected with 500 ng of pVEGFR2A, 
pVEGFR2B, pVEGFR2C, pVEGFR2D, pVEGFR2E, or pVEGFR2F, 250 ng 
pCDNA3.1-His-LacZ, and 250 ng ERa .  Cells were treated for 36-48 hr with 
Me2SO or 10 nM E2, and luciferase activity was determined as described in 
the Materials and methods.  Significant (p < 0.05) downregulation of 
luciferase reporter activity by E2 is indicated by an asterisk.  Results are 
expressed as means ±  S.E. for at least three determinations for each 
treatment group.   
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Figure 36. (Continued) C. Mutation analysis of pVEGFR2E in MCF-7 cells.  
MCF-7 human breast cancer cells were transiently transfected with 500 ng 
of pVEGFR2E, pVEGFR2Em1 (mutation of the 5' GC-rich element), 
pVEGFR2Em2 (mutation of the 3' GC-rich element), pVEGFR2Em3 
(mutation of both GC-rich elements), or pVEGFR2F, 250 ng pCDNA3.1-His-
LacZ, and 250 ng ERa .  Cells were treated for 36-48 hr with Me2SO or 10 
nM E2, and luciferase activity was determined as described in the 
Materials and methods.  Significant (p < 0.05) downregulation of luciferase 
reporter activity by E2 is indicated by an asterisk.  Results are expressed 
as means ±  S.E. for at least three determinations for each treatment group. 
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4.2.2. Domain requirements of ERa and hormone specificity in MCF-7 cells 
 We also investigated the receptor specificity of E2-induced inhibition of 
transactivation in cells transfected with pVEGFR2A and wild-type ERa or ERa 
mutants containing DNA-binding domain (DBD) (HE11C) or A/B domain 
(HE19C) deletions (Figure 37A).  The results showed that both the DBD and C-
terminal region of ERa were required for E2-dependent decreased luciferase 
expression.  Consistent with these observations, the antiestrogen ICI 182,780 
also reversed the effects of E2 on luciferase activity in MCF-7 cells transfected 
with ERa and pVEGFR2C (Figure 37B) whereas 1 uM ICI 182,780 had no effect 
on transactivation.  Receptor specificity for this response was demonstrated in 
MCF-7 cells transfected with pVEGFR2C and ERa or PR-B: E2, but not 
progesterone, decreased transactivation (Figure 37C).  These results suggest 
that E2-dependent downregulation of VEGFR2 is specific for ERa and requires 
the proximal GC-rich motifs at -58 and -44, suggesting a role for Sp proteins in 
mediating this response.   
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Figure 37. ER domain requirements and hormone specificity in MCF-7 
cells.  A. Comparative effects of wild-type and variant ERa  on E2-induced 
transactivation in MCF-7 cells.  MCF-7 cells were transiently transfected 
with 500 ng of pVEGFR2A and 250 ng of ERa  or variant (HE11C and 
HE19C) ERa .  Cells were treated with Me2SO or 10 nM E2, and luciferase 
activity was determined as described in the Materials and methods.  
Significant (p < 0.05) downregulation of luciferase activity is indicated by 
an asterisk.  Results are presented as means ±  S.E. for at least three 
determinations of each treatment group.  
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Figure 37. (Continued) B. Antiestrogen responsiveness of pVEGFR2C in 
MCF-7 cells.  MCF-7 cells were transiently transfected with 500 ng of 
pVEGFR2C and 250 ng ERa .  Cells were treated with Me2SO, 10 nM E2, 10 
nM E2 + 1 mM ICI 182,780, or 1 mM ICI 182,780 alone.  Luciferase activity 
was determined as described in the Materials and methods.  Significant (p 
< 0.05) downregulation of luciferase activity (*) is indicated.  Results are 
presented as means ±  S.E. for at least three determinations for each 
treatment group.  C. Hormone responsiveness of pVEGFR2C in MCF-7 
cells.  MCF-7 cells were transiently transfected with 500 ng of pVEGFR2C 
and 250 ng ERa  or PR-B.  Cells were treated with Me2SO, 10 nM E2, or 10 
nM progesterone.  Luciferase activity was determined as described in the 
Materials and methods.  Significant (p < 0.05) downregulation of luciferase 
activity (*) is indicated.  Results are presented as means ±  S.E. for at least 
three determinations for each treatment group.   
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4.3.3. Expression of Sp proteins and knockdown by RNA interference  
 Previous studies have demonstrated expression of Sp1 and Sp3 in breast 
cancer cells, and results in Figures 38A & 38B confirm expression of Sp1, Sp3, 
and Sp4 in these cells and their binding to the GC-rich region of VEGFR2.  
Incubation of nuclear extracts from MCF-7 cells with VEGFR2-32P 
oligonucleotide (-64 5’-CCG GCC CCG CCC CGC ATG GCC CCG CCT CCG-3’ 
-35) gave an intense mobile band and a less intense, more mobile retarded 
band (Figure 38C) (lane 2) that resemble the patterns previously observed for 
Sp protein-DNA complexes.  Coincubation with antibodies to Sp1 (lane 3), Sp4 
(lane 4), or Sp3 (lane 5) gave supershifted bands, while non-specific IgG did not 
affect the retarded bands (lane 6).  Coincubation with 100-fold excess of 
unlabeled VEGFR2 oligonucleotide reduced intensities of all retarded bands.   
Further confirmation of Sp1, Sp3, and Sp4 expression in MCF-7 cells was 
obtained in studies which used small inhibitory RNAs for Sp1 (iSp1), Sp3 (iSp3), 
and Sp4 (iSp4) to knockdown all three Sp proteins in MCF-7 cells (Figure 38B) 
as previously described in other cell lines (158).  Western blot analysis of whole 
cell lysates from MCF-7 cells transfected with iLamin (non-specific) showed that 
Sp1, Sp3, and Sp4 are expressed in MCF-7 cells (lane 1).  However, in cells 
transfected with iSp1 (lane 2), iSp3 (lane3), or iSp4 (lane4), there was 
decreased expression of Sp1, Sp3, and Sp4 respectively in whole cell lysates,  
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and in replicate experiments (at least three), the siRNAs significantly decreased 
expression of their targeted proteins.  The effectiveness of the RNA interference 
on cellular expression of Sp proteins was also determined by immunofluorescent 
staining (Figure 38C).  Staining for Lamin was clearly decreased in MCF-7 cells 
transfected with iLamin (a) but not in cells transfected with iSp1 (b) or iSp3 (c).  
Sp1 exhibited punctate nuclear staining in cells transfected with iLamin (d), and 
this staining was barely visible in cells transfected with iSp1 (e).  Similarly, Sp3 
exhibited a punctate nuclear staining pattern in MCF-7 cells transfected with 
iLamin (g), and transfection with iSp3 (h) virtually eliminated the Sp3 staining.  In 
the absence of the primary (f) or secondary (i) antibodies, no 
immunofluorescence was detected.  The Sp4 antibodies commercially available 
gave weak immunofluorescent staining patterns and could not be effectively 
used to confirm Sp4 protein knockdown as observed in the Western blots 
(Figure 38B). 
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Figure 38. Sp protein expression in MCF-7 cells and knockdown by RNA 
interference.  A. Sp protein binding to the VEGFR2 promoter -  EMSA.  
Nuclear extracts from MCF-7 cells were incubated with radiolabeled 
VEGFR2-32P alone or in the presence of unlabeled oligonucleotides and/or 
antibodies, and DNA-protein complexes were separated by EMSA as 
described in the Materials and methods.  Arrows indicate various retarded 
and supershifted complexes. 
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Figure 38. (Continued) B. Sp protein knockdown by Western blot analysis.  
MCF-7 cells were transfected with iSp1, iSp3, or iSp4, and whole cell 
lysates were analyzed by Western blot analysis as described in the 
Materials and methods.  The experiments were repeated (3X), and the Sp 
protein levels were significantly (p < 0.05) decreased by RNA interference 
(relative to iLamin) as indicated by an asterisk.  C. Sp protein knockdown -  
analysis by immunostaining.  MCF-7 cells were transfected with iLamin 
(control) (a, d, g), iSp1 (b, e), or iSp3 (c, h), and immunostained for Lamin 
(a - c), Sp1 (d, e), or Sp3 (g, h), as described in the Materials and methods.  
No primary antibody (f) and no secondary antibody (i) served as controls. 
Photographs were taken at the magnification of X60.  The level of Sp4 
expression in these cells was below the detection limit of the assay.  
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4.3.4. Role of Sp proteins in hormone-dependent downregulation of VEGFR2      
 Previous studies in Hec1A endometrial cancer cells showed that hormone 
dependent downregulation of VEGF involved ERa/Sp3 interactions with GC-rich 
promoter elements (156), and the role of ERa/Sp in downregulation of VEGFR2 
was further investigated in this study by RNA interference.  MCF-7 cells were 
cotransfected with pVEGFR2A and iLamin (control), iGL2, iSp1, iSp3, or iSp4, 
treated with E2, and luciferase activities were determined (Figure 39A).  E2 
induced downregulation of luciferase activity in cells transfected with iLamin, and 
activity was significantly decreased in both Me2SO- and E2-treated groups in 
cells cotransfected with iGL2 (which targets luciferase mRNA).  Basal luciferase 
activity was decreased in cells transfected with iSp1, iSp3, and iSp4; however, 
E2-induced downregulation of luciferase activity was observed only in cells 
transfected with iSp4.  These results indicate that hormone-responsiveness (i.e. 
downregulation) was primarily dependent on cooperative ERa/Sp1 and 
ERa/Sp3 interactions, and ERa/Sp4 played a minor role in this response.  The 
role of Sp proteins in mediating E2/ERa-dependent downregulation of VEGFR2 
was further confirmed by Real-time PCR analysis of VEGFR2 mRNA levels in 
MCF-7 cells cotransfected with either iLamin or iSp1, iSp3, and iSp4 (combined) 
(Figure 39B).  The results showed that the downregulation of VEGFR2 mRNA 
levels by E2 was inhibited by cotransfection with iSp1, iSp3, and iSp4, and these 
results complement the parallel studies using the pVEGFR2A construct (Figure 
39A).   
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Figure 39. Role of Sp proteins in hormone-dependent downregulation of 
VEGFR2.  A. Effects of iSp1, iSp3, and iSp4 on basal and E2-dependent 
activity in MCF-7 cells transfected with pVEGFR2A.  MCF-7 human breast 
cancer cells were transiently transfected with 500 ng of pVEGFR2A and 50 
nM of each siRNA, treated with Me2SO or 10 nM E2, and luciferase activity 
was determined as described in the Materials and methods.  Significantly 
(p < 0.05) decreased reporter activity after treatment with E2 (*) and 
decreased basal activity by siRNAs (**) are indicated.  Results are 
presented as means ±  S.E. for at least three determinations for each 
treatment group.  B. Effects of iSp1, iSp3, and iSp4 on VEGFR2 mRNA in 
MCF-7 human breast cancer cells.  MCF-7 cells were treated with Me2SO or 
10 nM E2 for 24 hr.  RNA was isolated using the RNeasy Protect Mini Kit 
(Qiagen), and samples were analyzed by Real-time PCR as described in the 
Materials and methods.  Significant (p < 0.05) downregulation of VEGFR2 
mRNA levels by E2 are indicated (*).  Results are presented as means ± 
S.E. for at least three determinations for each treatment group.   
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4.3.5. Protein interactions with the proximal VEGFR2 promoter 
 Most studies in MCF-7 and ZR-75 cells show that E2 activates several 
genes through ERa/Sp1 complexes, and this is associated with interactions with 
GC-rich promoter elements (226, 270).  The interactions of ERa, Sp proteins, 
coactivators, and corepressors with the proximal region of the VEGFR2 
promoter were further investigated in a ChIP assay.  The results (Figure 40B) 
showed that in the absence of E2, Sp1, Sp3, and Sp4 were associated with the 
VEGFR2 promoter, and the Sp1, Sp3, and Sp4 band intensities were similar 
after treatment with 10 nM E2 for 15 min, 1 or 2 hr.  A less than 2-fold increase 
in the Sp4 band was the most noticeable change.  The PCR bands obtained 
after immunoprecipitation with ERa, SRC-1, or SRC-3 antibodies also varied 
less than two-fold after treatment with 10 nM E2, and these proteins also 
appeared to be constitutively associated with the VEGFR2 promoter.  In 
contrast, the nuclear receptor corepressors NCoR and SMRT were minimally 
associated with the VEGFR2 promoter, and PCR analysis showed an increased 
association of these proteins with this promoter after treatment with 10 nM E2.   
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Furthermore, treatment of MCF-7 cells with 10 nM E2 resulted in increased 
association of ERa with the region of the pS2 promoter containing an ERE  
(Figure 40C), and this was consistent with previous reports of ChIP assays on 
the pS2 gene promoter (282).  In addition, E2 induced recruitment of SRC-3 but 
not SRC-1 to the pS2 promoter, and association of the corepressors NCoR and 
SMRT with the pS2 promoter exhibited minimal changes after treatment with E2.  
There was some increase in the PCR band intensity in SMRT antibody 
immunoprecipitates from cells treated with E2 for 2 hr.  However, in replicate 
experiments this increase in band intensity was minimal, although the increased 
band intensities for ERa and SRC-3 after treatment with E2 were consistently 
observed.  As a positive control for the ChIP experiment, Figure 40D shows the 
transcription factor TFIIB was constitutively bound to the proximal region of the 
GAPDH promoter, and the binding was also observed after treatment with E2.  
TFIIB did not interact with exon 1 of the CNAP1 gene. 
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Figure 40. Interaction of proteins with the proximal VEGFR2 promoter.  A. 
Summary of primers (Æ  ¨) and targeted regions of the VEGFR2 and pS2 
promoters used in ChIP assays. Analysis of protein interactions with the 
VEGFR2 (B) and pS2 (C) promoters by ChIP.  MCF-7 cells were treated with 
Me2SO (control) or 10 nM E2, and cells were harvested after treatment with 
hormone for up to 2 hr and analyzed in a ChIP assay as described in the 
Materials and methods. D. Binding of TFIIB to the GAPDH promoter. The 
ChIP assay was also used to examine binding of TFIIB to the GAPDH 
promoter (positive control) and to exon 1 of CNAP1 (negative control) as 
described in the Materials and methods. 
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4.3.6. Role of corepressor proteins in hormone-dependent downregulation of  
 
VEGFR2 
 
 The role of liganded ERa as a repressor of Sp protein-dependent 
transactivation was accompanied by recruitment of the corepressors SMRT and 
NCoR to the VEGFR2 promoter (Figure 40) suggesting a possible role for the 
corepressors in mediating this hormone-dependent response.  We therefore 
examined the effects of SMRT and NCoR knockdown by RNA interference in 
MCF-7 cells cotransfected with pVEGFR2A and siRNAs for SMRT (iSMRT) and 
NCoR (iNCoR).  The results (Figure 41) showed that iSMRT significantly 
reversed E2-dependent downregulation of luciferase activity suggesting a role 
for SMRT in mediating the repressive function of ERa in regulating VEGFR2 
gene expression.  
 
4.4. Discussion 
 Estrogen regulation of gene expression is highly complex and dependent 
on multiple factors including the structure of the ligand and the relative 
tissue/cell-specific expression of ERa, ERb, and various coregulatory proteins 
(283, 284).  The classical mechanism of E2-dependent upregulation of many 
genes involves ligand-induced ER homodimerization and interaction of the 
nuclear ER homodimer with estrogen responsive elements (EREs) in target 
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Figure 41. Effects of iNCoR and iSMRT on basal and E2-dependent activity 
in MCF-7 cells transfected with pVEGFR2A.  MCF-7 human breast cancer 
cells were transiently transfected with 500 ng of pVEGFR2A and 50 nM of 
each siRNA, treated with Me2SO or 10 nM E2, and luciferase activity was 
determined as described in the Materials and methods.  Significant (p < 
0.05) reversal of downregulated reporter activity by siRNAs is indicated (*).  
Results are presented as means ±  S.E. for at least three determinations for 
each treatment group.  
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 gene promoters.  Ligand-induced formation of the ER homodimer-DNA complex 
is accompanied by recruitment of coactivators and other nuclear factors and by 
interactions with the basal transcription machinery to activate gene transcription 
(285-287).  Studies on the molecular biology of ER action have subsequently 
revealed more complex mechanisms which involve DNA-bound ER interacting 
with other transcription factors such as Sp1, and ER-transcription factor 
interactions where the latter protein(s) but not ER binds its cognate response 
element (155, 270).  For example, ERa/Sp1, ERa/AP-1, and ERb/AP-1 
mediated transactivation through binding GC-rich and AP-1 motifs have been 
extensively investigated (155, 270, 288, 289). 
Several studies have examined more global gene expression profiles of 
estrogen-responsive genes in breast cancer and other cell lines (290-294).  
Frasor and coworkers reported that over 400 genes “showed a robust pattern of 
regulation” (290) by E2, and over 70% of these genes were downregulated.  
Thus, although E2 plays a major role in decreasing gene expression in MCF-7 
cells, mechanisms associated with this response have not been extensively 
investigated.  The mechanisms of E2-dependent inhibition of genes regulated by 
NFkB have been studied, and the results show that these effects are complex 
and dependent on the gene, cell context, and ligand structure (295-302).  At 
least one mechanism involves direct binding of ERa to nuclear NFkB, and this 
results in inhibition of coactivator recruitment and decreased NFkB binding to 
promoter elements and decreased transactivation.  The E2-dependent 
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downregulation of VEGFR2 mRNA levels (Figure 36A) and reporter gene activity 
in transfection studies (Figure 36B) in MCF-7 cells was in contrast to hormonal 
activation of this gene in ZR-75 cells (282).  Therefore, we further investigated 
this response in MCF-7 cells as a model for understanding the molecular 
mechanisms of E2-dependent downregulation of gene expression.   
The deletion and mutation analysis of the VEGFR2 promoter (Figures 
36B & 36C), coupled with the effects of antiestrogens and the requirement for 
wild-type ERa or HE11C (Figure 37), indicate that ERa interactions with Sp 
proteins are required for downregulation of VEGFR2 by E2 in MCF-7 cells.  The 
critical GC-rich sites at -58 and -44 were required for E2-dependent upregulation 
of VEGFR2 mRNA or promoter constructs in ZR-75 cells (282) and 
downregulation of these same responses in MCF-7 cells.  The major difference 
between the two cell lines was associated with the domains of ERa required for 
these responses.  In MCF-7 cells, deletion of the N-terminal A/B region did not 
affect transactivation in cells transfected with pVEGFR2 constructs whereas 
deletion of the DBD resulted in loss of transactivation (Figure 37A).  This 
suggested that decreased transactivation in MCF-7 cells treated with E2 was 
dependent on the C-terminal C-F domains of ERa containing both the DBD and 
AF-2.  In contrast, the DBD of ERa was not required for induction of 
transactivation in ZR-75 cells transfected with pVEGFR2 constructs (282), and 
similar results were obtained for induction of many other E2-responsive genes 
by both ERa/Sp1 and HE11C/Sp1 (155, 270).  Both AF-1 and AF-2 in the C- 
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and N-terminal regions of ERa were required for upregulation of ERa/Sp-
dependent gene expression by E2 (155, 270, 282); however, E2-dependent 
inhibition of transactivation in cells transfected with the pVEGFR2A construct 
required the DBD and AF-2 domain, but was AF-1 independent (Figure 37A). 
The pattern of retarded bands associated with Sp-DNA (VEGFR2 
oligonucleotide) interactions in MCF-7 cells (Figure 38A) was similar to that 
observed in ZR-75 cells (282) and was associated with binding of Sp1, Sp3, and 
Sp4 proteins which are expressed in both cell lines.  ERa enhances the on-rate 
of Sp binding to GC-rich motifs (153); yet, ternary ERa-Sp-DNA complexes were 
not detected in electorphoretic mobility shift assays in this study or in previous 
reports (155, 270).  However, using a ChIP assay, we have shown that ERa was 
constitutively bound to the GC-rich promoter (149) (Figure 40B), and treatment 
with E2 did not appreciably enhance the PCR bands associated with ERa.  The 
results are consistent with the fact that ERa binds Sp1 and Sp3 in the presence 
or absence of ligand (153, 156), and nuclear colocalization of ERa and Sp4 in 
breast cancer cells was observed in the presence or absence of ligand (data not 
shown). 
Studies on hormonal regulation of genes through ERa/Sp proteins have 
shown that ERa/Sp1 is involved in induced expression of several genes 
whereas downregulation of VEGF in Hec1A endometrial cancer cells was due to 
ERa/Sp3 interactions with proximal GC-rich motifs (156).  The role of Sp3 in 
mediating decreased VEGF expression in Hec1A cells treated with E2 was 
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supported by studies with dominant negative Sp3 which reversed the effects of 
E2.  The relative contributions of Sp1 and Sp4 were not determined.  The 
availability of siRNAs for Sp proteins has greatly facilitated studies on 
determining which specific Sp proteins are required for ERa/Sp action, and 
results in Figure 39 clearly demonstrated that ERa/Sp1 and ERa/Sp3 were 
primarily responsible for E2-dependent downregulation of VEGFR2.  The results 
do not exclude a role for Sp4 in this response since decreased Sp4 expression 
decreased the magnitude of the effects of E2 from 73% to a 49% decrease in 
luciferase activity (Figure 39A).  In contrast, loss of Sp1 or Sp3 totally abrogated 
the effects of E2 in cells transfected with pVEGFR2A suggesting that both Sp1 
and Sp3 are cooperatively involved in the ERa/Sp-induced suppression of 
activity.   
As indicated above, ERa decreases NFkB-dependent transactivation 
through multiple pathways (295-302), and ER and other nuclear receptors 
decrease expression of genes/ reporter genes by modulating the activity of other 
DNA-bound transcription factors.  PPARg-dependent suppression of 
thromboxane receptor expression in vascular smooth muscle cells is dependent 
on a GC-rich promoter sequence and may be due to decreased Sp-1 promoter 
(DNA) interactions (274).  Ligands for PPARg and PPARa also decrease 
VEGFR2 expression in retinal capillary endothelial and human umbilical vein 
endothelial cells, respectively, and these responses were associated with 
decreased Sp1/Sp3 and Sp1-DNA (promoter) binding, respectively (279, 280).  
 185 
In contrast, decreased VEGFR2 expression in MCF-7 cells treated with E2 was 
not associated with decreased association of Sp proteins to the VEGFR2 
promoter in ChIP (Figure 40) or electrophoretic mobility shift assays (Figure 
38A).  Moreover, studies with recombinant ERa plus Sp1 showed that ER 
enhances Sp1 binding to GC-rich oligonucleotides (153), and nuclear extracts 
from E2- and solvent- (Me2SO) treated cells gave retarded bands with similar 
intensities (149, 261).  Similar results were observed using treated nuclear 
extracts from MCF-7 cells and the VEGFR2-32P oligonucleotide (Figure 38A). 
Several studies report that corepressors NCoR and SMRT bind 
promoters in E2-responsive genes and play a role in modulation of nuclear 
receptor-mediated transactivation (149, 261, 303-307).  ChIP analysis of the 
proximal region of the VEGFR2 promoter indicates constitutive binding of NCoR, 
SMRT, SRC-1, and SRC-3.  However, after treatment with E2, there was 
increased binding of NCoR and SMRT but minimal changes in SRC-1 and SRC-
3 binding to the VEGFR2 promoter (Figure 40B).  In contrast, both ER and SRC-
3 were recruited to the E2-responsive region of the pS2 gene promoter whereas 
minimal changes were observed in binding of SRC-1, NCoR, and SMRT to the 
pS2 gene promoter (Figure 40C).  The recruitment of corepressors has 
previously been linked to ligand-dependent repression of genes (308-310), and 
we therefore further examined the effects of SMRT and NCoR knockdown on 
luciferase activity in cells transfected with pVEGFR2A (Figure 41).  The results 
showed that E2-dependent downregulation of activity was reversed, in part, after 
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cotransfection with iSMRT but not iNCoR.  These observations suggest a 
possible model for the mechanism of E2-dependent downregulation of VEGFR2 
gene expression (Figure 42).  ERa forms an ER/Sp complex on the VEGFR2 
promoter in the absence of ligand; however, after treatment with E2, the nuclear 
corepressor SMRT is recruited and ERa/SMRT act to depress transactivation.  
In the absence of E2, knockdown of SMRT does not decrease Sp-dependent 
transactivation associated with the VEGFR2 promoter (Figure 41) suggesting 
the repressed transactivation is associated with the liganded ERa-SMRT 
complex.  Moreover, at least two additional factors may also affect the activity of 
the ERa-SMRT complex.  First, since VEGFR2 is upregulated in ZR-75 cells 
(282) and downregulated in MCF-7 cells, then cell context-dependent factors 
must influence this pathway.  Furthermore, since many GC-rich promoters/ 
genes such as CAD and E2F1 are upregulated by ERa/Sp proteins in both ZR-
75 and MCF-7 cells (149, 261), a second factor influencing liganded ERa-SMRT 
inhibitory actions may be promoter context and other nuclear factors bound to 
the VEGFR2 promoter in MCF-7 cells.  While this model (Figure 42) does not 
fully define the mechanism of E2-dependent downregulation of gene expression, 
we have demonstrated that SMRT and other factors play a role in mediating this 
response.  Current studies are focused on further identifying other key elements 
involved in E2-dependent downregulation of VEGFR2 thereby providing insights 
on an important pathway of estrogen action involving gene repression that is not 
well understood.   
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Figure 42. Proposed model for the mechanism of E2-dependent 
downregulation of VEGFR2 gene expression in MCF-7 cells -  role of 
ERa /Sp proteins and involvement of the corepressor SMRT.  
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CHAPTER V 
 
SUMMARY AND CONCLUSIONS 
 
5.1. Regulation of VEGFR2 in pancreatic cancer cells 
Vascular endothelial growth factor receptor-2 (VEGFR2/KDR) is an 
important mediator of angiogenesis, and VEGFR2 mRNA is expressed in 
several pancreatic cancer cell lines.  Deletion analysis of the VEGFR2 promoter 
in Panc-1, AsPC-1, and MiaPaCa-2 pancreatic cancer cells shows that the 
proximal region of the promoter is primarily responsible for VEGFR2 expression, 
and two GC-rich sites at -58 and -44 are critical elements in all three cell lines.  
Panc-1, AsPC-1, and MiaPaCa-2 cells also express Sp1, Sp3, and Sp4 proteins 
which bind to the GC-rich region of the VEGFR2 promoter in electrophoretic 
mobility shift and chromatin immunoprecipitation (ChIP) assays.  RNA 
interference with small inhibitory RNAs for Sp1, Sp3, and Sp4 decreases 
VEGFR2 mRNA and reporter gene activity in transfection assays, confirming 
that VEGFR2 expression in pancreatic cancer cells is regulated by Sp proteins. 
The results suggest that VEGFR2 can not only be targeted by receptor tyrosine 
kinase inhibitors but also by drugs that interfere with Sp proteins.    
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5.2. Hormone-dependent upregulation of VEGFR2 in ZR-75 cells  
 Vascular endothelial growth factor receptor-2 (VEGFR2/KDR) is critical 
for angiogenesis, and VEGFR2 mRNA and protein are expressed in ZR-75 
breast cancer cells and induced by 17b-estradiol (E2).  Deletion analysis of the 
VEGFR2 promoter indicates that the proximal GC-rich region is required for both 
basal and hormone-induced transactivation, and mutation of one or both of the 
GC-rich motifs at -58 and -44 results in loss of transactivation.  Electrophoretic 
mobility shift and ChIP assays show that Sp1, Sp3, and Sp4 proteins bind the 
GC-rich region of the VEGFR2 promoter.  Results of the ChIP assay also 
demonstrate that ERa is constitutively bound to the VEGFR2 promoter and that 
this interaction is not enhanced after treatment with E2 whereas ERa binding to 
the region of the pS2 promoter containing an estrogen responsive element is 
enhanced by E2.  The ERE region of the pS2 promoter contains GC-rich sites, 
and Sp1, Sp3, and Sp4 are constitutively bound to the pS2 promoter in the 
presence or absence of E2.  Current studies are investigating recruitment of Sp 
proteins to other estrogen-responsive promoters to confirm that binding of Sp 
proteins is unique to GC-rich promoters.  RNA interference studies show that 
hormone-induced activation of the VEGFR2 promoter constructs requires Sp3 
and Sp4 but not Sp1, demonstrating that hormonal activation of VEGFR2 
involves a non-classical mechanism in which ERa/Sp3 and ERa/Sp4 complexes 
activate GC-rich sites where Sp proteins but not ERa bind DNA.  These results 
show for the first time that Sp3 and Sp4 cooperatively interact with ERa to 
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activate VEGFR2 and are in contrast to previous results showing that several 
hormone-responsive genes are activated by ERa/Sp1 in breast cancer cell lines.  
Interestingly, in experiments on VEGFR2, knockout of Sp3 or Sp4 proteins with 
the corresponding siRNAs resulted in total loss of hormone-inducibility, and this 
suggests that these Sp proteins could not compensate for each other which is 
consistent with the cooperative nature of these transcription factors. 
 
5.3. Hormone-dependent downregulation of VEGFR2 in MCF-7 cells 
Several studies have examined estrogen-responsive gene expression 
profiles in various cancer cell lines.  Many genes are upregulated by 17b-
estradiol (E2) in breast cancer cells; however, others are downregulated by E2.  
Since the mechanisms associated with hormone-dependent downregulation of 
gene expression have not been extensively investigated, we used the 
downregulation of VEGFR2 by E2 in MCF-7 cells as a model for understanding 
the molecular mechanisms associated with E2-dependent decreased gene 
expression in breast cancer cells.  E2 decreases VEGFR2 mRNA levels in MCF-
7 cells, and deletion analysis of the VEGFR2 promoter indicates that the 
proximal GC-rich motifs at -58 and -44 are critical for the E2-dependent 
decreased response in MCF-7 cells.  Mutation or deletion of these GC-rich 
elements results in loss of hormone-responsiveness and shows that the -60 to -
37 region of the VEGFR2 promoter is critical for both basal and hormone-
induced activity in these cells.  Western blot, immunofluorescent staining, and 
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RNA interference assays, in conjunction with electrophoretic mobility shift and 
ChIP assays, support a role for Sp proteins in hormone-dependent 
downregulation of VEGFR2 in MCF-7 cells, primarily through ERa/Sp1 and 
ERa/Sp3 interactions with the VEGFR2 promoter.  When expression of one of 
the three Sp proteins was knocked out using RNAi, reporter activity was partially 
lost and the other two Sp proteins could not totally compensate.  Using ChIP and 
transient transfection/RNA interference assays we show that the ERa/Sp 
protein-promoter interactions are accompanied by recruitment of the corepressor 
SMRT and that SMRT plays a role in the E2-mediated downregulation of 
VEGFR2 in MCF-7 cells.  Current studies are looking at coactivator/corepressor 
recruitment to other estrogen-responsive GC-rich promoters to confirm that 
corepressor recruitment is unique to downregulation of VEGFR2 in MCF-7 cells.  
This study illustrates a novel mechanism of hormone-dependent downregulation 
of a gene in breast cancer cells. 
 
5.4. Future implications 
 Molecular mechanisms of VEGF, VEGFR1, and VEGFR2 regulation are 
under intense investigation due to their importance in tumor angiogenesis (240).  
VEGFR2 is an important target for inducing antiangiogenesis because it is 
expressed almost exclusively on activated endothelial cells, such as those in 
tumors.  Thus, inhibitors of VEGFR2 are highly specific anti-tumor agents that 
block tumor growth and metastasis.  VEGFR2 inhibitors allow greater 
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accessibility to tumors because vessel endothelium is in direct contact with 
blood.  Furthermore, since endothelial cells have a normal complement of 
chromosomes and are genetically stable, they are less likely than tumor cells to 
develop resistance to antiangiogenic therapies targeting VEGF or VEGFR (176). 
Many human cancers are treated with radiation, and approximately 50% 
of all cancer patients receive radiation at some point during the course of their 
treatment.  However, radiation therapy has limited effectiveness due to normal 
tissue tolerance and development of radiation-resistance by tumor cells (311).  
Strategies that focus on inhibition of tumor angiogenesis are promising for 
cancer therapy, and the first antiangiogenic agent received FDA approval in 
2004.  Studies using the monoclonal antibody to VEGFR2, cp1C11, inhibit 
proliferation, reduce migration, and disrupt differentiation of endothelial cells and 
also block formation of new capillary-like networks.  Inhibition of VEGFR2 using 
DC101, a monoclonal antibody, significantly inhibited growth of tumor xenografts 
in athymic mice.   Endothelial cells or human tumor xenografts treated with 
cp1C11 and DC101, respectively, show a modest increase in radiosensitivity.  
This suggests that blocking VEGFR2 has an interactive cytotoxic effect with 
radiation on endothelial cells and that inhibition of VEGFR2 alone and in 
combination with radiation might be a valuable strategy for cancer therapy by 
targeting tumor vasculature and enhancing tumor responsiveness (311). 
 In ER(+) premenopausal breast cancer, expression of VEGFR2 is 
associated with the impaired effects of tamoxifen.  VEGFR2 status is a 
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significant predictor of tamoxifen-responsiveness in breast cancer patients.  In 
these cases, breast cancers expressing VEGFR2 might benefit from treatment 
with tamoxifen in combination with VEGFR2 inhibitors (312).  Currently, both 
VEGFR2 monoclonal antibodies and tyrosine kinase inhibitors are being tested 
in clinical trials.  Combining tamoxifen with EGFR and/or HER2 inhibitors is a 
promising therapy for endocrine resistant tumors, and in theory, this strategy 
could be used for treatment of ER(+), VEGFR2(+) tumors.  Antiangiogenic 
therapies may be useful as adjuvant therapy with tamoxifen and may be more 
effective in combination as a therapy for hormone-resistant breast cancer (312). 
Furthermore, tumor angiogeneisis can be inhibited in mice if a cellular 
response is induced against VEGFR2 (313).  Vaccination of mice using 
VEGFR2 epitope peptides significantly suppressed tumor growth and prolonged 
survival of the animals with limited adverse effects.  In antiangiogenesis assays, 
vaccination using these VEGFR2 epitope peptides suppressed tumor-induced 
angiogenesis.  These VEGFR2 epitope peptides might be an effective 
antiangiogenic immunotherapy for cancer (313). 
It has been shown that therapies targeting VEGF/VEGFR2 have great 
potential for cancer treatment.  Our results further support the importance of 
VEGFR2 in cancer and emphasize the complexity of VEGFR2 gene regulation in 
cancer cells.  By understanding the molecular mechanisms involved in 
regulation of VEGFR2 expression in various cancer cell lines, it may be possible 
to identify alternate methods for blocking angiogenic pathways.  Our results 
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demonstrate that both basal and hormone-induced expression of VEGFR2 are 
dependent on Sp proteins (Sp1, Sp3, and Sp4).  Several studies have 
demonstrated that Sp proteins can be targeted and either degraded or their 
activity as transcription factors can be inhibited by agents such as mithramycin 
that inactivate GC-rich sites (270).  Thus, identification of the important role of 
Sp proteins in mediating VEGFR2 expression reported in this study can lead to 
new antiangiogenic therapies by targeting Sp proteins.  
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